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ABSTRACT
USE OF PHOTOBIOMODULATION IN OSTEOCLAST FORMATION: POSSIBLE
INTERVENTION FOR THE TREATMENT OF OSTEOPOROSIS
by
Lisa Anderson-Antle
The University of Wisconsin-Milwaukee, 2014
Under the Supervision of Dr. Karen H. Morin
After critically examining the literature to gain a robust understanding for the
pathogenesis of bone loss, specifically osteoporosis, the development of a possible new
intervention to prevent or treat osteoporosis was explored. The purpose of this
dissertation was to pilot test a new protocol designed to answer the broad research
question: Does Near-Infrared Light Emitting Diode (NIR-LED) treatment affect
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) induced
osteoclastogenesis in a cell culture model?
Osteoporosis is defined as a disease characterized by low bone mass and
structural deterioration of bone tissue, leading to bone fragility and an increased
susceptibility to fractures, especially of the hip, spine, and wrist. Specifically,
osteoporosis has been shown to increase the risk for fracture resulting from a fall. The
World Health Organization reported in 2003 that osteoporosis-induced fractures burden
society due to the great health care costs for treatment and rehabilitation. Experts have
estimated that, between 2005-2025, the incidence and economic burden to treat
osteoporotic related fractures will increase 50% annually (Burge et al., 2007). The
development of additional interventions meant to slow the progression of osteoporosis
may contribute to decreasing this burden. Near-Infrared Light Emitting Diode (NIRLED) photobiomodulation has been found to be effective in improving wound healing,
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bone regeneration, mitochondrial function, and attenuating cellular oxidative stress. Little
is known regarding the use of NIR-LED and the formation of osteoclasts, which break
down bone.
This pilot study included two experiments using the WARP™ 75 light source.
RAW264.7 cells were cultured for 24 hours and induced to differentiate into osteoclasts,
using the cytokine Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).
Cultures were divided into groups according to RANKL dose (0, 2.5, 10, 25, 50 ng/ml)
and different energy densities (2.25, 4.5, 45 J/cm²), treated with light either once or on
four consecutive days using the WARP™ 75 (Quantum Devices, Barneveld, WI).
Osteoclast-like cells were stained for Tartrate-Resistant Acid Phosphatase (TRAP).
Multinucleated, TRAP+ cells were scored as osteoclasts, counted manually by
microcopy. Results were expressed as means and standard deviations, and groups were
compared by one-way ANOVA with posthoc Tukey. RANKL-induced osteoclast
formation by RAW264.7 cells occurred as expected in all experiments. Light-treatment
alone had no observable effect. A single light-treatment at 4.5 J/cm2 with RANKL added
(10 - 50ng/ml) suggested a biostimulatory effect upon osteoclastogenesis compared to
controls, as multiple light-treatments compared to single light-treatment were less
stimulatory in the energy density 4.5 J/cm2 and RANKL dose 25ng/ml group. In
conclusion, effects of NIR-LED treatment on osteoclastogenesis are RANKL dose and
light-intensity specific. NIR-LED light-treatment affects RANKL-induced osteoclast
formation suggestive of a biostimulatory effect, and multiple light treatments compared
to single light treatment may biostimulate osteoclastogenesis less.
These experiments provide the foundation to further investigate possible NIR-
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LED effects upon bone formation and include alternative bone formation quantification
utilizing alternative cellular assays. Contributing to this body of knowledge provides
insight for nurses’ application of new therapies to prevent and treat bone loss.
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CHAPTER ONE
Introduction
This chapter sets the context for the study. The following will be presented in this
chapter: the significance, statement of the problem, followed by the study method and
purpose, research questions and concluding with the implications for nursing practice,
research and policy. Within the statement of the problem, briefly, the definition,
diagnosis, and incidence of osteoporosis are reviewed, and the consequences of the
pathology significantly related to the older adult population are explored. Further, an
overview of osteoclast differentiation and the cellular-level effects of Near Infrared Light
Emitting Diode (NIR-LED) treatment (i.e., oxidative stress and mitochondrial function)
on osteoclast cells (bone-resorbing cells) are presented to familiarize the reader with this
study’s intervention.
The purpose of this dissertation was to pilot test a new protocol designed to
answer the broad research question: Does Near-Infrared Light Emitting Diode (NIRLED) treatment affect Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)
induced osteoclastogenesis in a cell culture model? Osteoporosis is defined as “a disease
characterized by low bone mass and structural deterioration of bone tissue, leading to
bone fragility and an increased susceptibility to fractures, especially of the hip, spine, and
wrist” (World Health Organization scientific Group, [WHOSG], 2003, p. 4) and is the
most common bone disorder (National Institutes of Health Consensus Development Panel
on Osteoporosis [NIH-CDPO] 2001) Specifically, osteoporosis has been shown to
increase the risk for fracture resulting from a fall, especially of the hip (Rizzoli, 2010;
Schwartz, Nevitt, Brown, & Kelsey, 2005). The incidence of non-vertebral osteoporotic

2

fractures has been associated with increased chronological age, increased number of fall
risk factors, and reduced bone density and strength (Crepaldi & Maggi, 2005; Cummings
et al., 1995). The World Health Organization (WHO) reported in 2003 that osteoporosisinduced fractures burden society due to the great health care costs for treatment and
rehabilitation. Reported in 2005, the yearly fracture rate for those individuals in the
United States 50 years and old was greater than 20 million, with an estimated cost of $17
billion which 72% of the expenditures were spent to treat hip fracture (Burge et al.,
2007), In 2008, estimates of cost to treat osteoporosis and fractures were reported as $22
billion (Blume & Curtis, 2011). These experts have estimated that, between 2005-2025,
the incidence and economic burden to treat osteoporotic related fractures will increase
50% annually. Due to the current societal demographic growth and rising healthcare
costs, it will become imperative to identify individuals at risk for falls and screen for
bone loss. The development of additional interventions meant to slow the progression of
osteoporosis may contribute to decreasing the burden of osteoporosis-induced fractures in
the aging population.
One unique multidisciplinary approach to study skeletal health in the aging
population involves teaming with researchers investigating skeletal health in a
microgravity environment. Microgravity during space flight simulates complications of
muscle (Trappe et al., 2001), and bone loss (Rodionova & Oganov, 2001) often
experienced by older adults from prolonged bed rest during hospitalization (Trappe,
2009) which may result in self-limiting behaviors due to the fear of falling (Fletcher &
Hirdes, 2004; Van Doorn et al., 2003),
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A model for simulating conditions of micro-gravity uses a human bedrest model
(Clement & Slenzka, 2006) Research in musculoskeletal health that develops and
validates countermeasures taken during long duration space flights involves interventions
and procedures designed to mitigate health and performance hazards present in a space
environment (Clement, Bukley, & Paloski, 2007). Some researchers investigating bone
loss in microgravity environments believe that there is the potential for translational
research that could impact the pathology of bone loss in the aging population (Rittweger,
2007). Therefore, continued collaborative interdisciplinary research with the National
Aeronautics and Space Administration (NASA) may assist researchers in using new
technologies to mitigate bone loss for the older adult population to prevent fracture
(Rittweger, 2007).
Statement of the Problem
The following section presents the essence and rationale for investigating osteoporosis.
Briefly, an overview of osteoporosis is provided relative to its incidence within the aging
population and its contribution to fall induced fractures. The proposed use of NIR-LED
as a possible future treatment for the management of osteoporosis, a brief review of bone
physiology and pathology, diagnosis as it relates to falls, fractures and frailty and finishes
with an overview of the cellular mechanisms of NIR-LED are discussed.
Aging Population
It is projected that by the year 2030, the United States population of older adults
will double to 71.5 million 8.9 million of these, will be over the age of 85 (U.S.
Department of Health and Human Services Administration on Aging [USDHHS-AOA],
2006) and represent the fastest-growing sector of the U.S. population. Similar
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projections apply globally with a world population of individuals over 60 years reaching
approximately two billion by the year 2050 (United Nations, 2010). In fact, the number
of Americans 65 and older has tripled between 1900-2005 (Friedland & Summer, 2005).
According to the Alliance for Aging Research (1999), 6,000 Americans turn 65 each day.
Further, it is projected that over the next 19 years, 10,000 Americans will turn 65 each
day (Cohn & Taylor, 2010). Over time, this sub-set of the American population overtime
will become vulnerable for disability, morbidity, and mortality (Ostir, Ottenbacher, &
Markides, 2004).
Incidence of Osteoporosis
In the US, osteoporosis affects approximately 10 million people over the age of
50 years and, of those, 8 million are women. In addition, 34 million Americans are at
risk for developing osteoporosis due to low bone mass (osteopenia) (Harvey, Dennison,
& Cooper, 2013; A. C. Looker, Melton, Harris, Borrud, & Shepherd, 2010). Due to
ethnic differences in bone and mineral metabolism (Norris, Micklesfield, & Pettifor,
2013), osteoporosis is present more often in Caucasian than Hispanic and African
American women. Few data exist that report ethnic patterns in men; however trends are
similar to women. Bone loss is present more often in Caucasian than Hispanic and
African American women.
There has been only a modest decline in the rate of osteoporosis over the past
years, despite the development and use of medications and weight-bearing exercise (A.
C. Looker et al., 2010). Based upon this fact, current interventions and treatments of
osteoporosis have not been effective enough to impact and decrease the prevalence of
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osteoporosis. Therefore, research investigating new interventions and treatments needs to
be considered.
Osteoporotic-Fall Induced Fractures.
Due to the bone loss and strength, experts have associated the presence of
osteoporosis with fall-induced fractures (Schwartz et al., 2005; WHOSG, 2003). Falls are
the leading cause of death by unintentional injury for individual 65 (Avdic, Pecar, &
Mujic-Skikic, 2004; Centers for Disease Control and Prevention National Center for
Injury Prevention and Control [CDCP-NCIPC], 2003; 2005; 2010a)
As individuals age they become susceptible to falling. Falls have been an
independent indicator for functional decline and are identified as the causal event for
40% of nursing home admission (Bischoff-Ferrari, 2009; Tinetti & Williams, 1997).
Further, a little over a half a million (1.4% of community dwelling older adults)
experience a low-impact fall resulting in fracture annually (Morrison, Fan, Sen, &
Weisenfluh, 2013). Hip fractures are the most serious osteoporosis-associated fracture
resulting in permanent disability (Harvey et al., 2013; WHOSG, 2003; Ziden, Wenestam,
& Hansson-Scherman, 2008). In fact, the mortality rate is estimated to be 20%-35%
within the first year after suffering a hip fracture (Goldacre, Griffith, Gill, & Mackintosh,
2002; Goldacre, Roberts, & Yeates, 2002).
Further, a hip fracture may be considered the “triggering event” contributing to
functional decline, possibly transitioning the individual into a frail state of health
(Morley, 2002; Runge & Hunter, 2006; Suh & Lyles, 2003). Half of the people who are
ambulatory prior to hip fracture cannot walk independently after the fall (Harvey et al.,
2013) and suffer from fear, anxiety and depression, dramatically impacting their quality
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of life (Ziden et al., 2008). However, it is unclear if a fall is an antecedent to frailty, or
conversely, whether frailty is an antecedent to falls (J.E. Morley, 2002). Therefore, it is
important to explore possible interventions to alter the development of osteoporosis with
the intent to preserve or rebuild the bone architecture to withstand the impact of a fall,
thus avoiding fracture.
Proposed use of NIR-LED
One area to investigate when exploring potential new interventions could be
cellular-level mechanisms involved with the pathology of osteoporosis. The intervention
employed in this study—near infrared light—already has a large body of research
supporting the idea that near infrared light has advantageous effects at the cellular level
(Brondon, Stadler, & Lanzafame, 2005; Karu, Piatibrat, & Kalendo, 1987; Karu, 1988;
1999; 2003; Lubart, Wollman, Friedmann, Rochkind, & Laulicht, 1992; Tim et al., 2014;
Whelan et al., 2008). However, the literature offers only a limited amount of research
studying the effects of near infrared light on bone.
The initial literature search yielded six NIR-LED in vitro studies (cell culture
model) (Pinheiro et al., 2002; Pinheiro & Gerbi, 2006; Renno, McDonnell, Parizotto, &
Laakso, 2007; Stein, Benayahu, Maltz, & Oron, 2005; Yamada, 1991) that investigated
osteoblast cells (bone-forming cells) and four in vivo studies (animal model) (Blaya,
Guimaraes, Pozza, Weber, & de Oliveira, 2008; Pinheiro et al., 2008; Pinheiro et al.,
2009; Torres, dos Santos, Monteiro, Amorim, & Pinheiro, 2008). Predominately, these
investigations explored bone remodeling which would more specifically measure
osteoclast and osteoblast interaction. Because we found one in vitro study that
investigated osteoclast cells (bone-resorbing cells) (Aihara et al., 2006), the decision was
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made to investigate the effects of NIR-LED on osteoclastogenesis due to this gap in the
literature.
Background
Presented below is a brief overview to introduce the literature’s main tenets that
provided foundational evidence for identifying gaps in the literature. This presentation
will allow the reader to understand the dissertation’s structure and introduce the main
content related to the following subjects: bone physiology, diagnosis of osteoporosis,
followed the discussion of osteoporosis as it relates to the incidence of frailty, falls, and
fractures in the older adult population. This section will conclude with a more in-depth
explanation for the study’s intervention, NIR-LED treatment.
Bone Physiology
Bone formation is central to growth and development during childhood and
adolescence (Bonjour, Theintz, Law, Slosman, & Rizzoli, 1994). Peak bone mass is
complete by early adulthood ((WHOSG, 2003). After the age of 20, bone resorption in
males becomes a central process that demineralizes bone at about 4% per decade.
Females maintain bone mineral content until menopause, then experience declines of
15% per decade (NIH-CDPO, 2001); WHOSG, World Health Organization Scientific
Group (2003).
There are four types of bone cells that contribute to the formation and
maintenance of bone: osteoprogenitor cells, osteocytes, osteoclasts, and osteoblasts
(Porth, 2009). Osteoprogenitor cells are undifferentiated cells that are the source of all
bone cells except osteoclasts which originate from monocyte/macrophages within the
hemopoietic lineage. Osteocytes are mature bone cells that maintain the bony matrix. In
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addition, they may respond to bone tissue strain and recruit osteoclasts to areas of bone
requiring bone repair/remodeling (Lanyon, 1993). There are interconnected passageways
called canaliculi that are found throughout the calcified matrix and contain extracellular
fluid (Hadjidakis & Androulakis, 2006). These passageways provide a communication
network between the neighboring osteocytes and blood system for the exchange of
nutrients and metabolites because diffusion does not occur is calcified bone (Porth,
2009).
Osteoclasts and osteoblasts are two types of cells within mineralized bone that
contribute to mineral homeostasis (Lemaire, Tobin, Greller, Cho, & Suva, 2004). They
are responsible for building and maintaining bone structure. Osteoclasts are boneresorbing cells that originate from monocyte/macrophages within the hemopoietic
lineage, and their activity is regulated by osteoblasts, bone-forming cells, and numerous
hormones and other growth factors: macrophage colony-stimulating factor (M-CSF),
interleukin-1 (IL-1), and tumor necrosis factor (TNF) (Hock et al., 2001). Osteoblasts are
differentiated mesenchymal stem cells, responsible for lying down the new bone matrix
that becomes mineralized, thus replacing old bone previously reabsorbed by osteoclasts
(Hadjidakis & Androulakis, 2006; Hock et al., 2001).
There are two pathways that induce osteoclastogenesis. On the osteoblast
stromal cell membrane, Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)
receptor, binds to the osteoclast precursor cell (macrophage) RANK receptor. When this
occurs, RANK signaling activates the transcription factor Kappa-B to differentiate into
osteoclasts (Kumar, 2010). The other pathway occurs with the osteoblast secretion of MCSF and the osteoclast precursor cell (macrophage) M-CSF receptor. When joined,
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tyrosine kinase activity is stimulated, also important to osteoclast formation. This
signaling occurs in tandem with the RANKL/RANK pathway. Further bone marrow
stromal/osteoblast cells secrete osteoprotegerin (OPG), a decoy receptor for RANKL,
preventing RANKL from binding with the osteoclast precursor cell’s RANK receptor,
preventing bone absorption and attenuating osteoclast differentiation (Kumar, 2010).
Diagnosis of Osteoporosis
Osteoporosis arises from the out-of-balance osteoclast/osteoblast activity in
remodeling bone (Manolagas & Jilka, 1995). In healthy remodeling tissue of the adult,
osteoblasts lay down a new matrix that becomes mineralized, thus replacing old bone
previously reabsorbed by osteoclasts (Hock et al., 2001). This occurs in both spongy
(cancellous) tissue and cortical (dense) bone, which together comprise intact bone; the
relative contribution of cancellous and cortical tissues to a given bone varies.
The diagnosis of osteoporosis is made by identification of reduced bone density of
vertebral and/or femur cortical and cancellous bone. Using dual energy x-ray
absorptiometry (DEXA) scanning, a bone mineral density (BMD) that exceeds 2.5
standard deviations (SD) below the mean BMD found in 30 year old women confirms a
diagnosis of osteoporosis. Osteopenia is identified by 1 to 2.5 SD below that same mean.
From 2005-2006, for older adult women in the U.S., the incidence of osteopenia
and osteoporosis was 49% and 10%, respectively (A. C. Looker et al., 2010). Among
older adult men, 36% had osteopenia, and 2% had osteoporosis (A. C. Looker et al.,
2010) estimating that 5.3 million older men and women had osteoporosis at the femur
neck and an additional 34.5 million had osteopenia. In data gathered by NHANES in
2005-2006, femur neck osteoporosis prevalence was lower by three percentage units in
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men and by seven percentage units among women compared to the 1988-1994 data
(Looker et al., 2010). Decreased prevalence in the 2005-2006 data may be attributed to
differences in DEXA technology even though the same manufacture scanner was utilized.
The 1988-1994 study, a first-generation pencil-beam scanner was used while the 20052006 study a third-generation scanner was employed. The authors attempted to adjust the
data to control for the scanner change, but the first generation scanner had few published
studies with direct comparison to the third generation scanner, and reported mixed results
of significant differences. Further, correlations for the decline in femoral osteoporosis
were not strongly associated with changes in body mass index or the use of osteoporosis
medication. When combining the incidence of osteoporosis and osteopenia from the
2005-2006 data compared to the 1988-1994 data, more older adults had low femur neck
BMD in 2005-2006, possibly due to the increased aged population (Looker et al., 2010).
Regardless of the decline in prevalence, the estimates of how many older adults
experience these conditions remain high.
Falls, Fractures, and Frailty
Because falls are the leading cause of death by unintentional injury for individuals
65 and older (Avdic (Avdic et al., 2004), Pecar, & Mujic-Skikic, 2004; Centers for
Disease Control and Prevention (Centers for Disease Control and Prevention National
Center For Injury Prevention and Control [CDCP-NCIPC], 2005; 2010a; 2010b; Centers
for Disease Control National Center for Injury Prevention and Control Office of Statistics
and Programming, 2003) mortality rate has also increased over the past decade (Stevens,
2006). Bone loss (osteoporosis) has been associated with falls and fractures (Sinaki et al.,
2002; Suh & Lyles, 2003; WHOSG, 2003) and a little over a half a million low impact
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falls result in osteoporotic fractures (Morrison et al., 2013). In 1999, in the European
Union, the Osteoporosis Foundation reported that every 30 seconds an individual has a
fracture resulting from osteoporosis (World Health Organization, 1999).
Vertebrae are particularly rich in cancellous tissue (spongy), and the hip and wrist
are rich with cortical bone (dense) (Wyngaarden, Smith, & Bennett, 1992). Vertebral
compression fractures are the most common osteoporotic bone injury often experienced
by women 45-60 years of age occurring in the early stages of the bone loss disease
process. They occur asymptomatically while performing normal activities of daily living
such as lifting, and occur three times more often than hip fractures (Harvey et al., 2013).
As the bone loss disease process progresses, cortical composite weakening occurs
and the prevalence of wrist and hip fractures become apparent (Wyngaarden et al., 1992).
A wrist fracture most commonly occurs when a women falls sideways or backwards and
uses her arm to break the fall, thus breaking their wrist (Melton & Cooper, 2001). A fall
induced hip fracture is the most serious osteoporosis-associated incidental fracture
resulting in permanent disability (Harvey et al., 2013; WHOSG, 2003). Hip fractures
most commonly occur at the femoral neck resulting from landing directly on the hip
during a fall (falling sideways) rather than falling forward (NIH-CDPO, 2001). As early
as 1990, the WHO declared that hip fracture may become a worldwide epidemic by the
middle of the 21st century, increasing from an incidence of 1.7 million in 1990 to a
projected 6.3 million by 2050 (C. Cooper, Campion, & Melton, 1992). Therefore,
impaired bone strength predisposes older adults to fracture when they fall and may lead
to the development of frailty (Runge & Hunter, 2006; Suh & Lyles, 2003). This transition
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may be acute if it stems from a “triggering event,” such as a hip fracture (Hamerman,
1999).
Frailty is often described as a decline in the functioning of the neuromuscular
system, abnormal aging, vulnerability to adverse health outcomes, and loss of
physiological reserve to handle minor stresses (Abate et al., 2007; Hamerman, 1999;
Kinney, 2004; Morley, 2002) and is most frequently identified in older adults over 85
years of age (Suzman, Willis, & Manton, 1992). The current prevalence of frailty in
persons aged 65 and older ranges from 4.0% to 17% (Collard, Boter, Schoevers, & Oude
Voshaar, 2012).
As the number of older adults increases, fall-risk will increase, as well as the
incidence of fall induced osteoporotic fractures. There is an extensive body of literature
concerning the study of bone loss and interventions to prevent bone loss over that past 15
years; however the incidence of osteoporosis remains relatively unchanged. Thus,
investigating innovative technologies that may improve bone cell function and overall
skeletal health in this population remains critical to preserve an older adult’s quality of
life is important.
Near-Infrared Light Emitting Diodes
Presented are a brief overview of the use of Near-Infrared Light Emitting Diodes
(NIR-LED) and rational for the proposed method of experimentation in a cell culture
model. A short review of associated tenets of aging affecting bone health, oxidative
stress, mitochondrial dysfunction and increased apoptosis is presented broadly and then
related to the aging skeleton. This section will end with the research questions
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formulated to begin a program of research investigating a potential intervention for the
treatment and management of osteoporosis.
The spectrum of electromagnetic radiation (ER) includes light and ranges from
radio waves to gamma rays. Light has amplitude (brightness), and wavelength defines
the color and angle of wave vibration. According to quantum theory, ER contains
particles called photons, packets of energy that move at the speed of light (Chung et al.,
2012). Typically a laser output is a narrow beam of light often named a “pencil beam”
(Chung et al., 2012). The peak irradiance is greatest at the center of the beam and
dissipates outward.
Light Emitting Diodes (LED) are semiconductors of light and emit low-intensity
red light in ultraviolet and infrared wavelengths (Chung et al., 2012). The mechanism
that occurs within the diode releases energy in the form of photons (electroluminescence
and color of light). An LED is less than 1mm2 in diameter, thus, LED devices are made
with numerous LED lights. The optical window of low level laser light treatment
(LLLT) is in the red and near-infrared wavelengths (600–1070 nm). Wavelengths that
effectively treat superficial tissues range between 600 and 700 nm and deeper tissues
require longer wavelength ranges between 780–950 nm. Wavelengths that are longer
range, that is, between 700–770 nm, have little biological effect (Chung et al., 2012).
Initial research used a Helium Neon (HeNe) laser at a wavelength of 632.8-nm. Most
recently semi-conductor diode lasers such as gallium arsenide lasers (GaAs) are used. It
is unknown if there really is a difference between lasers and LEDs.
In search of innovative technologies for interventions that may improve bone cell
function and skeletal health, particularly those that would inform the understanding of
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osteoclast differentiation (bone-resorbing cells), the pilot use of Near Infrared LightEmitting Diodes (NIR-LEDs) photobiomodulation was proposed as a possible future
intervention to treat bone loss and/or preserve bone health. Although the focus of this
study was to determine the effects of photobiomodulation upon osteoclastogenesis, it is
important to understand the cellular effects noted in the NIR-LED literature for future
research questions that may be appropriate to determine cellular effects in osteoclasts.
The theory of biological aging related to human aging has been associated with
cellular oxidative stress (OS) and mitochondrial dysfunction (Melov, 2000), and these
may induce bone loss (Srinivasan & Avadhani, 2007). Thirty years ago, somatic genetic
errors, mutations of the nuclear genome, were postulated as a basis for aging (Hayflick,
1985b; Shock, 1985) by negatively altering cell metabolism, resulting in free radical
oxidative stress (ROS) (Hayflick, 1985a). Research about mitochondrial DNA (mtDNA)
indicates that mutations of the mitochondrial genome are vulnerable to oxidative damage
(Linnane, Marzuki, Ozawa, & Tanaka, 1989) and may cause degenerative diseases and
aging.
Cell mitochondria, which are producers of cell energy, regulators of apoptosis—a
naturally occurring process of programmed cell death—and cell function, are vulnerable
to OS and have an essential role in accelerating cell death (Dirks & Leeuwenburgh, 2005;
Joza et al., 2005). Oxidative stress can result from the generation of excess free radicals
(Beckman & Ames, 1998) which causes an imbalance with cellular antioxidants that, in
turn, damages cellular components and function.

Specifically, free radicals are highly

unstable and reactive with other molecules, and can instigate oxidative cell destruction.
The oxygen molecule has an atypical placement of electrons within electron orbitals and
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oxygen prefers to accept one electron at a time during chemical reactions, rather than two
electrons. Accepting two elections at a time would keep the oxygen molecule in a stable
state. When electrons are accepted one at a time, the oxygen molecule becomes unstable;
and superoxide (O2-) and hydrogen peroxide (H2O2) are generated. These reactive oxygen
species undergo further biochemical cellular reactions, and results the production of
extremely reactive molecules such as hydroxyl radicals (OH-) (Beckman & Ames, 1998)
affecting mitochondrial function, and cellular energy production.
The aging skeleton is associated histologically by bone wall thinning due to a
decreased bone matrix depositing (Almeida & O'Brien, 2013). This is thought to be due
to an insufficient number of functioning osteoblasts available for mineral deposit related
to decreased bone marrow mesenchymal stem cells (MSC) (precursor osteoblast and
adipocyte cells), poor differentiation of osteoblast progenitor cells or more progenitor
cells utilized for adipocyte formation rather than osteoblastogenesis, as well as apoptosis
(cell death) (Almeida & O'Brien, 2013; Muruganandan, Roman, & Sinal, 2009). The loss
of the ability for MCS cells to regenerate due to aging leads to a diminished
compensation to stress and increase reactive oxidative species. The use of NIR-LED may
decrease oxidative stress and improve mitochondrial function by affecting COX-IV, a
specific segment of the cell’s energy production system, thus enhancing cell function
(Karu, 2008).
The use of NIR-LED (630-1000nm) photobiomodulation—an FDA-approved
treatment—has been found to be effective in improving wound healing (Whelan et al.,
2003), bone regeneration (Pinheiro et al., 2009), mitochondrial function (J. T. Eells et al.,
2004; Wong-Riley, Bai, Buchmann, & Whelan, 2001), attenuating cellular oxidative
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stress (Desmet et al., 2006; Karu et al., 1987), decreasing inflammation and pain, aiding
in recovery of ischemic cardiac injury (Oron, 2006; Oron et al., 2001), and attenuating
retinal/optic nerve degeneration (Eells et al., 2007; Eells et al., 2004; Eells et al., 2003;
Liang et al., 2006). Reducing oxidative stress delays the activation of the apoptotic
signaling pathways, thus preventing bone loss and mitochondrial dysfunction (Banfi,
Iorio, & Corsi, 2008). Mitochondrial dysfunction has been reported in several slowdividing tissue types such as central nervous system, cardiac, skeletal muscle, and liver
tissues (Nagley et al., 1992; Varanasi, Francis, Berger, Papiha, & Datta, 1999).
Investigators have suggested that mitochondrial dysfunction and sarcoplasmic reticulum
stress may stimulate apoptosis and alter the mechanical signaling in bone (Booth &
Criswell, 1997; Hock et al., 2001).
Photobiomodulation, also referred to in the literature as low-level laser therapy,
cold-laser therapy, or laser biostimulation, was introduced in the 1980’s. Laser lighttreatment uses light in the infrared to near-infrared region of the absorption spectrum
(630-1000nm), as this range is known to affect numerous cell functions that are
dependent on the energy production in the mitochondria (Desmet et al., 2006; Karu et al.,
1987). (Karu (1988) ) postulated that the mechanism of the effect of a low-power laser is
at the cellular level due to changes in components of the electron transport chain system
within the mitochondria.. The electron transport system of the cell is directly related to
the production of Adenosine triphosphate (ATP), the primary energy compound for the
cell.
The role of the electron transport chain oxidation reaction pathway (redox)
transfers electrons and signals synthesis of apoptotic proteins activating the caspase-3
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pathway (Hock et al., 2001; Karu, 1999). This cascade is responsible for signaling
apoptosis (programmed cell death). It occurs when the signal leaves the mitochondria,
fueling cytoplasmic transcription factors, which upregulates cytoprotective and
antioxidant genes that are thought to prevent free radical damage from oxidative stress.
This increased transcription preserves cell survival (Eells et al., 2007; Karu, 2003; Squier,
2001). The mechanism of action may be through release of nitrous oxide or initiating
superoxide signaling. Further, transcription factor nuclear factor B (NF-κ-B), regulated
by changes in cellular redox state, is activated with low level light treatment producing
protective and stimulatory gene products (Huang, Sharma, Carroll, & Hamblin, 2011).
Light treatment may improve oxidative metabolism and mitochondrial function, and
preserve cell life. It still remains unknown if the activation of macrophage nuclear factor
B (NF-κ-B) is helpful in attenuating osteoclastogenesis.
In order to study light treatment, researcher must understand how to calculate the
correct irradiation parameters. To define LLLT according to the “medicine” (irradiation
parameters) and “dose” (irradiation time) standards, delivery is a key to understanding
and developing interventions using light treatment. Energy Density J/cm2 often reflect
the dose of treatment, however, energy has two components, power and time. Energy (J)
= Power (W) x Time (s). There is reciprocity between the variables meaning that if the
power was doubled and the time is cut in half the same energy is delivered but a different
biological effect would be seen (Huang et al., 2009). It is best to describe the parameters
separate, irradiation parameters and dose. This study used a continuous wave NIR-LED
with a wavelength of 670nm, power intensity of 60mw/cm2 delivering and energy density
of 4.5 J/cm2 and 45J/cm2 in 80 and 800 seconds, respectively.

18

Methods
Cell Culture Model
A cell culture model was chosen because a proposal to test any kind of
intervention in a vulnerable population of older adults gives rise to many ethical
considerations. For example, directly extracting bone cells in a human model by a
researcher would be an invasive and painful procedure (WHOSG, 2003). Interventions
that alter the cellular function of bone cells require a careful progression of research.
Thus, to gain an understanding of the efficacy and safety of a technology that is
known to alter cellular functioning, an appropriate place to begin would be in a cell
culture model because an in vitro method is economical compared to animal and human
models, easily implemented for experimental replication to interpret data for protocol
development determining dose response curves, and is exempt from Institutional Review
Board submission. This research was undertaken using a cell culture model with RAW
264.7 animal cell line derived from mouse leukemia monocyte macrophages. These cells
are precursor osteoblastic cells (macrophages). This particular cell line requires the
induction of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) in order to
promote osteoclast formation. The induction method occurs when osteoblast stromal cell
membrane RANKL receptors, bind to the osteoclast precursor cell (macrophage) RANK
receptors. When this occurs, RANK signaling activates the transcription nuclear factor
Kappa-B to differentiate into osteoclasts (Kumar, 2010).
Two manufactures of RANKL (SigmaTM & PeproTechTM) were tested to
determine the best ligand to induce osteoclastogenesis because of poor osteoclast cell
counts in preliminary experiments. In order to determine if cellular response occurred
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during RANKL suspension, a vehicle control of Bovine Serum Albumin (BSA) was
tested and was found to be negative and the stability of the RANKL was preserved.
Based upon results of robust cell culture experiments, progressing the research
into an animal may be advantageous to begin using primary cells obtained directly from
experimental animals and, ultimately, if the intervention were deemed safe and beneficial
at the cellular level—a human model may be appropriate to further bridge research from
bench to bedside using non-invasive measurements of bone-mineral density. In other
words, if the outcomes from the cell culture model warrant positive effects, the research
could progress to experimentation in animals. In an animal model, the researcher is able
to use skeletal remains, thus enabling direct maceration of a whole bone in order to flush
and extract bone cells which are closer to human cells for study (Rittweger, 2007). If the
experimental treatment is deemed efficacious and safe in animals, then it may be
undertaken in human model.
In order to understand maximal does for RANKL and energy density dose
response curves were conducted in the experiments. Biphasic response has occurred in
low level light treatment (LLLT) research (Huang et al., 2009) however, a biphasic dose
response curve for RANKL is lacking in the literature. The “Arndt-Schultz Law”, the
model to describe dose dependence, states a weak stimuli will induce slight activity,
while a stronger stimuli will induce activity higher, but once a peak is reached (minimal
threshold) an even stronger stimuli will suppress the activity until it has a negative
response (Huang et al, 2009). Therefore, the biphasic curve, described as insufficient
energy, is applied there will be no response, if more is provided then the minimal
threshold is crossed, but if too much energy is given, the response will disappear. Huang
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and colleagues (2009) report that energy density (J/cm2) is used to describe the light
treatment dose, however, the energy density has two components, power and time. They
recommend describing the light treatment as two variables, the medicine (irradiation) and
the time (dose).
Purpose
Our primary goal in this study was to determine the effects of NIR-LED
treatment on osteoclast cell differentiation (osteoclastogenesis) in cell-cultured
RAW264.7 cells using the WARP 75 ™ NIR-LED light. Our specific research questions
and hypotheses were as follows.
Question 1. Is there a difference in osteoclast cell count between single lighttreated Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-induced cell
cultures as compared to non-light-treated controls? Hypothesis. Single light-treatment
of RANKL-induced cell cultures will impair osteoclastogenesis.
Question 2. Is there a difference in osteoclast cell count between light-treated
RANKL-induced cell cultures treated at different energy densities of light-treatment
(2.25, 4.5 and 45 J/cm2) compared to non-light-treated controls? Hypothesis. Lighttreatment of RANKL-induced cell cultures at a higher energy density (45 J/cm2) will
stimulate less osteoclastogenesis compared to lower energy densities (2.25 and 4.5
J/cm2).
Question 3. Is there a difference in osteoclast cell count between single lighttreated RANKL-induced cell cultures compared to multiple light-treated RANKLinduced cell cultures? Hypothesis. Multiple light-treatments of RANKL-induced cell
cultures will stimulate osteoclastogenesis less compared to single light-treated RANKL-
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induced cell cultures.
Experimental Control Research Question- Dose Response Curve: Is there an
expected biphasic dose dependent response curve in RANKL induced (0ng/ml, 2.5ng/ml,
10ng/ml, 25ng/ml and 50ng/ml) cell cultures? Hypothesis: Lower dose RANKL-induced
cell cultures will have lower osteoclast cell counts than higher dosed RANKL cell
cultures until the minimum dose threshold is reached then osteoclast cell counts then will
decrease inversely.
Implications
Conducting research brings a strong commitment and responsibility to
disseminate results to impact public policy, nursing practice, and research. Nursing
historically is rich with political activism. From the beginning of nursing’s evolution
pioneers such as Florence Nightingale and Lillian Wald began over a century ago to
improve deplorable hospital conditions and public health for all (Backer, 1993;
Nightingale, 1989). Nursing in the past has also been dominated by the political
influences of medicine. Due to subsequent professional conflicts, advocacy for
vulnerable populations at times was challenging (Mechanic & Reinhard, 2002). As
nursing has become more autonomous and has experienced professional growth, progress
is made working collaboratively with medicine and other bench scientists through
multidisciplinary professional organizations, advanced practice nursing, clinical practice
settings and public policy to bridge new partnerships.
Nursing Practice and Research
Nurses are interested in investigating new interventions to prevent or treat
osteoporosis because of its primary commitment to the patient, as nurses advocate and
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protect the health and safety of patients, as well as improve the quality of care (American
Nurses Association, 2001). Nurses recognize evidence based practice (EBP) as the gold
standard for providing safe and compassionate care (Brown, Wickline, Ecoff, & Glaser,
2009). Evidenced based pracice is recognized by the American Nurses Credentialing
Center’s Magnet programme as key component for quality care (McClure & Hinshaw,
2002). Nurses many times are the most prevalent and consistent health care provider that
older adults encounter throughout their health care service delivery. Nursing has the
opportunity to identify individuals at risk and implement timely interventions to prevent
disease or implement the most beneficial appropriate intervention for the patient. This
type of interventional research is the first step in moving bench science to the bedside.
Per the National Institutes of Health, translational research can be defined as a
two stage process: the application of innovative laboratory research into preclinical
studies to design human clinical trials and translation with implementation of best
practices into the community objectives to achieve cost-effectiveness in prevention and
treatment (National Institutes of Health, 2007). Research is transferred from the
laboratory’s bench (basic research) to the patient’s bedside (clinical research) then
clinical study and trial findings transferred into the community and practice settings to
improve health outcomes (Rubio et al., 2010).
Public Policy
As stated previously, the older adult population is aging in great numbers every
day. In fact, fracture totals in 2005 were estimated to be 20 million with a cost to treat
$17 billon, and estimated by 2025, fracture rate and costs will increase 50% (Burge et al.,
2007).

This program of research has one main public policy implication to discover
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interventions to treat and manage osteoporosis in an effort to preserve, re-build and
strengthen bone architecture. This in turn may ultimately decrease the incidence of
fracture rate and impact cost containment to treat osteoporotic-induced fractures.
Once significant benefit is established, the medical device must be approved by the
Federal Drug Association (FDA). Choosing the use of an FDA approved device avoids
the arduous process of establishing efficacy and safety. NIR-LED light used in this study
is an FDA approved device invented by Quantum Devices Incorporated (Barneveld, WI)
and was developed as a NASA technology entitled High Emissivity Aluminiferous
Lighting Substrate TM (HEALS), to grow plants for long-term space flight. Receiving
FDA approval, they successfully developed a commercial device; the Warfighter’s
Accelerated Recovery by Photobiomodulation (WARP 10), a portable Near Infrared
Light Emitting Diode (NIR-LED), used in combat to provide first aid for minor injuries
and pain and received FDA approval. In 2000, they received a Space Technology Hall
Of Fame Award for their Innovation of Light Emitting Diodes for Medical Applications
(National Astronautical Space Agency, 2008; Quantum Devices Incorporated, 2004).
Nursing and NASA technology have common goals, the care of astronauts and
patients. Since 1976, 1,300 space related technologies have been applied to industry,
daily life, and patient care (Plush & O’Rangers, 2004). Such examples include: cellular
phones and personal data assistants (PDAs), CT scanners/MRI, as well as the ventricular
assist device, a miniature heart pump based upon a NASA fuel pump which was
developed by Michael DeBakjey, MD (Plush & O’Rangers, 2004). Further, the
translation of technology has been made in this current study, as the NIR-LED was
developed for NASA to grow plants during space flight (National Astronautical Space
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Agency, 2008). Given time and funding, this proposed new intervention to either prevent
or treat osteoporosis has promise.
Future Chapters
The subsequent chapters of this dissertation are comprised of three manuscripts
on the topics of osteoporosis and current interventions as well as a summary chapter.
Chapter Two, the review of the literature, is divided into two sections; thus, two review
manuscripts were written according to submission guidelines for MEDSURG NURSING:
Official Journal of the Academy of Medical-Surgical Nurses. Manuscript One, New
Insights-Understanding the Etiology and Consequences of Osteoporosis, provides an
overview of the definition, significance, incidence and pathophysiology for osteoporosis.
This is followed by a discussion regarding outcomes of this pathology, osteoporotic
induced fractures and frailty. Manuscript two Nursing Implications for Osteoporosis
Management, reviews current nursing implications for the generalist nurse and
recommendations for nursing process, as well as pertinent osteoporosis medical
management to inform the nurse’s knowledge base.
The experimental bench research protocol development at the NASA Ames Bone
and Signaling Laboratory that was consequently used for the experiments in the final
manuscript is described in chapter III. The specific protocols are found in Appendix AG, tables Appendix H and letters of permission Appendix I. Further, the preliminary
data that were collected during the piloting of the experimental protocols are presented in
this chapter.
In Chapter IV, the third manuscript, experiment pilot data, considered the
dissertation study as described. This manuscript was presented at the 62nd International
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Astronautical Congress: African Astronaissance, Cape Town, South Africa, on October
3-7, 2011. Lastly in, the relationship between manuscripts is reviewed. Findings are
discussed, conclusions and limitations highlighted, and directions for future research
offered.
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CHAPTER TWO: REVIEW OF THE LITERATURE
This chapter is divided into two sections comprised of two manuscripts prepared
for submission to MEDSURG NURSING: Official Journal of the Academy of MedicalSurgical Nurses. These manuscripts comprise a two-part series. The first manuscript,
entitled New Insights-Understanding the Etiology and Consequences of Osteoporosis and
the second, entitled Nursing Implications: Osteoporosis Management set the stage for
the dissertation reported in Chapter Four. The first manuscript provides the context by
clarifying definitions, highlighting the prevalence, reviewing normal physiology and
pathology of bone, factors to consider for making the diagnosis of osteoporosis, and
osteoporosis health outcomes. Manuscript two is a review of current nursing
implications for the generalist nurse with recommendations for nursing interventions,
new insights in osteoporosis management.
Manuscript One
New Insights-Understanding the Etiology and Consequences of Osteoporosis
Abstract
Osteoporosis is a growing worldwide public health problem given the increasing
numbers of individuals over the age of 65, affecting 75 million people in Europe, Japan
and the United States. Osteoporosis, described as compromised bone strength, is a silent
epidemic occurring virtually unnoticed, associated with staggering consequences of
osteoporotic induced fractures, specifically, hip fracture. In the near future, due to
primary care provider shortages, generalist clinicians will be responsible to provide the
majority of health care to those at risk for this condition. It is important that generalist
nurses become familiar with the basic underpinnings associated with this disease process.
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The purpose of this review is to provide the generalist nurse with the most current
definition, an overview of bone physiology and pathology, including its causes, and
summarizes the negative health outcomes, including the societal financial burden.
Further, new insights in osteoporosis management for evaluation of bone architecture and
strength, new medications, and new therapies; Near-Infrared Light Emitting Diodes
(NIR-LED) treatment and whole body vibration (WBV) therapy are introduced.
Introduction
Osteoporosis, the most common bone disorder (National Institutes of Health
Consensus Development Panel on Osteoporosis [NIH-CDPO], 2001) is quickly becoming
a worldwide public health problem (International Osteoporosis Foundation, 2013). Given
the increasing numbers of individuals over the age of 65 and that it affects 200 million
people (Burge et al., 2007; Colón-Emeric, 2013). Older adults with low bone mineral
densities (BMD) are at risk for fracture when they fall. Therefore, the risk of
osteoporotic-induced fractures, specifically those of the hip, increases as persons age
(Rizzoli, 2010). Hip fractures experienced by the older adult population are one of the
most serious sentinel events that are associated with overall morbidity and mortality, and
are associated with high treatment costs to the health care system. It is projected that by
the year 2030, the US older adult population will double to 71.5 million, 8.9 million of
whom will be over the age of 85 (U.S. Department of Health and Human Services
Administration on Aging, 2006), thus being the fastest-growing sector of the U.S.
population. Similar projections apply globally with a world population of individuals
over 60 years reaching approximately two billion by the year 2050 (United Nations,
2010). Over time, this older adult population will become vulnerable for disability,
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morbidity, and mortality due to aging (Ostir, Ottenbacher, & Markides, 2004). The focus
of this manuscript is on individuals over aged 50 years.
Osteoporosis-induced fractures burden society by over-use of available medical
resources (Burge et al., 2007). In 2008, estimated US costs to treat osteoporosis and
fractures was reported as $22 billion (Blume & Curtis, 2011). Within a year of fracture,
one third of cases are admitted to long-term care; of these, 20% are found to be frail
(Orsini et al., 2005). In 2005, the cost associated with two million fractures was
estimated to be $17 billion, of which 72% of the expenditures were spent to treat hip
fractures. Costs are projected to increase approximately by 50% (Blume & Curtis, 2011;
Burge et al., 2007). However, these figures do not take into account indirect costs such
as lost wages or the decrease productivity of caregivers or the post-fracture medical
management expenditures (NIH-CDPO, 2001). Kilgore et al. (2009) reported the average
cost to treat a wrist fracture was $7788 and an open hip fracture $31,310 (Iowa
Foundation for Medical Care, 2008). Given current societal demographic growth and
rising healthcare cost it will become imperative to identify individuals at risk for falls,
screen for bone loss and implement appropriate tailored interventions to improve bone
loss and prevent falls. This in turn will ultimately impact morbidity and mortality
outcomes and conserve medical resources. In order to achieve these objectives, nurses
must build a foundation of knowledge stemming from the basic physiological and
pathological tenants associated with bone loss.
Osteoporosis is a silent epidemic because it occurs without symptoms or pain.
While considerable literature exists on this topic (European Foundation for Osteoporosis
and Bone Disease & National Osteoporosis Foundation, USA [EFOBD & NOFUSA],

29

1997; National Guideline Clearinghouse [NGC], 2006 [Revised 2010]; North American
Menopause Society [NAMS], 2010; World Health Organizaiton Scientific Group
[WHOSG], 2003), synthesizing the literature can be time consuming. Therefore, the
purpose of this critical review of the literature is to provide the generalist nurse with the
most current definition, an overview of bone physiology and pathology, causes, and
health outcomes. Fall-induced fractures, especially hip fractures, are highlighted given
their association with osteoporosis, in terms of their health, social, and financial toll.
Lastly future proposed cellular level physiological research utilizing near-infrared light
emitting diode treatment (NIR-LED) that may impact reversing, preventing, or slowing
bone loss is discussed. Nursing implications are discussed in another manuscript.
Method
An extensive search of the literature published between 2000 – 2013 was
conducted focusing on osteoporosis, its etiology, and societal and health outcomes.
Databases searched included PubMed, CINAHL, Academic Search Complete/EBSCO,
Medline, National Guideline Clearinghouse, Google Scholar, Primo Central/Ex-Libris, as
well as references from articles and books. Moreover, a Google web search was
employed to gather full text copies of standards and guidelines. Seminal articles prior to
1999 were subsequently authenticated from the extrapolated literature. Expert identified
literature also was reviewed. Of note, the Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism, eighth edition which is distributed to the entire
membership of The American Society for Bone and Mineral Research, was utilized to as
the source of leading expert bone health researcher opinions (Rosen, 2013).
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The following key words were used: bone, in combination with physiology,
pathology, remodeling, architecture, apoptosis, osteoblasts, osteoclasts, bone turnover,
NIR-LED, low level light laser therapy, and whole body vibration treatment. The term
osteoporosis was searched in combination with epidemiology, definition, guidelines,
position statement, primary and secondary causes, risk factors, cost analysis, fall induced
fractures, hip fracture/risk, falls and frailty and was limited to English. However, the
main focus of the search was on the age group of 50+ years.
The search, when feasible, was limited to meta-analyses (2), systematic reviews
(4), clinical cohort studies (18), epidemiological studies (11), professional guidelines (1),
position statements (6), government reports (8), theory (3), reviews of literature (29),
bench research (10), articles from peer-reviewed journals (75), professional texts (14),
and one qualitative study. Whenever possible, each article was critically evaluated for
quality and reliability using the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) checklist as a guideline to evaluate academic peer-reviewed
articles (Moher, Liberati, Tetzlaff, Altman, & The Prisma Group, 2009).
Findings
Findings are summarized in the following order: definition, incidence, and
significance for osteoporosis followed by an overview regarding bone physiology and
pathology associated with bone demineralization, identifying the primary and secondary
cause of osteoporosis, negative health outcomes, and societal financial burden. Lastly,
new alternative osteoporosis identifying diagnostics, medications and bioengineering
treatment such as NIR-LED treatment and whole body vibration (WBV) therapy are
discussed.
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Definition and Diagnosis for Osteoporosis
The definition of osteoporosis, evolving over time through a series of professional
position statements, is often described as compromised bone strength (EFOBD & NOFUSA, 1997; NIH-CDPO, 2001). It is defined conceptually as a skeletal disease
characterized by low bone mass and structural deterioration of bone tissue, leading to
bone fragility and an increased susceptibility to fracture, especially of the hip, spine, and
wrist (EFOBD & NOFUSA, 1997; NIH-CDPO, 2001).
The World Health Organization (WHO) defines osteoporosis by diagnostic
assessment of bone mineral density (BMD) measurements that categorize the degree of
bone loss (WHOSG, 2003). The diagnosis of osteoporosis is identified by reduced bone
density of vertebral and/or femur cortical and cancellous bone. Using dual energy x-ray
absorptiometry (DEXA) scanning, reported as grams of mineral per area volume, a bone
mineral density (BMD) that exceeds 2.5 standard deviations (SD) below the mean BMD
found in 30 year old women, diagnoses osteoporosis (EFOBD & NIHUSA, 1997; Kanis,
1994; NIH-CDPO, 2001; WHOSG, 2003). (see Table 1)
Incidence
In the US, osteoporosis affects approximately 10 million people over the age of
50 years of those, 8 million are women. In addition, 34 million Americans are at risk for
developing osteoporosis due to low bone mass (osteopenia) (Harvey, Dennison, &
Cooper, 2013; A. C. Looker, Melton, Harris, Borrud, & Shepherd, 2010). The incidence
of osteoporosis is more common in women than men due to postmenopausal hormonal
changes and a longer life expectancy (NIH-CDPO, 2001; WHOSG, 2003).
Due to ethnic differences in bone and mineral metabolism (Norris, Micklesfield,
& Pettifor, 2013), osteoporosis is present more often in Caucasian than Hispanic and
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African American women. Few data exist that report ethnic patterns in men; however
trends are similar to women. When comparing incidence rates of osteoporosis and
osteopenia between 2005-2008, 9% of non-institutionalized 50 year old Americans had
osteoporosis of either the femur neck or lumbar spine and approximately 50% had
osteopenia (Looker, Borrud, Dawson-Hughes, Shepherd, & Wright, 2012).
Bone Anatomy
The generalist clinician should have an appreciation of bone anatomy and
physiology so that he or she can practice knowledgeably and understand how
interventions to prevent and treat osteoporosis affect these physiologic pathways. Bone
is best described according to its function, architecture, and tissue type. Bone remodeling
occurs throughout the lifespan and has a specific systematic process in reabsorbing and
replacing bone.
Function. Anatomically, the function of bone supports the body while standing
erect, protects vital organs, and assists ambulation and movement through muscular
system linkages. Physiologically, bone is responsible for the manufacture of blood cells
in the bone marrow and serves as a reservoir for phosphorus, magnesium, and 99% of the
body’s calcium. Further, the bone’s ability to maintain metabolic function is achieved by
mineral homeostasis through acid-base balance (Boskey & Robey, 2013; Hadjidakis &
Androulakis, 2006; Sherwood, 2013).
There are two parts to the skeletal system: the axial skeleton (the cranium, thorax
and vertebral column), and appendicular skeleton (upper and lower extremities) (Porth,
2009). Every bone has an extracellular matrix (ECM) which is comprised of two main
components: mineral composite and collagen, as well as water, proteins, and lipids
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(Boskey & Robey, 2013). The mineral composite is made of hydroxylapatite, which are
mainly calcium phosphate salts, providing strength via crystallization around the collagen
fibers in the ECM. Collagen type I is the basic building block of the bone matrix and
contributes to bone strength (Sherwood, 2013).
Bone Architecture. There are two types of bone matrix: cancellous (spongy)
bone and cortical (compact) bone. Both types of bone matrix are found in all bone;
however, the relative contribution of cancellous and cortical tissues to a given bone varies
(Porth, 2009). Cancellous bone, found within the bone’s inner core, comprises 20% of
the skeleton, and is often referred to as trabecular bone because trabeculae form a lattice
pattern (Adler, 2000; Hadjidakis & Androulakis, 2006). The lattice is lined with bone
marrow and osteogenic cells and is fairly light, but able to withstand tensile strength for
weight bearing (Porth, 2009; Seeman, 2008), 2008). Cancellous bone is described as
being elastic compared to cortical bone (Hadjidakis & Androulakis, 2006). Vertebrae are
particularly rich with cancellous or trabecular bone. Cortical bone comprises
approximately 80% of the skeleton. It is a rigid, densely calcified, and compact matrix
that forms the bone’s outer shell, and it is the predominate type of tubular bones found in
the upper and lower extremities, hip, and wrist. Structurally, cortical bone is more
resistant to bending and torque (Hadjidakis & Androulakis, 2006; Porth, 2009).
Two important considerations in evaluating the bone quality are bone structure
and strength. Bone structure determines the energy load that bone can withstand, and the
energy load in turn affects the bone structure through adaptation by modeling and
remodeling bone tissue in response to the energy load (Seeman, 2008). Currently, bone
quality remains indefinable by current dual energy x-ray absorptiometry bone mineral
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testing (DEXA BMD) testing. Because spine and hip Bone Mineral Density (BMD) can
estimate approximately 70% of bone strength (Suh & Lyles, 2003), newer technologies
for measurement of bone quality may be achieved through areal BMD measurement
using computed tomography (Genant et al., 2008; MacNeil, Boyd, MacNeil, & Boyd,
2008). BMD, however, does little to help the clinician evaluate bone architecture. It is
important to understand that an increase in BMD does not always render improved bone
quality, a result that may affect true bone strength considerably. Recently, trabecular
bone scores (TBS) are being researched as an added measurement and may become a
standard measurement with traditional DEXA testing (TBSiNsight, 2014).
Bone architecture determines the energy load that a bone can withstand, and the
energy load in turn affects the bone architecture through adaptation. Remodeling bone
tissue responds to the energy load exerted upon that bone structure (Seeman, 2008). The
greater the energy load, the greater the rate of bone deposition or density and excess load
beyond bone tensile strength results in fracture (Sherwood, 2013). Therefore, weight
bearing exercise is imperative for bone architecture. Moreover, in order for one to stand
erect against gravity, the bones collectively must function like levers; they must be stiff
and able to resist buckling when absorbing energy, such as a spring (Seeman,
2008). Bone acting as a “spring” must change shape without cracking, must shorten or
widen according to the compression that the energy load expends, must lengthen or
narrow in tension, and remain light enough to allow for rapid motion (Seeman, 2008). If
bone is too stiff or too flexible, however, bone fragility may occur
Bone Tissue and Cells. There are two types of bone tissue: woven and lamellar.
Both types can be either mineralized or unmineralized (osteoid). Woven bone is not
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strong and is rapidly deposited as a temporary structure during fracture healing. Lamellar
bone is matured bone that forms slowly and is highly organized.
There are four types of bone cells that contribute to the formation and
maintenance of bone: osteoprogenitor cells, osteocytes, osteoclasts, and osteoblasts
(Porth, 2009). Osteoprogenitor cells are undifferentiated cells that are the source of all
bone cells except osteoclasts which originate from monocyte/macrophages within the
hemopoietic lineage. Osteocytes are mature bone cells that maintain the bony matrix. In
addition, they may respond to bone tissue strain and recruit osteoclasts to areas of bone
requiring bone repair/remodeling (Lanyon, 1993). There are interconnected
passageways, canaliculi, found throughout the calcified matrix that contain extracellular
fluid (Hadjidakis & Androulakis, 2006) that provide a communication network between
the neighboring osteocytes and blood system for the exchange of nutrients and
metabolites because diffusion does not occur is calcified bone (Porth, 2009).
Osteoclasts and osteoblasts are two types of cells within mineralized bone that
contribute to mineral homeostasis (Lemaire, Tobin, Greller, Cho, & Suva, 2004). They
are responsible for building and maintaining bone structure. Osteoclasts are boneresorbing cells that originate from monocyte/macrophages within the hemopoietic
lineage, and their activity is regulated by osteoblasts, bone-forming cells, and numerous
hormones and other growth factors, macrophage colony-stimulating factor (M-CSF),
interleukin-1 (IL-1), and tumor necrosis factor (TNF) (Hock et al., 2001). Osteoblasts
are differentiated mesenchymal stem cells, responsible for lying down the new bone
matrix that becomes mineralized, thus replacing old bone previously reabsorbed by
osteoclasts (Hadjidakis & Androulakis, 2006; Hock et al., 2001).
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There are two pathways that induce osteoclastogenesis. On the osteoblast
stromal cell membrane, Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)
receptor, binds to the osteoclast precursor cell (macrophage) RANK receptor. When this
occurs, RANK signaling activates the transcription factor Kappa-B to differentiate into
osteoclasts (Kumar, 2010). The other pathway occurs with the osteoblast secretion of MCSF and the osteoclast precursor cell (macrophage) M-CSF receptor. When joined
tyrosine kinase activity is stimulated, also important to osteoclast formation. This
signaling occurs in tandem with the RANKL/RANK pathway. Further bone marrow
stromal/osteoblast cells secrete osteoprotegerin (OPG), a decoy receptor for RANKL
preventing RANKL from binding with the osteoclast precursor cell’s RANK receptor.
Thus, preventing bone absorption and attenuating osteoclast differentiation (Kumar,
2010).
Bone Physiology
Normal Bone Remodeling. Bone is a connective and living tissue that
undergoes continuous remodeling. Approximately every 10 years, a healthy human adult
skeleton is completely replaced (Lippuner, 2012; Sherwood, 2013) and every year, 510% of bone is replaced in specific bones (WHOSG, 2003). Normal bone remodeling is a
coupling process between osteoclasts and osteoblasts, between bone gain and loss, where
bone absorption and bone formation is balanced (homeostasis) (NAMS, Bruzzaniti &
Baron, 2006; 2010). As the bone adapts to mechanical load and strain, old bone is
replaced with new tissue through the coordination between osteoblasts and osteoclasts
(Hadjidakis & Androulakis, 2006). Bone remodeling begins with bone resorption in both
cortical and cancellous bone by the osteoclasts over a period of a few days.
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Osteoprotegerin (OPG) production and is vital to the regulation of osteoclastogenesis,
menopausal transition and post-menopause, the RANKL secretion by osteoblasts is
greater than the OPG generation due to loss of estrogen (Tella, Gallagher, Tella, &
Gallagher, 2013).
Bone remodeling begins with bone resorption in both cortical and cancellous
bone by osteoclasts over a period of 30-40 days (Eriksen, 2010). Osteoclasts attach to the
mineralized bone surface and resorb bone via secretion of hydrogen icons and cathepsin
K (Raisz, 1999), creating irregular, scalloped cavities named Howship lacunae in
trabecular bone or cylindrical Haversian canals in cortical bone. Osteoprogenitor cells
found in the periosteum and endosteum will differentiate into cuboidal-shaped
osteoblasts. Osteoblasts lay down a new organic extracellular matrix in two stages;
ossification, formation of unmineralized bone (osteoid), and calcification that becomes
mineralized with calcium and phosphate and fills the resorption lacunae over
approximately 150 days (Eriksen, 2010; Raisz, 1999).
Bone structure reflects the quality of the bone tissue (EFOBD & NOFUSA,
1997). Microarchitectural bone changes may be independently associated with bone
weakness, but not associated with a change in BMD (Harvey et al., 2013). An
extracellular matrix (ECM) of bone is comprised of two main components: mineral
composite and collagen, as well as water, proteins, and lipids (Gehron-Robey & Boskey,
2008). The mineral composite is made of hydroxylapatite, mainly calcium phosphate
salts, which provide strength via crystallization around the collagen fibers in the ECM
(Sherwood, 2004). Collagen Type I is the basic building block of the bone matrix and
contributes to bone strength.
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Pathogenesis of Osteoporosis
There are primary and secondary causes for the pathogenesis of osteoporosis.
When secondary causes for bone loss cannot be determined, the patient is diagnosed with
primary osteoporosis (Ardawi, Al-Kadi, Rouzi, & Qari, 2011). Primary causes of bone
loss are due primarily to menopause and aging (senile osteoporosis) which overlap
clinically, as well as the failure to achieve optimal peak bone mass (PBM) and strength
initially during adolescence (NIH Osteoporosis and Related Bone Diseases (NIH
Osteoporosis and Related Bone Diseases ~ National Resource Center, 2009; Raisz,
2008). Achieving peak bone mass (PBM) and bone strength is critical to an individual’s
overall lifespan skeletal health and is a determinant of the future adult skeleton’s strength
(Raisz, 2008; WHOSG, 2003). Optimal PBM may not be obtained due to genetic
mutations, lack of adequate dietary calcium and vitamin D intake, as well as lifestyle
choices such as physical activity. Secondary causes occur idiopathically in younger men
and premenopausal women who present with osteoporotic fragility factures attributed to
iatrogenic factors and disease pathogenesis (Hudec & Camacho, 2013).
Osteoporosis arises from the out-of-balance osteoclast/osteoblast activity in
remodeling bone (Shih, 2012). Bone loss has been described as a two-stage process in
women. The first stage is due to menopausal estrogen loss usually around 51 years and
the second, that occurs post-menopausally, is a slow continuous loss of bone due to aging
rather than the loss of estrogen prior to menopausal transition. The first to two years of
perimenopause may account for the greatest amount of lost bone; trabecular (37%) and
cortical (6%) loss found before age 50 (Armas & Recker, 2012; Riggs et al., 2008). It is
estimated that menopausal transition spans 5-7 years. Approximately, 12% of total bone
mass is lost during this time which is equal to one T-score (-1 SD) of measured bone
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density by DEXA and corresponds to enough bone loss as diagnosed osteopenia (Armas
& Recker, 2012; Recker, Lappe, Davies, & Heaney, 2000). Bone loss occurs because
osteoclastogenesis becomes proportionally greater than osteoblastogenesis (Shih, 2012).
The beginning of the second stage varies individually in post-menopausal women and is a
slow continuous loss of bone due to aging rather than the loss of estrogen. During this
later stage cortical and trabecular bone loss occurs at an equal rate until the end of the life
span. Unlike women, men begin this slow continuous loss of bone due to aging during
middle age (Khosla & Riggs, 2005).
Independent of aging or estrogen deficiency, secondary osteoporosis may be due
to a group of heterogeneous causes leading to bone loss. Secondary causes of bone loss
occur in approximately two thirds of men, over half of premenopausal women and 30%
of postmenopausal women (Recker, 2011). One main cause is iatrogenic effects of
medications that negatively alter the bone remodeling homeostasis. However, not all
drugs have negative effect; some medications have been associated with increase bone
density (see Table 2). Specific attention has centered on proton-pump inhibitor use
associated with decreased BMD and possible increased hip fracture/fracture risk.
Calcium absorption is thought to be impaired with gastrointestinal PH changes (Gray et
al., 2010; Targownik, Lix, Leung, & Leslie, 2010). It has also been suggested that some
medications may, in fact, have an off label therapeutic benefit to skeletal health such as
the combined use of β-blockers and thiazides (Wiens, Etminan, Gill, & Takkouche,
2006), and lipid lowering agents (statins) (Uzzan, Cohen, Nicolas, Cucherat, & Perret,
2007), but investigators cannot recommend preventive treatment without further research.
Further, there are several specific disease states of the endocrine, hematological, gastro-
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intestinal systems that have their own epidemiologic characteristics and pathogenesis that
contribute to bone loss (Diem et al., 2007; Haney et al., 2007; Osteogenesis Imperfecta
Foundation, 2010; Yang, Lewis, Epstein, & Metz, 2006) (see Table 3).
Outcomes of Osteoporosis
Two main osteoporosis outcomes are highlighted: frailty and fall induced
osteoporotic fractures, specifically hip fracture. Both of these result in a societal and
financial burden to treat. Researchers have identified frailty as a precursor to falls and
falls as a precursor to frailty (Runge & Hunter, 2006). Falls and fractures accelerate
frailty in already frail older adults or acutely initiate transitioning into frailty due to a
“triggering event,” such as a hip fracture.
In a series of studies, the association between frailty and falls is well documented
in the literature (Ensrud et al., 2007; Runge & Hunter, 2006) in both men (Ensrud et al.,
2009) and women (Ensrud et al., 2008) and there is considerable research that associates
osteoporosis with fall-induced fractures (Morrison, Fan, Sen, & Weisenfluh, 2013;
Schwartz, Nevitt, Brown, & Kelsey, 2005). Therefore, individuals who may or may not
be frail, who experience a fall, and who have low bone mass, are more likely to
experience an osteoporotic induced fracture, which may accelerate or initiate frailty.
Frailty, described as a decline in the functioning of the neuromuscular system and
the loss of physiological reserve to handle minor stresses, increases susceptibility to
adverse health outcomes and progression of disease and comorbidities (Abate et al.,
2007; Fried et al., 2001; Morley et al., 2013). Frailty is seen most frequently in older
adults over 80 years of age. An individual is identified as being frail when at least three
of the following factors are present: unintentional weight loss (10 pounds or more in a
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year), self-reported exhaustion, weakness as measured by grip strength, observable
slowed walking speed and self-reported low physical activity (Fried et al., 2001;
Mahoney, Glysch, Guilfoyle, Hale, & Katcher, 2005; Morley et al., 2013). The current
prevalence of frailty in persons aged 65 and older ranges from 4.0% to 17% (Collard,
Boter, Schoevers, & C, 2012).
As individuals age they become susceptible to falling. Falls have been an
independent indicator for functional decline and are identified as the causal event for
40% of nursing home admissions (Bischoff-Ferrari, 2009; 2013; Tinetti & Williams,
1997). Approximately 1.4% of community dwelling older adults experience a low-impact
fall resulting in fracture annually (Morrison et al., 2013). Currently, falls remain the
leading nonfatal injury treated in the emergency room (Centers for Disease Control and
Prevention National Center for Injury Prevention and Control [CDCP-NCIPC], 2010) and
the leading cause of death by unintentional injury for individuals 65 and older (Avdic,
Pecar, & Mujic-Skikic, 2004; CDC-NCIPC, 2003; 2005). Consequently, over the past
decade, the mortality rate has also increased (Stevens, 2006). In older adults with low
bone mass, who are in a pre-frail state, a condition between frail and nonfrail, falling may
initiate functional decline initiating the progression into a frail state; and they are more
likely to experience another significant consequence of osteoporosis, fall-induced
fractures.
The lifetime fracture risk for white women over 50 years is 50% (Armas &
Recker, 2012) and for osteoporotic adults 60 ≥ years who experience a fracture, 24% of
women and 20% of men will re-fracture within five years; and within one year 26% of
women and 37% men will die, three times greater risk than the general population
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(Colón-Emeric, 2013; Kannegaard, van der Mark, Eiken, & Abrahamsen, 2010). Further,
a little over a half a million low impact falls result in osteoporotic fractures (Morrison et
al., 2013). Fall induced hip fracture is the most serious osteoporosis-associated incidental
fracture resulting in permanent disability (Harvey et al., 2013; WHOSG, 2003).
The three most common osteoporotic fall-induced fractures are vertebral
compression, wrist, and hip. Wrist and vertebral spine fractures are most often
experienced by women 45-60 years of age, and are thought to be attributed to age-related
changes of neuromuscular reflexes. A wrist fracture most commonly occurs when a
women falls sideways or backwards and uses her arm to break the fall, thus breaking their
wrist (Melton & Cooper, 2001). Vertebral fractures usually occur asymptomatically while
performing normal activities of daily living such as lifting, and occur three times more
often than hip fractures (Harvey et al., 2013). It is important to understand that vertebral
fractures are painful and affect patient morbidity, while hip fractures affect patient
mortality. Therefore, older adults living with back pain tend to self-limit mobility which
results in a functional decline, thus increasing risk for hip fracture and frailty.
Hip fractures most commonly occur at the femoral neck resulting from landing
directly on the hip during a fall (falling sideways) rather than falling forward (NIHCDPO, 2001). As early as 1999, the WHO declared that hip fracture may become a
worldwide epidemic by the middle of the 21st century, increasing from an incidence of
1.7 million in 1990 to a projected 6.3 million by 2050 (Cooper, Campion, & Melton,
1992). Further, estimates for the number of hip fracture and costs could possibly double
or triple by 2040 (US Department of Health and Human Services, 2004). The majority of
hip fractures are known to occur in Europe and North America, but over the next 50
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years, it is projected that 75 % of the world’s total hip fractures will occur in developing
countries. Reported in a systematic review, there is a global 10-fold variation in the
global 10 year hip fracture and fracture probability rates and more study is required to
initiate global strategies to affect rates of hip fracture (Kanis, Oden, et al., 2012).
Most importantly, of the individuals who experience a fall and consequent hip
fracture, many do not return to their original functional level nor resume original social
activities after the fall. Only one-third of older adults regain their pre-fracture functional
level (NIH-CDPO, 2001) and another third will be admitted to long-term care (NIHCDPO, 2001). Half of the people who are ambulatory prior to a hip fracture cannot walk
independently after the fall (Harvey et al., 2013), and suffer from fear, anxiety and
depression, which dramatically impacts their quality of life (Ziden, Wenestam, &
Hansson-Scherman, 2008).
In summary, osteoporosis is a growing world-wide problem requiring
international collaboration to investigate and develop strategies to predict and stratify risk
for falls and fractures, as well as address issues concerning access to appropriate therapy
and education. This disease process is silent and usually not diagnosed until a fracture
has occurred resulting in staggering consequences for the quality of life of many older
adults. The population of older adults is expected to increase exponentially, resulting in
rising health care costs and society burden to treat, as well as a growing population of
frail older adults. Therefore, researchers are actively working together to develop new
technologies for disease diagnostics, osteoporosis medications based on new findings in
bone biology, as well as new treatment options.
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New Treatment Insights
Generalist nurses with osteoporosis pathophysiological knowledge can appreciate
the new advances for the management of osteoporosis. Alternative diagnostics,
medications, and bioengineering treatment options are in various stages of discovery.
Newer technologies for measurement for bone quality may be achieved using areal BMD
testing, measuring bone for size, thickness, and volumetric mineral density using volume
quantitative computed tomography (vQCT) and micro-computed tomography (µCT)
scanning and are undergoing substantiation for specificity and reliably (Genant et al.,
2008; MacNeil et al., 2008). They potentially may provide valuable BMD measurements
in monitoring bone response to medical management.
Trabecular Bone Score (TBS), a measurement of bone microarchitecture not
captured in BMD testing, is a metric calculated from a two-dimensional lumbar-spine
DEXA scan image. This measurement is a newly recommended metric to further evaluate
postmenopausal women for bone loss and strength (Silva et al., 2014). A lower score
indicates weaker bone. In women who experienced fragility fractures, lower TBS scores
were found, but many of these women were not identified according to DEXA T-score as
osteoporotic or osteopenic. Possibly TBS will become a standard measurement for bone
strength, added to clinical practice guidelines, and be used as a predictor for fracture in
women not found to be osteopenic.
Currently, bisphosphonates, which are osteoclast antiresorptives, are the first line
medication used to manage osteoporosis (see Table 4). Based upon advances in
understanding mechanisms in parathyroid (PTH) bone stimulation pathways, a PTH bone
anabolic, Teriparatide (Forteo ®), is now considered first line treatment for severe

45

osteoporosis (Kanis, Reginster, et al., 2012; Rizzoli et al., 2011). Another drug in use,
Denosumab (Prolia ® or XGEVA®), a Receptor Activator of Nuclear Factor Ligand
(RANKL) -inhibitor has been effective in inhibiting osteoclast formation, thus decreasing
the incidence of vertebral, non-vertebral and hip fractures (Cummings et al., 2009).
Current experimental drugs, JTT-305, known as Calcilytics, stimulate PTH secretion in
vivo [animal study model] (Avdic et al., 2004) and human dose response studies are
promising (Cabal et al., 2013). Further, a molecular pathway, Wnt/ß-catenin, responsible
for osteoblastic differentiation and recruitment has been discovered. The drug, AMG 785,
consisting of antibodies to antagonize this pathway resulted in significant increases in
lumbar spine BMD (Kanis, Reginster, et al., 2012; Padhi, Jang, Stouch, Fang, & Posvar,
2011).
Some exciting developments in treatment involve using bioengineering equipment
such as near-infrared light emitting diode (NIR-LED) treatment and vibration therapy.
Low level light treatment has been found to be effective in many clinical settings, mainly
improving wound healing and cell regeneration and function, and decreasing
inflammation/pain (Desmet et al., 2006; Eells et al., 2004; Pinheiro & Gerbi, 2006;
Pinheiro et al., 2008; Pinheiro et al., 2009; Whelan et al., 2003; Wong-Riley, Bai,
Buchmann, & Whelan, 2001). The hypothesis behind light treatment is that light
absorption spectrum in the far-red to near-infrared range (630-1000nm) and low energy
densities 4J/cm2 positively affects numerous cell functions (Desmet et al., 2006).
Traditionally, lasers have been used at higher wavelengths and energy densities to cut,
coagulate, and ablate by intense heat tissue, thus destroying the tissue. At low intensity,
such as 670 nm, infrared wavelengths are thought to have cellular benefit rather than
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destructive properties. When the light is applied to the tissue, a photochemical
conversion of energy occurs, absorbed by non-specialized cellular photo acceptors that
enhances the production of energy, adenosine tri-phosphate (ATP), and ultimately
reduces cellular oxidative stress, known to negatively affect cell function associated with
aging (Eells et al., 2004; Karu, 1988). Light treatment increases osteoblastogenesis
(Stein, Benayahu, Maltz, & Oron, 2005; Yamada, 1991) and osteoclastogenesis (Aihara,
Yamaguchi, & Kasai, 2006) in a cell culture model and in animal models. It is suggested
that light treatment promotes osteogenesis increasing amounts of well-organized bone
trabeculae and vertical bone regeneration (Blaya, Guimaraes, Pozza, Weber, & de
Oliveira, 2008; Pinheiro et al., 2009; Torres, dos Santos, Monteiro, Amorim, & Pinheiro,
2008). Based upon this research, low level light treatment may be useful to treat the
osteoporotic population by applying the light to spine and hip. However, no current
studies exist.
Whole Body Vibration (WBV) has been reported to have potential benefits to
prevent and treat osteoporosis (Chan, Uzer, & Rubin, 2013). However this technology, if
not administered in the correct intensity, has risk to damage the musculoskeletal system.
Bone is sensitive to mechanical signaling, which is beneficial to build and maintain bone
mass; however parameters for duration, frequency or intensity remains unclear (Chan et
al., 2013). Studies have investigated bone response in postmenopausal women with low
BMD reporting significant increases in bone mineral density with 6 months of treatment
(Verschueren et al., 2004), but others report no changes in BMD in 11 weeks of treatment
(Gomez-Cabello et al., 2014). As a result, researchers need to develop WBV safety
protocol studies to determine the parameters for standard treatment, but it appears that
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low intensity vibration of one gravitational force (1g), earth’s gravitational force, is safe
and may be effective to treat osteoporosis (Chan et al., 2013).
Conclusion
The incidence of osteoporosis remains high within a population expected to reach
70 million by 2020, with costs to treat projected to double or triple by 2040 in the US
alone. Moreover, the worldwide incidence of osteoporosis is expected to reach 200
million people by 2050, contributing to a significant societal burden worldwide. Given
these numbers, the possibility that a nurse will interact with someone with osteoporosis is
quite real. Having a solid understanding of normal and pathologic bone anatomy and
physiology will be critical in order to provide evidence-informed care.
Although, as discussed, there are various promising advances in osteoporosis
management and professional organizations such as the International Osteoporosis
Foundation are readily evaluating literature and updating practice guidelines. This
organization has an extensive worldwide presence with 12 working groups in bone loss
health. The annual report is comprehensive (International Osteoporosis Foundation,
2013), but how does this information reach the generalist nurses, the healthcare
professionals who have the potential for the most frequent contact with patients? How
nurses can best care for persons with osteoporosis is the focus of another manuscript.
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Table 1
WHO Diagnostic Criteria for the Defining Osteoporosis
Definition
Bone Mineral Density
Normal
BMD within 1 SD below the mean BMD
of 30 year old women

T-Score
≥ -1

Low Bone
Mass
(Osteopenia)

BMD 1-2.5 SD below the mean BMD of
30 year old women

Between -1 and -2.5

Osteoporosis

BMD ≤ -2.5below the mean BMD of 30
year old women

≤ -2.5

Severe
≤ -2.5below the mean BMD of 30 year
≤ -2.5 with fragility
Osteoporosis old women that has ≥ 1 fractures
fracture
Sources: Kanis & Adami, 1994; EFOBD & NOFUSA, 1997; WHOSG, 2003

Table 2
Affecting Medications in Bones
Initiates Bone Loss
Glucocorticoids

Prevents Bone Loss
β-blockers

Anti-Hormonal

Thiazides,

Aromatase Inhibitors

Statins

Thiazolidinediones
Acid Suppressants
Anti-Epileptics
Selective Serotonin Receptor
Uptake Inhibitors
Long-Term Heparin use
Sources: Gray et al., 2010; Targownik et al., 2010; Uzzna et al., 2006
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Table 3
Secondary Causes Associated with Bone Loss
Endocrine
Hematological Rhematological
Hyperthyroidism
Primary
Hyperparathyroidism
Vitamin D Deficiency
Hypogonadism
Cushing’s Syndrome
Idiopathic
Hypercalciuria

Bone Marrow
Mastocytosis

Rheumatoid
Arthritis

GI
Diseases
Cohn’s
Disease

Other

Celiac
Disease

Chronic
Renal Failure

Osteogenesis
Imperfecta

Solid Organ
Transplant
Chronic
Obstructive
Pulmonary
Disease

Paget’s Disease
Diabetes Mellitus
Sources: Compston, 2008; Diem et al, 2007; Haney et al., 2007; Osteogenesis
Imperfecta
Foundation, 2010 and Yang et al., 2006
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Manuscript Two
Nursing Implications for Osteoporosis Management
Abstract
Osteoporosis is a worldwide silent epidemic affecting the quality of life of 75
million people 65 years and older. Osteoporotic induced fractures, an associated negative
health outcome, may contribute to initiating or accelerating the downward spiral of
frailty. The costs associated with bone loss are expected to increase to $85 billion in
2020 posing a significant societal financial burden. Given the dearth of geriatric
clinicians, generalist clinicians will be responsible for rendering the majority of health
care to populations at risk for this condition. Currently, osteoporosis and osteopenia are
significantly underdiagnosed and not usually assessed until after a fracture occurs.
Among the healthcare team, nurses have frequent patient contact, patient trust, and
opportunity to improve and implement evidence based practice.

It is critical that the

care they provide is drawn from the most current evidence. In a prior manuscript, the
etiology of osteoporosis was reported in preparation for this review. The purpose of this
review is to provide the generalist nurse with knowledge to appropriately assess and
identify osteoporosis, implement tailored interventions, provide disease monitoring and
discuss nursing implications. Ultimately, nurses, active members of the multidisciplinary
team, are positioned to assist patients in understanding bone loss.
Introduction
Nurses have the most frequent patient contact, are trusted among many patient
populations (Dinç, Gastmans, Dinç, & Gastmans, 2013), embrace the implementation and
improvement of evidence based practice (Lee et al., 2013), and are an integral part of the
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multidisciplinary health care tea (Wilkes et al., 2014). Estimates of cost to treat
osteoporotic-induced fractures are expected to at least double by 2040 (US Department of
Health and Human Services [USDHHS], 2004), placing a great societal financial burden
to care for the anticipated 70 million older adults in 2030 (U.S. Department of Health and
Human Services Administration on Aging, 2006). Nurses have an opportunity to guide
women and men to improved bone health and reduce or reverse bone loss, thus
preventing fractures and mortality and improving the quality life of older adults through
thoughtful risk and clinical assessment, attentively monitoring and implementing tailored
interventions (Teng, Curtis, & Saag, 2009). In this manuscript, the literature is reviewed
to provide the generalist nurse with knowledge to implement the nursing process to
appropriately assess and identify osteoporosis, implement tailored interventions, and
provide disease monitoring.
Given the rapidly expanding osteoporosis literature, it is nearly impossible for
nurses to remain abreast of all new recommendations for patient treatment. Therefore,
the purpose of this article is to provide a brief overview of the problem, and identify the
current practice recommendations for risk assessment, screening, diagnosis, treatment
options, prevention, and disease monitoring for the management of osteoporosis and
provide implications for nursing practice and policy. Information is presented in the
following order: bone loss and fall risk assessment, health history, screening, physical
exam, diagnostic tests, and tailored interventions, prevention and nursing implications. It
will become imperative to identify individuals at risk for falls, screen for bone loss and
implement appropriate tailored interventions to improve bone loss and prevent falls, in
order to effectively impact the combined outcomes of morbidity and mortality, and
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conserve medical resources. These nursing practice recommendations are aimed toward
adults 50 years and older.
Problem
Nurses must recognize that osteoporosis is a silent killer and not a customary
disease associated as a general characteristic of aging. Nonetheless, it is well known that
bone loss can be currently identified, prevented and managed (National Osteoporosis
Foundation [NOF], 2010 [revised 2013]). Osteoporosis, the most common skeletal
disease seen in older adults, is characterized by low bone mineral density (BMD) with
microarchitectural bone deterioration that compromises bone strength, thus, increasing
risk for bone fragility and fracture (National Institutes of Health Consensus Development
Panel on Osteoporosis [NIH-CDPO], 2001; NOF, 2010 [revised 2013]; Nuti et al., 2009).
Primary causes of osteoporosis are due primarily to menopause and aging (senile
osteoporosis) and the failure to achieve optimal peak bone mass (PBM) and strength
during adolescence. Secondary causes occur idiopathically in younger men and
premenopausal women who present with osteoporotic fragility factures attributed to
iatrogenic factors and disease pathogenesis (Bonjour, Theintz, Law, Slosman, & Rizzoli,
1994; National Institutes of Health Osteoporosis and Related Bone Diseases ~ National
Resource Center, 2009; Raisz, 2008).
In the US, 10 million people over the age of 50 years are affected by osteoporosis;
of these, 8 million are women and an additional 34 million Americans have low bone
mass (osteopenia) (A. C. Looker, Melton, Harris, Borrud, & Shepherd, 2010).
Osteoporosis is more common in women than men due to postmenopausal hormonal
changes and longer life span and more prevalent in Caucasian women and men than
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Hispanics and African-Americans (Looker, Borrud, Dawson-Hughes, Shepard, & Wright,
2012).
Not all individuals at risk for bone loss are identified and treated. Giangregorio,
Papaioannou, Cranney, Zytaruk, and Adachi (2006) found that only 30% of patients were
diagnosed with osteoporosis prior to a fracture. In the National Osteoporosis Risk
Assessment Study (NORA) of women 50 years and older, almost half of the 200,160
subjects had low bone mineral density (BMD), osteopenia, and 7% met the criteria for
osteoporosis and were not receiving treatment. Further, 11% had a history of an
osteoporotic related fracture retrospectively beginning at age 45 (Siris et al., 2001).
For white women over 50 years, the lifetime fracture risk is 50% (Armas &
Recker, 2012) and every year in the US, there are over a half a million low impact falls
that result in an osteoporotic fracture (Morrison, Fan, Sen, & Weisenfluh, 2013).
Currently, falls are the leading cause of death by unintentional injury for individuals 65
and older (Centers for Disease Control and Prevnetion National Center for Injury
Prevention and Control [CDCP-NCIPC], 2003; 2005; 2010) . The estimated lifetime risk
for experiencing an osteoporotic fracture (vertebral, wrist, and hip) is 40%, similar to the
lifetime risk for coronary heart disease ((World Health Organization Scientific Group
[WHOSG], 2003). With an aging population, the incidence of falls will increase, as will
fracture risk.
Hip fracture is the most serious incidental fracture associated with morbidity and
mortality in older adults (Harvey, Dennison, & Cooper, 2013; Johnell & Kanis, 2006;
Ziden, Wenestam, & Hansson-Scherman, 2008), and the most costly fracture to treat
(Kilgore et al., 2009). In 2008, estimated US costs to treat osteoporosis and fractures was
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reported as $22 billion (Blume & Curtis, 2011). Hip fractures usually result in
hospitalization, with mortality rates within the first year reported in men (37.1%) and
women (26.4%) (Kannegaard, van der Mark, Eiken, & Abrahamsen, 2010). In fact, 50%
of those ambulatory prior to fracturing their hip, cannot walk independently (Harvey et
al., 2013), suffer from fear, anxiety, and depression which dramatically impacts their
quality of life (Eastwood et al., 2002; NOF, 2010 [revised 2013]; NIH-CDPO, 2000;
Ziden et al., 2008).
Method
An extensive search of the literature focusing on osteoporosis, its etiology,
societal and health outcomes published between 2000 – 2013 was conducted. Databases
searched included PubMed, CINAHL, Academic Search Complete/EBSCO, Medline,
National Guideline Clearinghouse, Google Scholar, Primo Central/Ex-Libris, as well as
references from articles and books. In order to gather full text copies and guidelines, a
Google web search was conducted. Articles published prior to 1999 were considered
seminal and were authenticated from the extrapolated literature. Further, expert opinion
literature was reviewed and of note, the Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism, eighth edition, published by The American Society for
Bone and Mineral Research, was utilized to obtain leading expert bone health
researcher’s opinions (Rosen, 2013). The term osteoporosis was searched in combination
with epidemiology, definition, clinical practice guidelines, diagnosis and treatment, risk
factors and assessment, cost analysis, nursing interventions, exercise, calcium, vitamin D,
bisphosphonates, and estrogen. The search was limited to English, focused on the age
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group of 50+ years, and utilized US practice guidelines addressing osteoporosis
management.
Critical appraisal of the literature followed the recommendations of nursing
researchers Polit and Beck (2008) evaluating for existence of research questions,
hypotheses, study design, methods of sampling and data collection, and analysis.
Systematic reviews were evaluated using the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) method (Moher, Liberati, Tetzlaff, Altman, &
The Prisma Group, 2009). The search, when feasible, was limited to National Guideline
Clearing House (2), professional guidelines (5), professional position statements (11),
meta-analyses (1), systematic reviews (6), clinical trials (5), clinical cohort studies (21),
epidemiological studies (6), reviews of literature (15), articles from peer-reviewed
journals (57), professional texts (7), and government reports (19).
Findings
Over the past 20 years, clinical practice guidelines have evolved into sophisticated
tools designed to guide clinical decision making, optimize efficiency and patient care by
facilitating the translation of research to the bedside and serves as an excellent nursing
resource. These guidelines are statements that reflect a systematic review of evidence
that examines the scientific quality of relevant literature assessing the risks and benefits
for specific types of clinical care (Institute of Medicine of the National Academies,
2011). Their purpose is not to dictate patient care, but to provide healthcare professions
with quality information to make informed clinical decisions which may be tailored to
each distinctive patient.
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Osteoporosis Management
The main goals in osteoporosis management are to accurately identify patients at
increased risk for fracture and educate patients at every opportunity regarding disease
process, prevention, and treatment options (McCloskey, 2009). The nurse must be aware
of the appropriate time in the lifespan to screen individuals for bone loss through health
history, risk assessment, physical exam, tailored interventions and yearly follow up.
Menopausal transition has become the focus in bone health research, suggesting
screening women prior to the age of 65. It is thought that the greatest amount of bone
loss occurs one year prior to the final menstrual period and the first two years after the
final menstrual period (Lo, Burnett-Bowie, & Finkelstein, 2011). The exact point in time
is difficult to determine, however, because definitions of menopausal status lack clarity
and vary individually. Updated clinical practice guidelines address the need to consider
screening perimenopausal women and men age 50-69 years with one osteoporosis risk
factor (Lim, Hoeksema, & Sherin, 2009; Michigan Quality Improvement Consortium
[MQIC], 2014; North American Menopause Society [NAMS], 2010). Also, some
researchers believe that risk should be assessed in adolescence (Schettler & Gustafson,
2004). A synthesis of five clinical practice guidelines can be found in Table 1.
A disconnect between evidence-based practice and real-world clinical practice in
diagnosing and preventing osteoporosis despite the great advancement in identifying and
treating osteoporosis (Teng et al., 2009) presented in the literature, however,
improvement is needed in transferring these interventions into clinical settings (NOF,
2010 [revised 2013]; Rojas-Fernandez, Lapane, MacKnight, & Howard, 2002; Warriner
et al., 2009). Actually, identification of osteoporosis was reported to be greater in older
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adults, yet, treatment occurred more often in younger individuals (Giangregorio et al.,
2006).
Giangregorio, Papaioannou, Cranney, Zytaruk, and Adachi (2006) in their
systematic review of 35 studies that investigated osteoporosis treatment after
experiencing a fragility fracture reported a little less than half were diagnosed with
osteoporosis prior to fracture; and of those identified with osteoporosis, one third did not
take calcium/vitamin D supplements or osteoporotic medications, the most common diet
and medication interventions Also reported, (Siris et al., 2001) of the National
Osteoporosis Risk Assessment Study of women 50 years and older, 7% of the subjects,
not previously diagnosed, met the criteria for osteoporosis and were not receiving
treatment and 11% had a history of an osteoporotic related fracture retrospectively
beginning at age 45.
Once an individual has been screened and is identified at risk or with low BMD
through risk assessment and/or BMD testing, the individual requires a detailed history
and physical, diagnostic tests as to evaluate further for fracture risk and rule out other
secondary causes for low BMD. Through this work up, interventions can be
implemented to modify risk factors, and initiate pharmacological treatment if appropriate
to treat osteoporosis (NAMS, 2010). Therefore, enhancing the nurse’s knowledge about
appropriate risk assessment, interventions and vigilant monitoring has potential to
improve patient outcomes.
Health History. It is important to not consider a possible diagnosis of
osteoporosis based solely upon a measurement of low bone mass. Nurses should begin
with a detailed health history. The history should include obtaining information about

74

five major risk factors: calcium intake through diet history, alcohol and cigarette use,
menarche history, medication review for drugs attributed to bone loss such as
glucocorticoids, and sun exposure review (NOF, 2010 [revised 2013]; WHOSG, 2003).
Screening. The National Osteoporosis Foundation (NOF) recommends that all
post-menopausal women and men 50 years and older receive a comprehensive bone loss
assessment employing a detailed history and physical, Bone Mineral Density (BMD)
testing and vertebral imaging, if needed, and a calculation of the World Health
Organization (WHO) 10-year Fracture Risk Assessment Tool (FRAX®) probability score
(Lim et al., 2009), as well as fall risk assessment (NOF, 2010 [revised 2013]; NAMS,
2010). The University of Michigan practice guidelines recommend assessing for risk
factors to perform the FRAX© in all women at risk, then if needed, measure BMD if the
10-year hip fracture risk score ≥ 9.3% (equivalent risk of a 65 year old women) (MQIC,
2012 [revised 2014]).
Many nurses are aware that the screening measurement of BMD alone is a strong
predictor for fracture; however, it has low sensitivity because the majority of fractures
occur in the diagnostic osteopoenic range (McCloskey, 2009). The combination of BMD
scores and clinical risk factors increases the discrimination value of predicting fracture
risk (Kanis et al., 2007). One tool that includes this combination is the FRAX©. This
tool, typically used in men and women 65 years and older, has also been adopted
internationally as a valid and sensitive for use in men and women age 40-50. It is
available in a desktop application and more information regarding the development and
international utilization and endorsement of the FRAX can be found in Table 2. It is
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administered efficiently, requiring minimal training and is especially useful in
communities where BMD testing is scarce (NOF, 2010 [revised 2013]).
The FRAX© tool identifies the most pertinent independent risk factors for fracture
and bone loss: prior fragility fracture, parental hip fracture history, tobacco use, history
or use of long-term oral glucocorticoids, alcohol consumption ≥ to 3 units, and a
diagnosis of Rheumatoid Arthritis. These factors are then calculated into an algorithm
with the individual’s body mass index (McCloskey, 2009), as BMI is a significant risk
factor for bone loss. Currently, the tool is available in several languages through the
website or downloaded at http://www.shef.ac.uk/FRAX (World Health Organization,
2012).
In addition to using the FRAX, a multifactorial fall assessment is essential since
the majority of osteoporotic-induced fractures occur due to falls. Assessment should
include an evaluation of orthostatic hypotension, muscle strength, gait and balance with
use of adaptive aids, functional status, and home environment. Further, an assessment for
comorbidities known to increase risk such as a history of falls (strongest predictor),
depression, syncope, arrhythmia, poor vision, and fear of falling should be included
(Panel on Prevention of Falls in Older Persons & British Geriatrics, 2011). Lastly,
performing a comprehensive pharmacology review to identify medications known to
increase the risk of falling such as benzodiazepines, psychotropics, narcotic analgesics,
and anticonvulsants is recommended (NOF, 2010 [revised 2013]; Panel on Prevention of
Falls in Older Persons & British Geriatrics, 2011).
Physical Exam. Height loss of 1.5 inches or greater indicates the strong
possibility for vertebral fracture and requires BMD testing and vertebral imaging (NOF,
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2010 [revised 2013]; NAMS, 2010). Chronic and acute back pain with percussive
tenderness over the thoracic spine 11-12 and first lumbar, the most common sites for
vertebral fracture, should be assessed for the presence of acute vertebral fractures
((NAMS, 2010; Siminoski, Warshawski, Jen, & Lee, 2006). In addition, weight should be
monitored for changes in body mass index as this will affect interpretation of future BMD
values and weight loss over time has been associated with bone loss (NAMS, 2010).
Although kyphosis, height loss, and back pain can occur without the presence of
osteoporosis, such conditions call for further evaluation and consideration of the presence
of osteoporosis, thus being accurate in obtaining height measurements become critical.
In addition, entering data into the electronic medical record can enhance sharing within a
healthcare system. Such a strategy would alert nurses to be vigilant when future hospital
admission occur.
Diagnostic Tests. It is important that nurses are familiar with the most common
tests. A primary care provider would then order BMD testing, as well as routine
laboratory tests (see Table 3) (Ardawi, Al-Kadi, Rouzi, & Qari, 2011; Dawson-Hughes,
Harris, Ceglia, & Palermo, 2014; NOF, 2010 [revised 2013]; NAMS, 2010; WHOSG,
2003) These laboratory values are useful to rule out secondary causes of bone loss such
as anemia, multiple myeloma, GI malabsorption, vitamin D deficiency,
hyperparathyroidism, renal failure, and hypothyroidism.
Tailored Interventions. Nurses have the ability to initiate interventions to
prevent falls, provide patient education to engage health promotion, evaluate medication
interactions, improve osteoporosis medication compliance and provide yearly bone loss
monitoring. Interventions are aimed to impact modifiable bone loss risk factors.
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However, some risk factors such as not reaching optimal peak bone mass by the end of
adolescence, aging, sun exposure, genetics, and heredity are non-modifiable. Others can
be modified by nutrition, lifestyle choices, body mass index, falls, history of prior
fracture, low bone density, muscle strength, and frailty (NIH-CDPO, 2001; Suh & Lyles,
2003; WHOSG, 2003).
Fall prevention is one of the most important interventions to implement.
Multicomponent interventions, such as muscle strengthening, balance and weight-bearing
exercises, referrals to multiple resources such as occupational and physical therapy, home
care and primary care, and vitamin D supplementation are most effective (Chang et al.,
2004). Specific examples are provided in Table 4. Nurses have the opportunity through
patient education to inform women about bone health early in menopause transition.
Patient education could be implemented using the resources from the NOF (National
Osteoporosis Foundation: Bone Source, 2013). These materials are created to provide
osteoporosis facts, prevention, fitness programs, as well medication information. Further,
electronic medical record programs incorporate patient education topics into the
outpatient visit summary, taken home by the patient. This may occur in the outpatient
setting or during an inpatient admission.
The most common interventions in the prevention and maintenance of BMD are
overall lifestyle changes to diet, exercise routines, and lifestyle change. Dietary
modifications target sufficient calcium/vitamin D and protein intake, in addition to a
weight and non-weight bearing exercise programs, smoking cessation, and moderate
alcohol consumption (Carter, Kannus, & Khan, 2001; Kannus, Uusi-Rasi, Palvanen, &
Parkkari, 2005; NAMS, 2010). Further, nurses have the ability to assess patient’s needs
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and refer for physical therapy and nutritional evaluation and gerontological clinical nurse
specialist consultation.
Age-related changes of the gastrointestinal tract, such as malabsorption and
changes in gastric PH can impair calcium and vitamin D absorption (Perez-Lopez et al.,
2012) and some patients require supplementation. Bone stores 99% of the body’s
calcium and if intake of calcium is inadequate, calcium is leached from the bones to
maintain serum calcium homeostasis. Vitamin D is essential for calcium absorption, as
well as cardiac and skeletal muscle function. The best sources for calcium and vitamin D
absorption are found in a patient’s diet (see Table 5). Adult calcium intake is 500-700mg
a day (NOF, 2010 [revised 2013]); therefore, it is important to evaluate the patient’s diet
history for calcium intake. General supplementation recommendations are provided in
Table 5.
Weight bearing and strengthening exercises are instrumental in preventing falls,
but also have a known physiological response that improves and preserves bone health
((National Guideline Clearinghouse [NGC], 2010 [revised 2012]; NOF, 2010 [revised
2013]). Implementing these fall prevention weight bearing interventions will achieve
this positive bone remodeling result (NAMS, 2010; Howe et al., 2011). Postmenopausal
women who exercised lost 0.85% and 1.03% less bone at the spine and hip, respectively,
and those who used combinations of weight and strengthening exercise regimes averaged
3.2% less bone loss than women who did not exercise (Howe et al., 2011).
The two most important lifestyle changes the nurse can recommend to patients are
to quit smoking and to consume alcohol moderately. Smokers lose bone more rapidly,
reach menopause two years earlier, and have higher rates of fracture than non-smokers
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(NAMS, 2010). Low to moderate alcohol consumption [one drink per day or >3 drinks
per week] has been reported to have protective of bone health effects (Sommer et al.,
2013). However, women who consume three or more drinks a day are associated with
low BMD, falls and may indicate alcoholism (NOF, 2010 [revised 2013]).
Since there are multiple medications to treat osteoporosis, knowledgeable nurses
are critical to guide the administration and compliance to medication therapy. There are
several medications to inhibit bone resorption and stimulate bone formation
(Kleerekoper, 2008) (see Table 6). Post-menopausal women who have experienced a hip
or vertebral facture have a T-score ≤ -2.5, and are osteopenic with a FRAX score of ≥
20% or Hip FRAX score of ≥ 3% should be pharmacologically treated for osteoporosis
(NGCH, 2010 [revised 2012]; NOF, 2010 [revised 2013]; NAMS, 2010).
Hormone replacement therapy (estrogen-progesterone) and Selective Estrogen
Receptor Modulators (SERMs) are useful to preserve bone and prevent fracture in the
beginning of the post-menopausal period; however, patients need to be informed
regarding the risk factors of developing breast cancer (Chlebowski et al., 2003), deep
vein thrombosis, and stoke (NAMS, 2010). Bisphosphonates are the first-line treatment
to inhibiting bone loss by slowing the osteoclast activity and are reported to decrease
vertebral fractures 40-70% and hip 15-35% (NAMS, 2010). Bisphosphonates are
metabolized through the renal system; therefore, renal function must be evaluated prior to
initiating therapy and nurses must assist monitoring serum creatinine levels for signs of
renal failure (see Table 6). The most common side effect is gastrointestinal upset,
because the medication must be taken on an empty stomach sitting upright for 30-60
minutes. Further, suppressing bone turnover with long term bisphosphonate therapy may
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attribute to bone brittleness, however this has been reported in small case studies and still
remains controversial (Neviaser, Lane, Lenart, Edobor-Osula, & Lorich, 2008; NAMS,
2010). Newer medications such as parathyroid hormone and Denosumab (Prolia or
Xgeva), a Receptor Activator of Nuclear Factor kappa-B (RANK) Ligand (RANKL)
Inhibitor, are used in high risk patients for fracture due to breast or prostate cancer (Food
and Drug Administration, 2002, 2013a, 2013b, 2013c, 2013d). (see Table 6)
Yearly height and weight measurement, along with repeating BMD testing, are
recommended every 2-5 years to monitor an individual’s response to pharmacologic
treatment and 1-2 years if not treated (Lim et al., 2009; NAMS, 2010; ). Also, a primary
care provider may wish to order bone turnover markers (BTMs) measured in 3-6 months
after initiating medication management. These are reported to be useful in monitoring
response to treatment or evaluating treatment adherence (NOF, 2010 [revised 2013]).
However, clinicians must use caution with interpretation of results because of the lack of
test assay standardization, diet influences, and variation in day-to-day values (Lim et al.,
2009; Miller et al., 1999; NGC, 2010 [revised 2011]; NAMS, 2010). Lastly, fall risk
assessment should be addressed yearly.
Nursing Implications
Implications for practice and policy can be drawn from the literature, even as new
original research questions are proposed to determine cellular bone loss causality and
potential points in the lifespan to intervene and preserve bone health. A nurse driven
comprehensive lifespan bone health program may be beneficial to preserve and treat bone
loss. Bone remodeling occurs throughout the lifespan and has a specific systematic
process in reabsorbing and replacing bone. It is important to understand how crucial to
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optimize peak bone mass early in the lifespan because individuals whom have low peak
bone mass are at higher risk for facture and osteoporosis. Once peak bone mass is
reached, it must then be preserved throughout the lifespan (Bonjour et al., 1997; Kannus
et al., 2005; Mahon et al., 2010; Weaver & Heaney, 2008). Therefore, interventions
should be implemented in the following areas of practice: beginning with maternal-child
health, adolescent, and proceeding to perimenopause, menopause and postmenopause.
Practice
Nurses have the ability to impact osteoporosis screening, management, and
medication adherence through patient education in both inpatient and outpatient settings.
Bone loss is a multifaceted healthcare concern. Ultimately, research is needed to create
comprehensive intervention programs that are collectively implemented throughout a
health care system.
For example, (Majumdar et al., 2007) designed a Canadian nurse case
management intervention study. They divided patients into two groups, usual care, and
nurse case management. Usual care received osteoporosis, fall prevention, and dietary
patient education materials and were encouraged to discuss these materials with their
caregivers and/or primary care provider. The intervention group was provided one-onone counseling with a nurse case manager. Here they discussed the risks and benefits of
bisphosphonate therapy, arranged BMD testing, and if needed obtained prescriptions
from their primary care provider. This program was implemented throughout three
hospital health care systems and was found to be cost-effective, with a cost of $50 per
patient and requiring approximately 70 minutes of case management. Osteoporosis
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treatment was significantly improved in the nurse case manager group over the standard
care group (67% vs. 26%) (Majumdar et al., 2007).
Further, Australian researchers created a patient education nurse driven program
that provided post-fracture information. One group received a patient education letter
and the other group received in addition to the letter free BMD testing (Bliuc, Eisman, &
Center, 2006). A significant increase in osteoporosis workup was found in those who
received a letter and free BMD, but no effect in treatment rates (6%) was seen. Further,
23% of patients contacted their physician, and of these only 25% were recommended
treatment. Comparing these two studies results, one-to-one patient education and case
management is a key to improving osteoporosis management outcomes.
These above mentioned intervention programs can be replicated in the outpatient
setting. Anticipating future shortages of primary care providers, nurses will be
responsible to care for those at risk for bone loss. The best clinical setting for generalist
nurses to impact the negative outcomes for osteoporosis are in outpatient care settings
because approximately 994 million patients are seen annually (Hsiao, Cherry, Beatty, &
Rechtsteiner, 2010). Most concerning is the lack of registered nurses working in this
setting.
Over the past five years, 2008-2013, only (9%) and (7%) of registered nurses
(RNs) were employed in the outpatient clinics compared to (62%) and (60%) of medical
assistants, respectively (Bureau of Labor Statistics, 2008a, 2008b, 2013a, 2013b). Of
concern is the report from the American Academy of Ambulatory Care (2012) that RNs
are performing below their scope of practice while unlicensed assistive personnel are
performing above their scope of practice. Since 2008, the US has undergone a major
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change in health care delivery, mainly the enactment of the Healthcare Affordability Act,
resulting in shifting services from the inpatient to outpatient settings. In 2013, 58% of
RNs worked in inpatient settings; therefore, it is evident that there is a significant
difference in the access to registered nurses for the majority of the patient population
(Bureau of Labor Statistics, 2013a).
Due to perceived cost savings, hospital systems choose to employ more
unlicensed personal than registered nurses, thus providing “nursing care” through
numerous types of licensed and unlicensed nursing staff. Role confusion exists because
of lacking standardization or quality control which may impact negatively patient safety.
Use of RNs in outpatient settings has demonstrated improvement in quality patient
outcomes and safety, patient satisfaction, reducing adverse events and
hospital/emergency room visits (American Academy of Ambulatory Care, 2012; Haas,
2008). Critical to improving osteoporosis outcomes is recognition that educated RNs are
needed not only to provide bone health risk assessment and patient education in the postmenopausal population, but across the lifespan.
With this said, nurses in outpatient clinic settings, can develop a comprehensive
bone health educational programs that provides intervention at the four points of the
lifespan: maternal/infant health, pediatrics, peri-menopause/menopause (women’s
health) and post-menopause (gerontology). Each point in the life span has implications
for nursing practice. Much is known about post-menopausal bone loss; however,
researchers are beginning to study other points in the lifespan. This is evident by the
addition of approximately 30 more chapters added to the Primer on the Metabolic Bone
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Diseases and Disorders of Mineral Metabolism, eighth edition, providing new advances
in basic bone biology and clinical osteoporosis management (Rosen, 2013).
Maternal/Infant. No discussion is complete without recognizing the importance
of early bone health assessment. The tenets of fetal bone development are beneficial to
later in life bone health. The body of literature concerning maternal/infant calcium and
vitamin D status is developing. It is known that calcium demands are greater during
pregnancy and lactation, instrumental to fetal growth, and commonly prescribed if a
women’s intake is < 500 mg/day, but the use of vitamin D supplementation remains
vague. However, there is concern that the physiological demands of pregnancy for
calcium and vitamin D are not being met by the use of prenatal vitamins and require
assessment during prenatal visits (Hacker, Fung, & King, 2012).
Vitamin D deficiency and insufficiency is prevalent in western and non-western
pregnant women. It is associated with impairing fetal bone development, low birth
weight, and poor childhood growth (Cooper, Javaid, Westlake, Harvey, & Dennison,
2005; De-Regil, Palacios, Ansary, Kulier, & Pena-Rosas, 2012; Mahon et al., 2010).
However, due to limited quality studies, recommendations to use vitamin D
supplementation remains questionable as there is inconsistent results regarding efficacy
and safety for use during pregnancy (De-Regil et al., 2012), this topic continues to be
actively researched today as a worthwhile intervention.
Vitamin D deficiency, common in the newborn population, is found more often in
African American newborns. There is concern regarding the vitamin D contents of breast
milk, which is dependent on the mother’s vitamin D status, and infant formulas. Both
provide an adequate intake of essential vitamins and minerals but not necessarily enough
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vitamin D (Weaver & Heaney, 2008). Of infants supplemented with 400IU of vitamin D
daily, an increase in mean vitamin D measurement was found but not to optimal newborn
levels (Hanson, Armas, Lyden, & Anderson-Berry, 2011). Further research is required to
provide clear recommendations for supplementing vitamin D in pregnancy and newborns.
Pediatrics. Pediatric researchers regard bone loss as a “pediatric disease with
geriatric consequences” (Randi-Schoenfeld, Ng, Henderson, & WU; 2010 p. 104 ) and
believe evaluation should begin in adolescence (Schettler & Gustafson, 2004). High
calcium intake in prepubertal girls has been associated with increased Peak Bone Mass
(PBM) accrual, and adolescence milk consumption positively affects postmenopausal
BMD. Because 90% of PBM is attained by age 18 (NIH Osteoporosis and Related Bone
Diseases ~ National Resource Center, 2009) preventive medicine (Randi Schoenfeld, Ng,
Henderson, & Wu, 2010) and physical therapist researchers (Magee, Stuberg, &
Schmutte, 2008) have engaged to develop adolescent educational interventions. An
internet based educational program significantly improved knowledge, self-efficacy, and
calcium consumption, but was not as effective to impact life-style change (Randi
Schoenfeld et al., 2010).
Nurses can assess calcium and vitamin D intake, provide nutritional guidelines,
present adolescent health patient education, and monitor status throughout adolescence.
Further, evaluation for specific adolescent risk factors associated with impairing PBM;
anorexia nervosa, exercise-induced amenorrhea, use of oral contraceptives, poor
adolescent physical activity, and cigarette smoking should be added to the electronic
medical record (Anderson, Chad, & Spink, 2005; Krall & Dawson-Hughes, 1993; Martin
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et al., 2004; Randi-Schoenfeld et al., 2010; Schettler & Gustafson, 2004; WHOSG,
2003).
Perimenopause. This is one of the most significant gaps in the literature:
identifying menopausal transition, specifically perimenopause. It is alarming that only
one preventive guideline recommends screening all patients with potential risk, therefore
peri-menopausal (NGC, 2010 [revised 2012]). However, others screen peri-menopausal
women only if they present with risk factors, most likely a fracture (NGC, 2010 [revised
2012]; NOF, 2010 [revised 2013]; NAMS, 2010).
Bone loss is reported to be stable during pre-menopause, but accelerates
significantly in late perimenopause (Finkelstein et al., 2008). In the 5-7 year span of
perimenopause and menopause, approximately, 12% of total bone mass is lost; which is
equal to one T-score (-1 SD) of measured bone density by DEXA, and corresponds to a
diagnosis of osteopenia (Armas & Recker, 2012; Recker, Lappe, Davies, & Heaney,
2000). Most bone loss studies and interventions have focused on post-menopausal
women; however, menopausal status definitions lack clarity (Lo et al., 2011). Therefore,
menopausal transition has come into the forefront of the bone health research and may be
useful to identify when to screen women for bone loss.
The stage of menopausal transition is not evaluated regularly but is defined as
premenopausal; regular menstrual cycles between 26-32 days, peri-menopausal; cycles
longer than 35 days, irregularity > 5 days between cycles or hot flashes > 5 days per
cycle, and postmenopausal; > one year between cycles. In a nine year prospective study,
trabecular bone loss in midlife women averaged 3.2% per year, a 28.8 % total loss of
bone with the greatest percentage of loss occurred between years 2-6, accelerating in late
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peri-menopause (Seifert-Klauss et al., 2012). Researchers in search of bio-markers for
perimenopause found accelerated bone loss was associated with increased gonadotropin
levels, follicle stimulating hormone, luteinizing hormone and 17 β –estradiol, and may be
helpful to determine a women’s menopausal stage (Seifert-Klauss et al., 2012) (see Table
7). The above definitions and values were successfully supported by study data to
determine pre and post menopause (Seifert-Klauss et al., 2012), but the use of clinical
bone markers, osteocalcin, bone-specific alkaline phosphatase, and c-terminal telopeptide
cross-linked collagen type I, were not able to operationally define the perimenopausal
state. However, during menopausal transition, bone markers were the greatest. These
menopausal transition indicators could be incorporated into a women’s yearly
gynecological exam assessed by nursing. The question remains whether bone health
screening occurs too late in the life-span.
Post-Menopause. The majority of post-menopausal women more than likely will
have experienced some degree of bone loss (Reid, 2013). However, it still remains a
significantly under diagnosed condition as osteopenia presents asymptomatically (Teng et
al., 2009; USDHHS, 2004). Because the greatest amount of bone lost early in
menopausal transition is trabecular bone, bone loss is not discovered until a patient
presents with back pain as a result of a vertebral facture (Rachner, Khosla, & Hofbauer,
2012).
Nursing is an active member of the multidisciplinary team positioned to assist
patients in understanding bone loss. Through risk and clinical assessment, attentive
monitoring, will assist to improve osteoporosis health outcomes by early identification
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and implementing timely interventions, thus in turn precludes fractures and mortality,
improving the quality life of older adults and averting the transition into frailty.
Policy
Policy implications are twofold. First, in order to be effective, hospital systems
must employ more registered nursed in their clinic systems to provide assessment and
second, to provide research data to support screening perimenopausal women beginning
at age 45. Exploring the literature, specifically, employment of outpatient registered
nurses was positively associated with cost-savings and patient outcomes. Specific
articles written to reflect policy implications are lacking; found were the political agenda
and position statements formulated by the American Academy of Ambulatory Care
Nursing website (American Academy of Ambulatory Care, 2014).
Perimenopause has been a focus in the literature since the mid-1990s. However,
the prevention and screening for osteopenia or evaluating perimenopausal women for
bone loss is lacking. The phases of menopausal transition are becoming more
understood, but lack of research supporting early screening of women without risk factors
is void in the literature. Therefore, it is uncertain with limited statistical evidence that
practice guidelines will change in the near future, but active programs of research exist.
The University of Michigan successfully has investigated follicle-stimulating
hormone (FSH) levels in 629 women, aged 24-44 for 14 years, and identified four
menopausal transitions with eight chronological aging periods occurring between ages
26-60 years (Sowers et al., 2008). Further they found, spine and femoral neck bone loss
accelerated at FSH stage 3, defined as FSH levels of 34 mIU/ml corresponding 2-3 years
before their final menstrual period (FMP). Bone loss continued into FSH stage 4 and
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they concluded that accelerated bone loss was associated with 2 years prior and 2 years
after their FMP (Sowers et al., 2010).
In 2012, the University of Michigan Management and Prevention of Osteoporosis
practice guidelines recommended the inclusion that all men and women patients having
clinical risk factors for bone loss to calculate a FRAX© score. Based on this research,
perimenopausal women would be included (MQIC, 2012 [revised 2014]) and then if
needed, measure BMD if the 10-year hip fracture risk score ≥ 9.3% (equivalent risk of a
65 year old women) (Lash, Van Harrison, McCort, Nicholson, & Velez, 2013).
Implementing this tool is non-invasive and quickly administered and has the potential to
be included routinely during yearly visits and potentially identify those not outwardly at
risk with beginning stages of bone loss.
Conclusion
Nurses are active members of the multidisciplinary team positioned to assist
patients in understanding bone loss. Osteoporosis and osteopenia are significantly
underdiagnosed and usually are not assessed until after a fracture occurs. Osteoporosis
research over the past two decades has been extensive. However, only a modest impact
has been show in decreasing fracture rates; thus, the societal economic impact to treat
remains high and will only increase as the population ages. Nurses have an opportunity
through thoughtful risk and clinical assessment and attentive monitoring, to improve
osteoporosis health outcomes. Through early identification of bone loss, implementing
timely interventions that improve or prevent bone loss will in turn preclude fractures and
mortality, and ultimately improve the quality life of older adults and averting the
transition into frailty.
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Table 1
Osteoporosis Management Practice Guideline Synthesis
WHO (2003)
No recommendation
Risk
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Assessment
Use FRAX
+
Fall Risk
+
Clinical
DEXA Preferred
None Stated
Evaluation
Age
Order DEXA
With Risk Factor
Fx/ Fragility Fx
2nd Causes
Peri-menopause
Steroid use
X-ray Osteopenia
Low BMI
Maternal hx of hip fx
Kyphosis-Height Loss
Rheumatoid Arthritis
Alcohol use > 2 day
Smoker
Adolescent Screen
Vertebral Imaging
R/O Secondary Causes
Labs
CBC, CMP, TSH

Diagnosis
Interventions

Serum 25(OH) D
Biomarker
WHO Definition
Age to Implement
Advise Diet
Calcium: mg/day, Age

Any of below
+
+
Premature
6 months
Consider w/risk
+
+
+
+
+
+ cortisol

+
+
+
Elderly

Children-Adolescence
No
Vitamin D: IU/ daily, Age 400-800
Elderly

ACPM (2009)
♂/♀ ≥ 50
+
+
All ♀ ≥ 65
♂ ≥ 70

NAMS (2010)
♀ ≥ 65
+ Consider Peri-M
+
+
All ♀ ≥ 65
♂ ≥ 70

MQIC (2012[revised 2014])
All at Risk
+ PM
+
+
White ♀≥ 65
♀/♂ FRAX score > 9.3%

NOF (2013)
PM ♂ & ♀ ≥ 50
PM ♂ & ♀ ≥ 50
+
+
♀ ≥ 65
♂ ≥ 70

♀/♂ 50-69
+
+
Premature
> 3 months
+
+
+
+
+
-

♀ ≥ 50
♀ ≥ 50
+ PM
Consider
+
+
Parental
+
+
+
+
+
+

+
+
+
Consider
+
+
1st o Relative ≥ 50
+
+
≥ 3 day
+
Only Assess Height yearly
+

♂ & ♀ 50-69
♂ & ♀ after 50
+
No-consider with risk
3 months
+
Parental
+
+
+
+
No
+
+

+

-

Limited utility
+
-

+
+
+
+
1500
♀ ≥ 50
800-1,000
♂&♀

?
FRAX >20%
All
1,200
♂&♀
800-1,000

PTH, Urine: cortisol,
histamine, protein
electrophoresis
+
Predict Fx Risk
+
PM & ♂ 50 ≥

1200
♀/♂ ≥50
800-1,000
♀/♂ ≥50

1,000, ♂ 50- 70
1,200 , ♀ 51 ≥ ♂ 71 ≥
800-1,000, PRN in
♂ & ♀ ≥50

104

104

Medication

Monitoring

Exercise
Weight Bearing
Muscle Strengthening
Balance Training- PT/OT
Adolescence
Fall Prevention
Lifestyle
Patient Education
Smoking/Alcohol Cessation
Treat
w/ Hip or Vertebral Fx
T-Score ≤ -2.5
Osteopenia PM
Osteopenia and
FRAX score ≥ 20%
OR Hip-≥ 3%
Steroid Use & T-Score ≤ -1.0
Duration
Medication Preference

Repeat DEXA

WHO (2003)

ACPM (2009)

NAMS (2010)

MQIC (2012)

NOF (2013)

+
+

+
-

+
+

+
+

+
+

-

+

+

+
+
+
+
+

+
+

+
+

?
+

?
+

+
+

+
Consider
-

+
-

+ PM
+ PM
+
+

+
+
Consider
+

+
+ Includes Lumbar
♀ & ♂ ≥50
+

Counsel HRT
Consider
SERM
Bisphosphonat
es

unknown
*Bisphosphonates
*Estrogen
*Raloxifene &
Teriparatide

+
Use Generic
Steroids: Use
Bisphosphonates
Men: Alendronate

3 – 5 years
Clinician Choice

-

2 years

Bisphosphonates
SERM Raloxifene
in younger PM
ET/EPT early PM
Teriparatide PM
high risk for fx
Calcitonin NOT
first- line treatment
2-5 years/untreated
1-2 years/treated
Clinical Changes
Yearly
Yearly
No

If normal
Insufficient evidence when
to repeat
Yearly
-

2-5 years

+
+
Use to monitor
3-6 months, Monitor
Response/Adherence
Response /Adherence
WHO = World Health Organization, ACPM = American College of Preventive Medicine, NAMS = North American Menopause Society, MQIC = Michigan Quality Improvement
Consortium, NOF = National Osteoporosis Society
FRAX = Fracture Risk Assessment Tool, ♂ = Female, ♀ = Male, Peri-M = Perimenopausal, PM = Post-Menopausal, FX= fracture, HX = History
CBC = Complete Blood Count, CMP = Complete Metabolic Panel, TSH = Thyroid Stimulating Hormone, PTH = Parathyroid Hormone
PRN = as needed, PT/OT = Physical – Occupational Therapy, BMI = Body Mass Index, DEXA = dual energy x-ray absorptiometry, SERM = Selective estrogen receptor
modulators, ET/EPT = Estrogen/Estrogen-Progesterone Therapy, HRT = Hormone Replacement Therapy
+ = guideline recommends, - = absent in guideline
Height/BMI
Fall Risk
Biomarkers

+
-
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Table 2
Osteoporosis Management Resources
Organization
Link
Who Fracture Risk Assessment
www.shef.ac.uk/FRAX/
Tool

Resources
Desktop application
iPhone© application
Web Version 3.8

International Osteoporosis
National Osteoporosis Foundation
Japan Osteoporosis Foundation

www.iofbonehealth.org
www.nof.org
www.jpof.or.jp

Management
Practice Guidelines
Data & Publications
Patient Education Materials

The European Society for Clinical
and Economic Aspects of
Osteoporosis and Osteoarthritis
National Guideline Clearing House

www.exceo.org

Publications
Reports

www.guideline.gov
search/search.aspx?term=
osteoporosis

162 Reported Osteoporosis
Practice Guidelines
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Table 3
Baseline Laboratory Tests for Osteoporosis
Baseline Labs
CBC

Disorder
Low HCT/HG: Anemia, Sickle Cell, Multiple
Myeloma, Alcohol Abuse

Reference Range
HCT 35-52 %
HG 12-18 g/dL
PLT 150-450
103/mm3
WBC 4-11 103/mm3

Serum Chemistries

Hypercalcemia: Malignancy or
Hyperparathyroidism

CA 8.6-10.2
mg/dL

Hypocalcemia: absorption of calcium from
bone, GI Malabsorption
Low Magnesium: alters calcium absorption
and metabolism

MG 1.6-2.6
mEq/dL

Low Creatinine: associated with increased
hyperparathyroidism

CRT 0.6-1.3
mg/dL

Elevated Creatinine: Multiple Myeloma, Renal
failure
TSH

Elevated TSH: Hypothyroidism

TSH 0.3-3.0
mIU/L

Liver Function
Tests

Elevated ALT/AST: Alcohol Abuse, Liver
Disease

ALT 10-40 IU/L
AST 10-34 IU/L

Serum 2525(OH)D 30ng/mL
Hydroxyvitamin D
Low values indicates Vitamin D Deficiency
Sources: Clinical Laboratory Reference, 2013; Jacobs-Kosmin, 2013; NOF, 2010[revise
2013]
CBC = Complete Blood Count, HCT=Hematocrit, HG=Hemoglobin, PLT= Platelets,
WBC= White Blood Count, BMP= Basic Metabolic Panel, CA=Calcium, MG=Magnesium,
CRT=Creatinine, TSH- Thyroid-Simulation Hormone ALT-Alanine Aminotransferase,
AST=Aspartate Aminotransferase, 25(OH)D=Serum 25-Hydroxyvitamin D
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Table 4
Fall Prevention
Intervention
Muscle Strengthening

Component
Core & Lower Extremities: In home program
 Ankle cuff weights 3 times a week: 2-5 lbs., 2 sets of 10 repetitions
2 times a day for 10-20 min.(Gardner et al., 2001)
 LiFE in-home exercise program; set of integrated balance and
strength train exercises integrated into activities of daily living
(Clemson et al., 2012)

Balance




Walking; tandem; on toes-heels, backwards, sideways
Turning Around, Stair Climbing, Stepping & Picking Up Objects,
Sit to Stand
(Campbell et al.,1997; Clemson et al., 2012; Gardner et al., 2001)

Weight Bearing Exercise






TaiChi (Bischoff-Ferrari, 2013)
Dancing (Howe, Rochester, Neil, Skelton, & Ballinger, 2011)
Yoga (Tiedemann et al., 2013)
Walking-Jogging; 30 min- three times a week Increase 5 min.
per week until total of 30 min (Gardner et al., 2001; BischoffFerrari, 2013) (Heike A. Bischoff-Ferrari, 2013) (Heike A.
Bischoff-Ferrari, 2013) (Heike A. Bischoff-Ferrari, 2013) (Heike
A. Bischoff-Ferrari, 2013)

Referrals

Diet

Optometry; cataract evaluation (Bischoff-Ferrari, 2013)
Primary Care
Neuropathy-Arthritis Evaluation
Medication review; Beers List (AGS 2012 Beers Criteria Update
Expert Panel, 2012)
Community Fall Prevention Programs
Home Health: NOF, 2010[revised 2013]
Home Assessment; remove obstacles, throw rugs, install bathroom
assistive devices
Footwear Evaluation; use athletic shoes (Menz et al., 2006)
Functional Assessment; include fear of falling evaluation
Homemaker Services
PT- OT; assistive device evaluation,
Lifeline Monitoring
Vitamin D Supplementation-800-1000 IU daily (Bischoff-Ferrari, 2013)

AGS = American Geriatrics Society
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Table 5
Bone Loss Prevention
Intervention
Diet Modification

Component
Diet History:
 Calcium rich foods: milk, cheese, yogurt, fortified juices
 Vitamin D rich foods: fish (salmon-tuna), fish liver oils, fortified
milk and cereals
 Moderate sun exposure
Supplementation:
 Institutes of Medicine
Men aged 50-70- 1000 mg of calcium daily
Women > 51 & Men > 7- 1,200 mg calcium daily


Collective Guideline Recommendations
Women & men age 50 and older: 1200-1500mg of calcium
daily, 800-1,00 IU Vitamin D daily

Weight Bearing
Exercise

Walking-Jogging; 30 min- three times a week

Medication
Management

Administration and Side Effect Profile See Table 5

Lifestyle Modification

Smoking cessation
Moderate alcohol consumption
Healthy basal metabolic index

Monitoring

Yearly follow up: height-weight, BMD 2-5 years, Fall Risk

Sources: Lim et al., 2009; NOF, 2010 [revised 2013]; NAMS, 2010; Office of Dietary Supplements:
National Institutes of Health, 2013, 2012; National Research Council, 2011
(National Research Council, 2011; Office of Dietary Supplements: National Institutes of Health, 2013; Office of Dietary
Supplements: National Institutes of Health, 2012)(National Research Council, 2011; Office of Dietary Supplements:
National Institutes of Health, 2013; Office of Dietary Supplements: National Institutes of Health, 2012)(National Research
Council, 2011; Office of Dietary Supplements: National Institutes of Health, 2013; Office of Dietary Supplements:
National Institutes of Health, 2012)(National Research Council, 2011; Office of Dietary Supplements: National Institutes of
Health, 2013; Office of Dietary Supplements: National Institutes of Health, 2012)
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Table 6
Osteoporosis Medications
Medication
Hormone Replacement
Selective estrogen receptor modulators
EVISTA

Administration/Monitoring
Prescribed Post-Menopausal

Common Side Effects
Blood Clot
Breast Cancer
Stroke

Bisphosphonates:
Alendronate (Fosamax)
Risedronate (Actonel)

Take on empty stomach with 8oz. of
water sitting upright for 30 min.

GI Upset

Oral: Take on empty stomach with 8oz.
of water sitting upright for 60 min
IV: administer over 15-30 sec every 3
months

GI Upset
Renal Failure:
monitor creatinine
levels

IV: administer over 15 min every 1-2
years
Pre-treat with acetaminophen

Arthralgia
Headache
Myalgia or fever

Use in high risk for fracture and
secondary bone loss
Administer subcutaneously daily
Do not stop abruptlyrapid bone loss ensues
Do not use in patients with:
Skeletal radiation treatment
Bone metastases
Hyperkalemia
History of skeletal cancers

Leg cramps
Nausea
Dizziness
Risk of osteosarcoma

Use high risk for fracture with bone loss
due to breast or prostate cancer:
Bone metastases from solid tumors or
giant cell tumor of bone
Administered subcutaneously every six
months
Monitor for hypocalcaemia, cellulitis,
rash, Osteonecrosis of the Jaw (ONJ)
and atypical femur fractures
Do not stop abruptly-rapid bone loss
ensues

Fatigue
Hypophosphatemia
Nausea
Arthralgia
Headache
Back pain
Extremity pain

Boniva

Zoledronic Acid (Reclast)

Parathyroid:
Teriparatide (Forteo)

Receptor Activator of Nuclear Factor
kappa-B (RANK) Ligand (RANKL)
Inhibitor:
Denosumab (Prolia/Xgeva)

Sources: Chlebowski et al., 2003; FDA, 2002, 2013a, 2013b, 2013c, 2013d, 2013e; Kleerekoper,
2008
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Table 7
Standard Menopausal Status Laboratory Values
Laboratory Test
FSH

Pre-Menopause
1.5 – 8.5 mIU/ml

Post-Menopause
30-100 mIU/ml

LH

1 – 15 mIU/ml

20-60 mIU/ml

Estradiol

30-120 pg/ml FP
100-210 pg/ml LF

10-35 pg/ml

FSH=Follicular Stimulating Hormone, LH=Luteinizing Hormone, FP=Follicular Phase, LF=Luteal
Phase
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CHAPTER THREE: METHODOLOGY
This chapter is divided into two sections: the experimental protocol and
procedures are presented in the first section, and the series of four experiments performed
during protocol development are presented in the second section. The actual written
protocols and procedures may be found in Appendices A-G.
Introduction
Bone loss in astronauts, a subject of scientific and practical interest to NASA,
(Willey, Lloyd, Nelson, & Bateman, 2011) occurs as a consequence of microgravity
environments; bone loss in older adults, a major focus of this investigator, occurs as a
consequence of aging and/or pathological disease processes. This shared interest in bone
loss led to a collaborative relationship between this investigator and the NASA Ames
Research Center Bone and Signaling Laboratory, located in Mountain View, California.
Bone loss is thought to occur due to an imbalance in osteoblast and osteoclast
activity. A search of the literature for an appropriate experimental protocol revealed that,
although there were a few protocols for investigating the effects of Near Infrared Light
Emitting Diode (NIR-LED) in osteoblast cell culture models (Renno et al., 2007;
Yamada, 1991), there were no existing protocols to examine the effects of NIR-LED on
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-induced
osteoclastogenesis (osteoclast proliferation and differentiation) in cell culture. Therefore,
the first step in this study was to develop a protocol that would allow the investigation of
the effects NIR-LED photobiomodulation affecting osteoclast proliferation and
differentiation in a cell culture model. The purpose of this chapter is to describe the
development of a new experimental protocol conducted at the NASA Ames Bone and
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Signaling Laboratory. A custom designed protocol resulted in an experimental design
that would allow the investigation of NIR-LED treatment in a cell culture model as an
intervention possibly to prevent and/or treat bone loss.
Before undertaking the creation of an experimental protocol, a review of the
literature was conducted to identify any experimental protocols similar to this study’s
hypothesis. The literature search yielded five similar experimental protocols and
procedures investigating the use of NIR-LED treatments affecting osteoclastogenesis
(Aihara, Yamaguchi, & Kasai, 2006), osteoblastogenesis (Renno et al., 2007; Yamada,
1991) and other different cell-type culture models (Wong-Riley et al., 2001; Wong-Riley
et al., 2005). This protocol was developed by first creating a template that combined
aspects of an existing experimental protocol investigating osteoclastogenesis at NASA
Ames Bone and Signaling Laboratory. The existing experimental protocol was entitled
“collection medium protocol” (see Appendix A) and was created by a post-doctoral
fellow for another experimental project that investigated the effects of heavy ion
irradiation on osteoclastogenesis in cancellous tissues under the conditions of
musculoskeletal disuse (Yumoto et al., 2009). This osteoclast cell culture protocol was
found to be successful in yielding consistent proliferation and differentiation of osteoclast
cells therefore; it was used as a template protocol model.
Section One
Protocol Description
Each experiment took 7 days to complete and was comprised of the following
steps: Step 1) preparation of the RAW 264.7 cell line derived from mouse leukemia
monocyte macrophages and culture medium for cell propagation (see Appendix B); Step
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2) propagation of the RAW 264.7 cell line (see Appendix C); Step 3) cell plating (see
Appendix D) and RANKL induction: cell culture days 0 and 1 (see Appendix E); Step 4)
NIR-LED treatment—single light treatment groups: cell culture day 2; NIR-LED
treatment—multiple light treatment groups: cell culture day 2, 3, 4, 5; Step 5) TRAP
staining: cell culture day 7 (see Appendix F); and Step 6) manual cell counting rules (see
Appendix G). The final schematic experiment timeline which will be discussed in detail
in the second portion of the manuscript is presented in Figure 1.
Figure 1
Experiment Protocol Timeline
Day 0

Day 1

Plate
RAW
Cells

Add
RANKL

Day 2

NIR TRT
#1

Day 3

NIR TRT
#2

Day 4

Day 5

Change Medium: NIR TRT
Add fresh RANKL
#4
NIR TRT
#3

Day 6

Day 7

------TRAP Staining ----

Protocol Development There are six steps in this experiment protocol and
procedure. The first step is to obtain fresh cultured cells from a manufacturer, and
second, propagate the cell line to prepare for experiment cell plating. The third step is to
cell plate the experiment according to experimental groups. After this, the fourth step is
to conduct the intervention, providing NIR-LED treatment to experimental groups, and
fifth, at experimental end, stain the cells in preparation for the sixth step, manual cell
counting. Problems encountered during the development of the experimental protocol
and decisions made to change the protocol or procedure as to avoid confound variables to
the experiment are presented in section two.
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Step 1: Preparation of the Cell Line and Culture Medium
Cell line: The RAW 264.7 cell line is derived from mouse leukemia monocyte
macrophages obtained from American Type Culture Collection (ATCC). This cell line
was developed by Raschke and colleagues in 1978 and is kept in a cell repository for
purchase through the ATCC for research (American Type Culture Collection [ATTC],
2009; Raschke, 2010; Raschke, Baird, Ralph, & Nakoinz, 1978) (See Figure 2). A
microscopic cell appearance example is presented in Figure 2. The letter of permission
can be found in Appendix J.

Figure. 2
RAW 264.7 Cell Appearance

(American Type Culture Collection, 2009)
http://www.atcc.org/~/media/6FC6DC948CC64496A158674CEFEE7826.ashx
Frozen RAW 264.7 cells were shipped directly from ATCC to the laboratory and
were handled under bio-safety level 2, moderate risk-suitable for personnel with specific
training in handling pathogenic agents (U.S. Department of Health and Human Services
Public Health Service, 2007), and were stored at -80°C in a polypropylene 3ml conical
tube.
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Culture Medium: In the late 1950’s, Eagle (Sigma-Aldrich, 2010) developed
one of the first cell culture growth mediums called Basal Medium Eagle (BME). Eagle
then modified this medium with a higher concentration of essential nutrients which was
named Modified Eagle's Medium (MEM). Dulbecco (JR Scientific Inc., 2007) made one
of the many modifications to Eagles BME, thus naming the culture medium Dulbecco’s
Modified Eagle's Medium that contains a four-fold concentration of amino acids and
vitamins compared to BME to support growth of primary mouse and chicken cell cultures
it is one of the most widely used cell culture growth mediums. Alpha Modification of
Modified Eagle's Medium (ά-MEM) was developed to grow hybrid mouse and hamster
cells (Atlanta Biologicals, 2010) and is further supplemented with additional amino acids
and vitamins.
The ATCC recommends a base culture medium consisting of Dulbecco’s
Modified Eagle's Medium (DMEM) (Raschke, 2010) stored at 2-8°C with the added
components of 10% fetal bovine serum (FBS) (ATTC, 2009; Invitrogen, 2010a).
However, the Ames Bone and Signaling Laboratory found that RAW 264.7 cell growth
was greater when ά-MEM Invitrogen Catalog number: 12571071 (Invitrogen, 2010b)
with the added components of 10% FBS (Yumoto et al., 2009) was used for experiments
stored at 2-8°C.
Cell culture growth medium was prepared prior to cell line thawing (RAW 264.7
cells) and the manufactures procedure for heat inactivation was followed (HyClone,
2003). The culture medium used for RAW 264.7 cell propagation was ά-MEM, with
10% FBS. The FBS was derived from the blood of animals (bovine, equine, porcine).
Fetal bovine serum must be heat inactivated and filtered prior to being added to the base
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medium. The FBS was heat inactivated by heating in a 56°C water bath to destroy heatlabile complement proteins. The medium was ready for cell culture propagation and cell
line thawing was initiated. Both procedures are found in Appendix B.
Step 2: Propagation of the RAW 264.7 Cell Line
The goal was to propagate a healthy cell line for experimentation and there are
two stages in this step. To begin, cells must be propagated over a week to observe for
proper cell function and judge their viability for experimentation.
According to Cooper (2000), cell division is variable depending on cell type, but
most eukaryotic cells in culture divide approximately every 24 hours. There are two
basic parts of the cell cycle: mitosis (nuclear division) and interphase (DNA replication).
During cell mitosis there is the separation of the daughter chromosomes, ending with
cytokinesis (cell division). Since mitosis and cytokinesis only last for about one hour, the
majority of the cell cycle is spent in interphase where cell growth and DNA replication
occur to prepare for cell division in RAW 264.7 cells. By allowing newly plated cells to
proliferate over several days, the researcher is able to observe the morphology (cell
appearance) and behavior of the cell line (RAW 264.7) prior to experimentation. In order
for successful propagation to occur, the cell line was maintained in an incubator (Thermo
Scientific: CO2 Series II water jacketed) at 37°C in 5% CO2 for no longer than 30 days,
and passaged (as described below) (Rice University, 2010) every three days with 10%
FBS with ά-MEM according to the ATCC cell propagation guidelines to maintain
optimal cellular metabolism and health (Raschke, 2010). The incubator provides an
environment maintained at a consistent temperature. Once the cell line is determined to
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be healthy by observed cell growth by increasing cell confluence (coming together), cells
may be used for experimentation.
RAW 264.7 cell passaging: Passaging culture cells means to split or divide cells
from mature cell culture plates. This procedure is done to maintain the viability and
growth of cells within the cell culture line. When RAW 264.7 cells are left in culture for
an extended period of time, usually greater than three days, they become confluent (run
together) and grow in clumps. If the cells are not “split up” they will grow on top of one
another and will eventually die due to the lack of surface area upon which to grow. Cell
passage is the method by which cell clumps are dislodged via cell scraping and then subcultures are created. A certain percentage of cells are re-suspended with fresh medium in
new cell culture dishes according to cell concentration ratios. (see Appendix. C)
Step 3. Cell Plating Procedure
This step required two experimental days, Day 0 (Plate labeling & cell plating)
and 1 (RANKL induction).
Day 0: Plate labeling: Each plate was labeled according to experimental
condition: number of light treatments (1 or 4), energy density (varied by experiment: 4.5
or 45 J/cm2), RANKL dose (varied by experiment: 0, 25, or 50 ng/ml or 0, 2.5, 10, 25 or
50ng/ml). The following is a labeling example used for the experiments: control (no
light treatment), single light treatment, and multiple light treatment groups, respectively.
1. Control [0-0-0], translates to [0] light treatment, energy density [0 J/cm2], and RANKL
Dose [0 ng/ml].

2. Single [1-4.5-50], translates to [1] light treatment, energy density

[4.5 J/cm2], and RANKL Dose [50 ng/ml]. 3. Multiple [4-45-25], translates to [4] light
treatments, energy density [45 J/cm2], and RANKL Dose [25 ng/ml].
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Experimental conditions, RANKL dose, and energy density are described in
subsequent sections in which the NIR-LED equipment and procedure are explicated.
However, in the first four experiments due to the limitations of the WARP™ 10, the
surface area of light illumination could optimally irradiate 2 wells at one time (well row
B by columns 3-4). Therefore, multiple 24-well plates had to be used (see Figure 3 in
List of Figures). In the final two experiments, the WARP™ 75 surface area of light
illumination was great enough to irradiate a maximum of 15 wells at one time (well row
A-B by columns 2-6).
The experimental condition labeling procedures for the final two experiments
used a higher sample number than our first four experiments summarized in Appendix H,
Table 1. Summarizing the steps involved to cell plate the experiment included: the
number of wells for each cell culture plate was calculated. Second, medium was placed
into the wells, and then from the propagated cell line culture, a cell suspension was
calculated to determine the amount of cells to be deposited into each well. On Day 0
(first day of experiment) RAW 264.7 cells were plated at 2 x 104 cells per well (4x104
cell/ml) in two center wells of a 24-well plate (well diameter: 1.77mm) for the first four
experiments and 5 wells for the last two experiments for each experimental condition.
The full procedure is found in Appendix D.
Day 1- RANKL Induction Procedure: The plates were cultured for 24 hours
prior to RANKL induction. At the end of the 24 hour period, RANKL was added to each
plate well at a dose of 0, 2.5, 10, 25 or 50ng/ml. This particular cell line requires the
induction of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) in order to
promote osteoclast formation. The induction method is a follows: Osteoblast stromal
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cell membrane RANKL receptor, binds to the osteoclast precursor cell (macrophage)
RANK receptor. When this occurs, RANK signaling activates the transcription nuclear
factor Kappa-B to differentiate into osteoclasts (Kumar, 2010).
In order to calculate the correct RANKL dose added to the cell culture, a serial
dilution was used. A serial dilution is a stepwise dilution of a substance, in this case
RANKL. At each step of dilution, the dilution factor changes as seen in Table 2,
Appendix H.
The original stock concentration of RANKL from the manufacturer was 100µg/ml
(PeproTech). Converted to ng this would be 100 x 103 ng/ml. For experimental use,
RANKL was aliquoted into smaller volumes (10µl) at a 1250ng/ml concentration (see
Appendix E)
Step 4: NIR-LED Treatment
NIR-LED treatment was initiated on Day 2 for all experiments regardless of
whether the experiment was testing single or multiple light-treatments. Experiments in
which multiple light-treatments were the focus had repeated exposure on Days 3-5 for a
total of 4 light treatments. A continuous wave NIR-LED WARP™10 (Quantum Devices,
Barnevelle, WI) with a wavelength of 670nm, power intensity of 60mw/cm2 and energy
density of 5 J/cm2 was used in the experiments because it was shown in previous studies
to produce positive cellular effects (Desmet et al., 2006; Eells et al., 2007; Eells, 2004;
Karu, 1988; Liang, Whelan, Eells, & Wong-Riley, 2008; Pinheiro et al., 2002; Whelan et
al., 2003; Whelan et al., 2008; Wong-Riley et al., 2001; Wong-Riley et al., 2005). The
dosage of light treatment was determined by applying the following formula: Power
(mW/cm2) x Time (seconds) ÷ 1,000 = Energy Density (J/cm2) in order to deliver 4.5
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J/cm2 and 45 J/cm2. To ensure delivery of an accurate energy density of 4.5 J/cm2 and 45
J/cm2, each light treatment was timed to 80 seconds to deliver 4.5 J/cm2 and to 800
seconds to deliver 45 J/cm2.
Light treatment began on cell culture Day 2 (Stein et al., 2005; Yamada, 1991)
under a sterile laminar hood with the dish lid in place. When multiple light treatments
occurred, three more consecutive days of treatments for a total of four treatments were
performed. The plates receiving multiple light treatments were treated according to the
following protocol. On culture day two of the light treatment, plate 1 was treated first and
then plate 2, 3, and 4 were treated. On culture day three of the light treatment, plate 2 was
treated first, and then plates 3 and 4 were treated while plate 1 was placed at the end of the
treatment order. On culture day four of the light treatment, plate 3 was treated first and
then plates 4, 1, and 2. On culture day five of the light treatment, plate 4 was treated first
and then plates 1, 2 and 3 were treated. This was to control for objectivity and amount of
time the plates were out of the incubator.
Step 5: TRAP Staining Day 7
For purposes of these experiments, TRAP staining (SIGMA #387) was the method
employed for manual osteoclast cell counting. Using a visual cell counting classification
tool, those multinucleated cells that were stained with a light pink/purple were identified
by light microscopy (inverted microscope, 10x magnification; Nikon Eclipse TS100) and
counted. The procedure used for TRAP cell staining was obtained from SIGMA Acid
Phosphatase Leukocyte Kit (prod #387) (see Appendix F). Cells were fixed with a
formaldehyde solution to stop the cellular activity and prepares them for staining. The
cells were stained with fast garnet solution which identifies the release of the enzyme,
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TRAP. The cells that were both stained a light pink/purple and were multinucleated were
assumed to be releasing TRAP and, therefore, were considered osteoclast cells.
Step 6: Manual Cell Counting Classification Tool
When macrophages differentiate into osteoclast cells, the enzyme, bound in the
cell membrane, Tartrate-Resistant Acid Phosphatase (TRAP) is stained for cell counting.
This enzymatic activity has been historically regarded as one of the reliable markers of
osteoclast identification (Nakano, Toyosawa, & Takano, 2004). There are several
methods to identify osteoclast cells, such as TRAP staining (Susa, Luong-Nguyen,
Cappellen, Zamurovic, & Gamse, 2004), TRAP5b ELISA assay (Halleen et al., 2000), or
computer imaging of histological slides (Reed, Conzemius, Robinson, & Brown, 2004).
However, for this study a visual cell counting classification tool was developed to
guide in the cell counting process (see Appendix G). Plates were blinded. To be
counted as an osteoclast, all cells were TRAP+ stained with a pink/purple or dark purple
bordering on black (if nuclei were visible). To determine the faintest acceptable pink, the
stain color should match the RANKL control pink stain. The counted cells should be
stained darker than the control faint pink. The cell was counted if there were three or
more nuclei present. While clumps of TRAP+ mono-nucleated cells were not counted,
and cells connected by cell processes were counted as separate cells. Mean osteoclast
well counts per well and standard deviations were calculated by taking the sum of
multinucleated TRAP+ osteoclast cells for each well and dividing by the well surface
area, expressed as cells per cm2. To determine light treatment effects, differences
between osteoclast cell counts in treatment plates and controls were calculated.
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Six experiments were conducted. Presented below are the first four experiments
conducted. These four experiments were used as an exercise by which to develop the
experimental protocol and procedure to ensure the reliability of equipment and cell
culture and procedure techniques. Results are reported with the subsequent change to the
experimental protocol and procedure. The final two experiments are presented in
Chapter IV, in the manuscript entitled, Effects of Photobiomodulation in Osteoclast
Formation in Vitro: a Pilot Study and represent the culmination of the dissertation work.
The following are the equipment testing experiments for the WARP™ 10 and
WARP™ 75 NIR-LED lights [e1386, e1389] which are followed by the four WARP™
10 NIR-LED experiments (e1386, e1380, e1383, e1384, and e1385). Each experiment is
identified by an experiment number (assigned and recorded by the NASA Bone and
Signaling Laboratory). Problems that occurred and the resolution to correct the problem
within the protocol are discussed for each experiment.
Equipment Testing Experiments
In order to determine the functionality and possible experimental confounding
effect of the WARP™ 10 and WARP™ 75, NIR-LED lights, two equipment tests were
conducted.
e1386: WARP™ 10 and e1389: WARP™ 75 Equipment Tests: In laser
medicine the most common use of lasers has been in surgery to cut, coagulate, or ablate
tissue. The laser’s mechanism of action in this instance is to destroy tissue and provide
precise surgical incisions. This is achieved by heating the tissue at a high irradiation
intensity and energy density. However, there are other uses for lasers.
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The rationale for testing the equipment was to determine possible confounding
variables that could affect the experiments. In the 1980’s photobiomodulation—referred
to in the literature as low-level laser therapy, cold-laser therapy, or laser biostimulation—
was introduced. This laser “light treatment” uses light in the infrared to near-infrared
region of the absorption spectrum (630-1000nm) which is known to affect numerous cell
functions that are dependent on the energy production in the mitochondria (Desmet et al.,
2006; Karu et al., 1987). At low light intensity, such as 670 nm, a photochemical
conversion of energy absorbed by non-specialized photoacceptors on the mitochondria
and generates heat (Karu, 1988; 1999; Letokhov, 1991). Raising the temperature of these
molecules triggers biochemical reactions that may activate or inhibit cellular enzymes
that turn cellular functions “on” and “off” (Karu, 1999). This may result in positive or
negative events. If the heat generated exceeds the optimal cell line temperature for cell
growth, in this case body temperature (37°C), it is referred to as “heat shock”. Heat
shock at 41°C can stress the cells and result in the release of heat shock proteins, which
may cause harm to the cell (Levin, Wickliffe, Leppla, & Moayeri, 2008). Several
investigators reported that continuous wave light treatment generates minimal local
heating of photoacceptors because the wavelength used is of low irradiation intensity
(670nm) (Karu, 1992; Letokhov, 1991), thus, heat shock is avoided.
Because there were only a few studies testing local heating of photoacceptor
molecules, this principle was investigated. In addition, there was concern regarding
possible heat shock due to the use of the WARP™ 10 and WARP™ 75, because they
were commercial continuous wave light sources that automatically shut off every 80
seconds requiring a manual restart. Therefore, the 80-second light treatment (4.5 J/cm2)
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did not require manual restarts, but the 800 second light treatment (45J/cm2) required 10
manual restarts. This manual restarting of the light treatment causes a brief surge of local
heating. This surge could be considered pulsing light treatment which has been shown in
the literature to give a greater biological effect than continuous wave light treatment
(Karu, 1992).
Light treatment temperature testing was performed with a thermistor in both the
WARP™ 10 (e1386) and WARP™ 75 (e1389) as described in the “Light Treatment
Procedure”. Cell culture plates were removed from the 37°C incubator and placed on a
metal table. The temperature of the cell culture medium at the beginning of the
experiment was 30.7°C – 32.3°C. The temperature testing procedure at room
temperature was repeated two or three times at 80 seconds and 800 seconds (the length of
both light treatment groups in this experiment). During the light treatment exposure the
temperature of the cell culture medium never rose above 37°C.
Treated with the WARP™ 10 for 80 seconds, the cell culture medium had an overall
drop in temperature of 0.9°C – 1.4°C, while that treated for 800 seconds had an overall
drop in cell culture medium temperature of 5.6°C–7.6°C. The cell culture medium
treated with the WARP™ 75 had an overall drop in temperature of 1.8°C for both the 80and 800-second light treatment. During the WARP™ 75 multiple light treatments (which
required 10 manual restarts), temperature of the cell culture medium initially dropped by
0.9°C–2.3°C, but then at approximately 265 seconds (4 minutes, 25 seconds) into the
treatment, the temperature increased overall by increments of 1.6°C–1.8°C. It was
concluded that heat shock had most likely not occurred because temperature change did
not reach 41°C.
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Section Two
Four Protocol Development Experiments
NIR-LED Experiments
Experiments e1380 and e1383 tested multiple light treatments and single light
treatments. Experiments e1384 and e1385 tested only single light treatment. All
experiments tested energy densities of 4.5 & 45 J/cm2. Lastly, RANKL dose response
was tested at 0, 25, & 50 ng/ml in experiments e1380, e1383, e1384, e1385. (see
Appendix H Table 3)
Experiment # 1: e1380
In this experiment, six complications were encountered. Each complication is
discussed with its subsequent decision made in changing the protocol or procedure. This
experiment multiple light treatments and single light treatments at 4.5 J/cm2 and 45 J/cm2
at RANKL doses of 0, 25, and 50ng/ml were tested. A lack of osteoclast cell
differentiation was noted in this first experiment. The following are the encountered six
complications.
1. A lack of osteoclast cell differentiation may have occurred due to premature
RANKL induction. In accordance with the “collection medium protocol” (see Appendix
A) RANKL induction occurred 6 hours after cell plating. Possibly, the RAW 264.7 cells
did not have enough time to adhere to the well plate and proliferate sufficiently for
osteoclast cell differentiation. Correction: Therefore, other NIR-LED cell culture model
experiments found in the literature (Renno et al., 2007; Wong-Riley et al., 2001; Yamada,
1991) were consulted and the decision was made to induct RANKL 24 hours after cell
plating to allow for better cell/plate adhesion. This decision was reached because it was
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thought that when the medium was changed, many free floating cells were extracted
leaving too few cells to propagate and adhere.
2. A lack of osteoclast cell differentiation may have occurred due to
miscalculating the cell density when preparing a cell suspension used to plate cells at cell
density of 4 x 104 cells per/ml. An error was made in loading the hemocytometer: there
were too few cells counted in the cell suspension. Correction. In subsequent
experiments, the investigator consulted with the lab technician to avoid errors such as
checking mathematical calculations and observing the investigator’s pipetting technique
because many cell wells were void of cells mid-well due to investigator aggressive
pipetting, resulting in loss of reliable data collection. The investigator practiced pipetting
to prevent mid-well washing, hemocytometer calculation, and propagating cells RAW
cells. The importance of consistent cell plating with correct cell suspension is
imperative because if too many or few cells are plated, cell wells may encounter cell
confluence (making cell counting difficult) or non-cell adhesion.
3. A lack of osteoclast cell differentiation may have occurred due to leaving all of
the cell culture plates out of the incubator during all of the light treatments. Correction.
In future experiments each cell culture plate was kept outside the incubator only for the
length of its light treatment, approximately 80 to 800 seconds. A decrease in cell well
medium temperature may affect cell differentiation adding a confounding variable
because the control did not encounter the same experimental conditions.
4. A lack of osteoclast cell differentiation may have occurred due to pre-mature
NIR-LED shut-off and limitations of the WARP™ 10 unit. Because the WARP™ 10 is a
commercial product for the general public, it is battery powered and automatically turns
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off every 80sec to avoid overheating because of repeated consecutive use. In addition,
over the span of the treatment time the light intensity may have diminished due to it being
battery operated affecting the dosing of NIR-LED photobiomodulation and altering
reliable data collection. Correction. These limitations had to be accepted during these
preliminary experiments and were controlled by manually restarting the WARP™ 10 by
switching to rechargeable batteries which were cooler and may have delayed overheating,
by changing to fresh batteries more frequently, and by allowing the light to cool five
minutes between the 45 J/cm2 treatments. This was done to avoid heating the cell culture
medium.
5. A lack of osteoclast cell differentiation may have occurred due to the
investigator error of cell plating only two control wells. It was determined that two
control wells were too few because one well was lost due to contamination, leaving only
one control well. Correction. An extra set of control wells per experimental condition (n
= 5). In the final experiments reported in chapter four, two sets of controls were plated (n
= 10) to prevent the loss of controls. If an experiment’s controls do not produce reliable
cell counts or are flawed, the experiment data cannot be interpreted. If the first control
was flawed, then the second control was used for data analysis.
6. Lastly, a lack of osteoclast cell differentiation may have occurred due to
possible RANKL derogation. In order to determine if the potential cause for poor
osteoclastogenesis occurring in experiment e1390, it was thought that possibly the
PeproTech RANKL may have derogated due to freezing/thaw cycles or perhaps the
carrier protein, Bovine Serum Albumin (BSA), added to the RANKL delusion was
responsible for the lack of osteoclastogenesis. This also may have occurred due to using a
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manufacturer of RANKL (PeproTech) that differed from the manufacturer of the “culture
medium protocol” (Sigma) (see Appendix A). Therefore, experiment e1382 was
conducted by the lab technician who compared osteoclastogenesis using PeproTech
RANKL and Sigma RANKL and BSA vehicle control. Correction. Based on
experimental results, PeproTech RANKL was chosen for subsequent experiments
because it yielded three times more osteoclasts with doubled RANKL, larger cell size,
and dark-pink and/or purple TRAP+ stained cells with bright distinctive nuclei compared
to Sigma RANKL. Further, BSA did not affect cell growth or morphology. Therefore,
RANKL could be reconstituted for future experiment use in sterile pyron-free water with
0.1% BSA carrier protein which will remain stable for three months stored at -20oC.
Consequently, RANKL used in e1390 was derogated and any unused RANKL that was
prepared for osteoclast induction was discarded after use and not refrozen. If the
cytokine added to cell cultures is derogated, a poor biological signal results and data
analysis may be flawed due to derogated cytokine versus a freshly suspended cytokine.
Conclusion. Because of the above complications the data collected in this
experiment were not reliable and were not analyzed. However, alterations were made to
the experimental protocol in experiment #2 (e1383). Overall, the investigator acquired
cell culture knowledge in technique, control of samples, cytokine preparation, cell
plating, and suspension. The most important protocol change was the increase in number
of control cell wells because losing control data nullifies an entire experiment. New
information and learning was evident by understanding how manufactures of RANKL
may differ, inexperienced cell culture skills can alter data collection reliability, as well as
simple miscalculation errors.
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Experiment # 2: e1383
With these protocol changes mentioned above, the biphasic dose response curve
for both RANKL dose and energy density were repeated in our next experiment to
illustrate the expected dose response to photomodulation and RANKL dose. If
insufficient energy or RANKL dose was delivered, there would be no response because
the dose minimum threshold was not met. However, if too much energy or RANKL
dose, minimum threshold was crossed then biostimulation disappears and only
bioinhibition occurs (Huang, 2009). A new treatment variable was added, multiple light
treatment, the literature reflected a gap in this type of NIR-LED light treatment (Huang,
2009). This experiment tested multiple light treatments and single light treatments at 4.5
J/cm2 and 45 J/cm2 at RANKL doses of 0, 25, and 50ng/ml.
1. It was noted that the expected normal RANKL dose response during
osteoclastogenesis was reversed between RANKL doses 25 ng/ml and 50 ng/ml in one of
the control plates. A normal dose response during osteoclastogenesis would be a one-fold
increase from the 25ng/ml to the 50 ng/ml doses. Correction. Because there was a
correct dose response in the treatment plates, it was unclear where an error had been
made. Possibly the RANKL dose was inversely inducted. The backup control was used
for data analysis. No changes were made to the protocol.
2. Investigator error was noted in miscalculating the cell density when preparing a
cell suspension for plating cells, even though this was checked by the lab technician. An
error may have been made when loading the hemocytometer, again resulting in too few
cells for the cell suspension. However, there was success in osteoclastogenesis
throughout all experimental and control plates, so it was thought that enough cells
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adhered to the cell plate. The lab technician questioned the cell plating density because
there was confusion in the lab notes from the “conditioned medium protocol”. The
“conditioned medium protocol” stated that the cell plating density was 4x104 cells/ml (see
Appendix A). Usually, cell plating density is reported as the number of cells per well not
the number of cells per milliliter. The lab notebook stated the cell plating density to be
2x104 cells/well. This may result in too few cultured RAW cells and therefore few
osteoclasts may differentiate with RANKL. Correction. To check if the cell plating
density was correct, the lab technician calculated that 4x104 cells/ml equals 2x104
cells/well. The protocol continued to use 4x104 cells/ml. Due to this continued problem
of calculating the cell density and cell plating, the lab technician calculated and
performed the cell density and cell plated experiment e1384 as to correct problems with
intra-rater reliability.
Conclusion. The effects of single light treatments at energy densities of 4.5 J/cm2
and 45 J/cm2 at RANKL doses of 0, 25 and 50ng/ml are presented in Figures 4 and 5.
Comparing single NIR treatment at 4.5 and 45 J/cm2 and RANKL dose 25ng/ml the there
was less of a biostimulatory effect by 54% (see Figure 4) and 32% respectively (see Figure 5).
To a lesser extent, osteoclastogenesis was inhibited in RANKL dose 50ng/ml at 4.5 J/cm2

and 45 J/cm2, 37% and 10% respectively compared to controls. The dose response of
RANKL may have reached minimal threshold at 25ng/ml and require testing a lower
RANKL dose. However, light treatment was not biostimulatory at both energy densities.
If a normal biphasic energy density dose response was evident, there should be evidence
of stimulatory effect. Therefore, a lower energy density variable (2.25 J/cm2) was added
to the experiment #4 e1385 protocol. It is premature to determine if these energy
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densities are biostimulating or bioinhibiting, as it is possible the energy density is too
intense for the RAW RANKL induced osteoclast in vitro cell type compared to other
light treatment cell culture studies using similar variables. Further knowledge was gained
in regards to protocol development based upon dose response curves.
Figure 4
e1383 WARP™ 10: Single NIR treatment 4.5 J/cm2 RANKL dose 25 &50ng/ml
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Figure 5.
e1383 WARP™ 10: Single NIR treatment 45 J/cm2 RANKL dose 25 &50ng/ml
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A summary of the effects of multiple light treatments at energy densities of 4.5 J/cm2
and 45 J/cm2 at RANKL doses of 0, 25 and 50ng/ml are presented in Figures 6 and 7.
Multiple light treatments at 4.5 & 45 J/cm2 and RANKL dose 25ng/ml inhibited
osteoclastogenesis by 70% (see Figure 6) and 44%, respectively compared to controls
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(see Figure 7). No effect was seen in RANKL dose 50ng/ml at 4.5 J/cm2 and 45 J/cm2 or
in single vs. multiple light treatment groups. The same rational was applied to these
results as above to investigate variables that may produce a stimulatory response.
Therefore, the protocol was simplified to test single light treatment at 4.5 J/cm2 and 45
J/cm2 with RANKL doses 0, 25, and 50ng/ml in order to gain a better understanding of
the inhibition or biostimulatory effect.
Figure 6
e1383 WARP™ 10 Multiple light treatment 4.5 J/cm2 RANKL dose 25 &50ng/ml
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Figure 7
e1383 WARP™ 10 Multiple light treatment 45 J/cm2 RANKL dose 25 &50ng/ml
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Experiment #3 e1384
Two complications problems were encountered in this experiment which tested only
single light treatments at 4.5 J/cm2 and 45 J/cm2 at RANKL doses of 0, 25, and 50ng/ml.
1. Increased cell well confluence, cell floaters, and large cell clumps were noted in all
control plates starting on cell culture day 1. It was noted that the expected normal
RANKL dose response during osteoclastogenesis was reversed between RANKL doses
25ng/ml and 50 ng/ml in the control plates (see Figure 8). The experiment was continued
because all other cell wells in treatment plates were progressing normally. However,
when TRAP staining was performed fewer TRAP+ cells were noted in the control wells
and it was determined that the control plates were flawed. Correction. The data from the
controls were was not to be used in the data analysis; however the results from this
experiment could be used to determine NIR-LED effects between single-treatment 4.5
J/cm2 and 45 J/cm2 light treatment groups. In reflection, it would have been more cost
effective to have stopped the experiment and restart the protocol. The loss of controls
nullified the majority of the experimental data.
Figure 8
e1384 WARP™ 10 Dose Response Control Plates 4.5 J/cm2& 45 J/cm2 RANKL dose 25
&50ng/ml
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Problem 2: A protocol error was made on Cell Culture Day 0 which is the day
that RANKL is added to the medium. Usually the cell culture medium is changed only
on Day 3; however the investigator mistakenly changed the medium and then added
RANKL on Day 0. There was a concern that some cells were discarded with the medium,
leaving too few cells to adhere to the cell plate. Resolution: In order to control for this
change in the protocol to determine the reliability of the data collected from e1384 NIR
#3 another experiment e1385 NIR #4 was conducted to determine if changing medium on
cell culture Day 0 vs. Day 3 would effect osteoclastogenesis.
Conclusion: Presented in Figure 9 is the comparison of the effects of single light
treatments at energy densities of 4.5 J/cm2 and 45 J/cm2 at RANKL doses of 0, 25 and
50ng/ml. Comparing Single Light treatments at an energy density of 4.5 J/cm2 vs. 45
J/cm2 at RANKL dose 25ng/ml and 50ng/ml, 4.5 J/cm2 inhibited osteoclastogenesis by
29% and 5%, respectively. It appears that the 4.5 J/cm2 treatment dose stimulated
osteoclastogenesis less than the 45 J/cm2 light treatment dose. The RANKL dose appears
to produce a stepwise progression, therefore the RANKL dose should be replicated with
possibly additional low dose RANKL added. It is unclear if the energy density response
is significant, and the experiment would benefit from testing at a lower energy density.
Figure 9
e1384 WARP™ 10 Single Light Treatment 4.5 J/cm2vs. 45 J/cm2 RANKL dose 25 &50ng/ml
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Experiment #4 e1385
This experiment was performed using the final protocol developed from the
previous experiments. The purpose of this experiment was to determine if changing the
medium on cell culture day 0 instead of cell culture day 3 affected osteoclastogenesis in
e1384. This experiment tested only single light treatments at 4.5 J/cm2 and 45 J/cm2 at
RANKL doses of 0, 25, and 50ng/ml. There were no problems associated with this
experiment and it was determined that changing the medium did not affect
osteoclastogenesis.
Conclusion
RANKL induced osteoclast formation by RAW cells occurred as expected in all
experiments, however in e1383 and e1384 a typical dose-dependent response (0, 25, 50
ng/ml) was not observed in controls but in treatment groups. In all experiments using
light treatment without the induction of RANKL at these doses and regimes, no effect
was measured on osteoclast formation. A single NIR light treatment at energy density
4.5 J/cm2 may inhibit RANKL (25ng/ml)-induced osteoclast formation seen in e1383.
However, controls were in inverse dose response. Multiple light treatments may be more
effective in inhibiting osteoclastogenesis than single light treatment alone as seen in
e1390. Based upon these summarized data, protocol modifications were made
accordingly and effects were noted for future comparison to pilot data. The final protocol
timeline reflects the experimental design divided by cell culture Days 0-7. (see Figure 1)
In some of the experimental control groups, there was a progressive biological
dose response in osteoclast cell count that correlated to increasing doses of RANKL.
Low dose RANKL-induced cell cultures had lower osteoclast cell counts compared to
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RANKL-induced cell cultures with progressively increasing RANKL doses.

After a

successful experimental protocol was developed, the next step was to use this protocol in
a pilot study to obtain reproducible data validating the experimental methodology. A
pilot study was planned with the use of a more reliably functioning light source (WARP
™ 75) (as determined by e1389) to allow for greater control to deliver light treatments
with low variability of energy density and light intensity. Added lower doses of RANKL
dose 2.5 and 10ng/ml and lower energy density dose 2.25 J/cm2 was added and multiple
vs. single light treatments will be retested.
Presented in the next chapter are the results of the final two experiments that were
used for data analysis in the Chapter IV manuscript, Effects of Photobiomodulation in
Osteoclast Formation in Vitro: a Pilot Study.
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CHAPTER FOUR: DATA ANAYLSIS
The following chapter is a manuscript reporting the findings from the final two
experiments e1837 and e1390 and represents the culmination of this dissertation work.
This manuscript was presented at the 62nd International Astronautical Congress: African
Astronaissance, Cape Town, South Africa, on October 3-7, 2011.
Effects of Photobiomodulation in Osteoclast Formation in Vitro: A Pilot Study
Abstract
Introduction: Near-Infrared Light Emitting Diode (NIR-LED)
photobiomodulation has been found to be effective in improving wound healing, bone
regeneration, mitochondrial function, and attenuating cellular oxidative stress. Little is
known regarding the use of NIR-LED and the formation of osteoclasts, which break
down bone. Purpose: Determine if the use of NIR-LED 670nm photobiomodulation may
attenuate or amplify osteoclast differentiation in the RAW264.7 cell line. Methods:
RAW264.7 cells were cultured for 24 hours and induced to differentiate into osteoclasts,
using the cytokine Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).
Cultures were divided into groups according to RANKL dose (0, 2.5, 10, 25, 50 ng/ml)
and different energy densities (2.25, 4.5, 45 J/cm²), treated with light either once or on
four consecutive days using the WARP™ 75 (Quantum Devices, Barneveld, WI).
Osteoclast-like cells were stained for Tartrate-Resistant Acid Phosphatase (TRAP).
Analysis: Multinucleated, TRAP+ cells were scored as osteoclasts, counted manually by
microcopy. Results were expressed as means and standard deviations, and groups were
compared by one-way ANOVA with posthoc Tukey. Results: RANKL-induced
osteoclast formation by RAW264.7 cells occurred as expected in all experiments. Lighttreatment alone had no observable effect. A single light-treatment at 4.5 J/cm2 with

139

RANKL added (10 - 50ng/ml) suggested a biostimulatory effect upon osteoclastogenesis
compared to controls, as multiple light-treatments compared to single light-treatment
were less stimulatory in the energy density 4.5 J/cm2 and RANKL dose 25ng/ml group.
The effects of the NIR-LED treatment on osteoclastogenesis are RANKL dose and lightintensity specific. Conclusion: Effects of NIR-LED treatment on osteoclastogenesis are
RANKL dose and light-intensity specific. NIR-LED light-treatment affects RANKLinduced osteoclast formation suggestive of a biostimulatory effect, and multiple light
treatments compared to single light treatment may biostimulate osteoclastogenesis less.
Introduction
Older adults often experience complications of muscle (Degens & Alway, 2003,
2006; Trappe, 2009) and bone loss during the process of aging (Khosla & Riggs, 2005),
after prolonged bed rest during hospitalization (Crepaldi & Maggi, 2005), and/or from
self-limiting behaviors due to the fear of falling after returning home after
hospitalization (Fletcher & Hirdes, 2004). Microgravity during space flight simulates
these complications in astronauts. Research concerning these skeletal health problems
that develop and validation of countermeasures to the pathological consequences of
microgravity during long-duration space flights involves interventions and procedures
designed to mitigate health issues and performance hazards present in a space
environment (Clement, Bukley, & Paloski, 2007). It is highly likely that lessons learned
from this research could be applied to the development of innovative technologies for
interventions that may improve bone cell function and skeletal health in at-risk older
adults. Some researchers investigating bone loss in microgravity environments believe
that there is the potential for translational research that could affect the pathology of bone
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loss in the aging population (Rittweger, 2007). Collaboration between clinical and bench
science researchers may develop, enhancing the use of new technologies that may
mitigate bone loss for the older adult population to prevent fracture (Rittweger, 2007).
Translation of NASA Technologies. Quantum Devices Incorporated
(Barneveld, WI) developed a NASA technology, entitled High Emissivity Aluminiferous
Lighting Substrate TM (HEALS), to grow plants for long-term space flight. In 2000,
they received a Space Technology Hall Of Fame Award for their Innovation of Light
Emitting Diodes for Medical Applications (National Astronautical Space Agency, 2008;
Quantum Devices Incorporated, 2004). They successfully developed a commercial
device, the Warfighter’s Accelerated Recovery by Photobiomodulation (WARP 10), a
portable Near Infrared Light Emitting Diode (NIR-LED), used in combat to provide first
aid for minor injuries and pain. Further, this application is proposed to be helpful in
improving medical care for long-term space flight (Whelan et al., 2001; Whelan, 2000).
It may be beneficial to explore other medical implications for the use of the WARP 10
as an innovative intervention that may improve bone cell function and skeletal health.
Thus, proposed use of this technology was to study the effects of NIR-LED treatment
on osteoclast cell differentiation.
Statement of the Problem
Defining of Osteoporosis. One major area of musculoskeletal health research is
the study of the pathogenesis of osteoporosis. The conceptual definition for osteoporosis
was determined to be a skeletal disease of compromised bone strength. A disease
characterized by low bone mass (bone mineral density) and/or structural deterioration of
bone tissue (microarchitecture), leading to bone fragility and an increased susceptibility
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to fractures, especially of the hip, spine, and wrist (European Foundation for
Osteoporosis and Bone Disease & National Osteoporosis Foundation of USA, 1997;
National Institutes of Health Consensus Development Panel on Osteoporosis, 2001). The
operational definition for osteoporosis was determined by a set of diagnostic
measurements. Currently, there is no reliable measurement for bone strength; however,
bone mineral density (BMD), a surrogate measurement, estimates approximately 70% of
bone strength (Suh & Lyles, 2003).
Bone structure reflects the quality of the bone tissue, such as the architecture,
turnover, accumulated damage to the bone tissue and the amount of mineralization
(European Foundation for Osteoporosis and Bone Disease & National Osteoporosis
Foundation of USA, 1997). It has been reported that microarchitectural bone changes
may be independently associated in bone weakness, but not associated with a change in
BMD (Harvey, Dennison, & Cooper, 2013). Osteoporosis is the most common bone
disorder (National Institutes of Health Consensus Development Panel on Osteoporosis,
2001), a growing worldwide public health problem due to the increasing numbers of
individuals over the age of 65 (Suh & Lyles, 2003) and is reported to affect an
estimated 44 million Americans (National Osteoporosis Foundation, 2010). It has
been reported that bone degradation increases risk for fall-induced fractures (Grahn
Kronhed, Blomberg, Lofman, Timpka, & Moller, 2006) and specifically hip fracture, a
well-documented problem within this population (Lim, Hoeksema, & Sherin, 2009)
which has markedly increase health care cost (World Health Organization Scientific
Group, 2003).
It is projected that by the year 2030, the United States (U.S.) population of

142

older adults will double to 71.5 million (U.S. Department of Health and Human
Services Administration on Aging, 2006) . In 2007, data from the U.S. Census
Bureau estimated that there are more than 84,000 centenarians in the U.S., and their
population is projected to increase sevenfold by 2040 (U.S. Census Bureau & U.S.
Department of Commerce Economics and Statistics Administration, 2007). This aging
population is at risk for disability, morbidity, and mortality related to bone loss which
is an identified risk factor for fracture resulting from a fall (Hall, Williams, Senior,
Goldswain, & Criddle, 2000; Ostir, Ottenbacher, & Markides, 2004).
Fifty-five percent of people aged 50 years and older are affected by osteoporosis
(National Osteoporosis Foundation, 2010 [revised 2013]). There has been only a
modest decline in the rate of osteoporosis over the past 15 years despite the
development of interventions using medications and weight-bearing exercise. According
to the World Health Organization, osteoporosis has the potential to become an epidemic
by the middle of the 21st century, from an incidence of 1.7 million in 1990 to a
projected 6.3 million by 2050 (World Health Organization, 1999).
Bone Physiology. In brief, the physiology of bone homeostasis includes the
activity of four cell types responsible contribute to the formation and maintenance of
bone: osteoprogenitor cells, osteocytes, osteoclasts, and osteoblasts (Porth, 2009).
Osteoprogenitor cells are undifferentiated cells that are the source of all bone cells except
osteoclasts which originate from monocyte/macrophages within the hemopoietic lineage.
Osteocytes are mature bone cells that maintain the bony matrix. In addition, they may
respond to bone tissue strain and recruit osteoclasts to areas of bone requiring bone
repair/remodeling (Lanyon, 1993). There are interconnected passageways, canaliculi,
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found throughout the calcified matrix that contain extracellular fluid (Hadjidakis &
Androulakis, 2006) that provide a communication network between the neighboring
osteocytes and blood system for the exchange of nutrients and metabolites because
diffusion does not occur is calcified bone (Porth, 2009).
Osteoclasts and osteoblasts are two types of cells within mineralized bone that
contribute to mineral homeostasis (Lemaire, Tobin, Greller, Cho, & Suva, 2004). They
are responsible for building and maintaining bone structure. Osteoclasts are boneresorbing cells that originate from monocyte/macrophages within the hemopoietic
lineage, and their activity is regulated by osteoblasts, bone-forming cells, and numerous
hormones and other growth factors, macrophage colony-stimulating factor (M-CSF),
interleukin-1 (IL-1), and tumor necrosis factor (TNF) (Hock et al., 2001). Osteoblasts are
differentiated mesenchymal stem cells, responsible for lying down the new bone matrix
that becomes mineralized, thus replacing old bone previously reabsorbed by osteoclasts
(Hadjidakis & Androulakis, 2006; Hock et al., 2001).
There are two pathways that induce osteoclastogenesis. On the osteoblast
stromal cell membrane, Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)
receptor, binds to the osteoclast precursor cell (macrophage) RANK receptor. When this
occurs, RANK signaling activates the transcription factor Kappa-B to differentiate into
osteoclasts (Kumar, 2010). The other pathway occurs with the osteoblast secretion of MCSF and the osteoclast precursor cell (macrophage) M-CSF receptor. When joined,
tyrosine kinase activity is stimulated, also important to osteoclast formation. This
signaling occurs in tandem with the RANKL/RANK pathway. Further bone marrow
stromal/osteoblast cells secrete osteoprotegerin (OPG), a decoy receptor for RANKL,
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preventing RANKL from binding with the osteoclast precursor cell’s RANK receptor.
This prevents bone absorption and attenuating osteoclast differentiation (Kumar, 2010).
In healthy remodeling tissue of the adult skeleton, 5-10% of existing bone at
specific bone sites is replaced every year, but it is not replaced uniformly throughout the
skeleton (World Health Organization Scientific Group, 2003). As to not alter the
bone’s shape, bone resorption and formation occur within the same space (resorption
lacunae) of the bone. Bone remodeling occurs in both spongy or trabecular (cancellous)
tissue and dense/compact bone (cortical) tissue, which together comprise intact bone.
The percentage of cancellous and cortical tissues in a given bone varies according to the
type of bone. Vertebrae are particularly rich with cancellous tissue, while the hip and
wrist are rich with cortical composites of bone (Wyngaarden, Smith, & Bennett, 1992).
Normal bone remodeling is a coupling process, a balance between bone gain and
loss, where bone absorption and bone formation are balanced (North American
Menopause Society, 2010). Bone remodeling begins with bone resorption in both
cortical and cancellous bone by osteoclasts over a period of 30-40. Osteoclasts attach to
the mineralized bone surface and resorb bone via secretion of hydrogen icons and
cathepsin K (Raisz, 1999, 2008), creating irregular, scalloped cavities named Howship
lacunae in trabecular bone or cylindrical Haversian canals in cortical bone. Osteoblasts
lay down a new organic extracellular matrix in two stages: ossification, formation of
unmineralized bone (osteoid), and calcification that becomes mineralized with calcium
and phosphate and fills the resorption lacunae over approximately 150 days (E. Eriksen,
2010; Raisz, 1999).
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Bone Pathology. Osteoporosis arises from an imbalance in osteoclast/osteoblast
homeostasis (uncoupling) in remodeling bone (Lemaire et al., 2004; Manolagas & Jilka,
1995). Bone loss in osteoporosis has been described in a two-stage model. The first stage
is the loss of sex steroids (estrogen) resulting in rapid trabecular bone loss by 20-30% and
in cortical bone loss by 5-10% (Khosla & Riggs, 2005) due to an increase in
osteoblast/osteoclast activity (Parfitt, 1990). Osteoclastogenesis is proportionally greater
than osteoblastogenesis during this period of time (Jilka, Weinstein, Takahashi, Parfitt, &
Manolagas, 1996). The duration of this first stage differs according to individual
variables, but does not last indefinitely (Jilka et al., 1996). This stage usually lasts 5-10
years in women (Drake & Khosla, 2013). Stage two follows approximately 8-10 years
postmenopausal which is a period of time of slow continuous bone loss due to aging
where cortical and trabecular bone loss occurs at an equal rate until the end of the life
span (Drake (Drake & Khosla, 2013; Parfitt et al., 1983). Men also experience a slow
process of bone loss from middle age to the end of the lifespan that is similar to the
second stage of bone loss seen in postmenopausal women (Drake & Khosla, 2013).
Aging, in addition to loss of sex steroids or parathyroid hormone (Parisien et al., 1992;
Steiniche et al., 1989), has been associated with bone loss and a decrease in the thickness
of the bone wall and a decrease growth factors. These growth factors are the precursors
for osteoblastogenesis (Ho et al., 1987) and directly influence osteoclastogenesis (Lips,
Courpron, & Meunier, 1978; Parfitt et al., 1983).
There are four major pathways for the pathogenesis of osteoporosis: failure to
achieve optimal peak bone mass and strength, accelerated bone loss due to increased
bone absorption, inadequate bone remodeling, and increased falls (Raisz, 2008). Bone
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loss (Crepaldi & Maggi, 2005) is one of the general characteristics of aging, along with
increased mortality, vulnerability to disease (Cristofalo, 1988), progressive deterioration
of tissues (Looker, Melton, Harris, Borrud, & Shepherd, 2010; Shock, 1985), and other
conditions. Bone loss is a problem that worsens as people age. Osteoporosis arises from
the out-of-balance osteoclast/osteoblast activity in remodeling bone. Because vertebrae
are particularly rich in cancellous tissue (Wyngaarden et al., 1992), vertebral compression
fractures are the most commonly associated osteoporosis bone injury (Neyhart & Gibbs,
2002). Hip and wrist fractures commonly result from cortical composite weakening;
occurring later in life than is usually the case with vertebral fractures (Wyngaarden et al.,
1992). Therefore, bone strength is impaired, predisposing older adults to fractures when
they fall. Thus, there are numerous risk factors associated with bone loss.
Falls and Fractures. Serious injury occurs in 10-15 % of falls (Centers for
Disease Control and Prevention, 2006). In the U.S., osteoporosis causes 1.5 million
fractures every year. There is considerable research that associates osteoporosis with fallinduced fractures (Kendler et al., 2010; Schwartz, Nevitt, Brown, & Kelsey, 2005; World
Health Organization Scientific Group, 2003). The lifetime risk for osteoporotic fractures
(vertebral, wrist, and hip) is estimated to be 40% which is similar to the lifetime risk for
coronary heart disease (World Health Organization Scientific Group, 2003).Vertebral
compression fractures are the most commonly associated osteoporosis bone injury.
Unlike vertebral fractures, hip and wrist fractures commonly result from cortical
composite weakening that can occur later in life (Wyngaarden et al., 1992). Ninety
percent of osteoporotic-induced fractures, specifically hip fractures among older adults in
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the U.S., are caused by falls (Cummings, Kelsey, Nevitt, & O'Dowd, 1985; Grisso et al.,
1991).
Falls Morbidity and Mortality. Hip fracture mortality rates have been reported
to be three times higher for individuals with hip fracture as opposed to the mortality rate
of the general population (Kannegaard, van der Mark, Eiken, & Abrahamsen,
2010). The rate of mortality associated with hip fractures within the first year is
estimated to be 20% - 35% (Goldacre, Roberts, & Yeates, 2002; North American
Menopause Society, 2010) and is greatest immediately after the fracture (Center,
Nguyen, Schneider, Sambrook, & Eisman, 1999). Long-term care is required for
approximately 25% of women, and 50% have some form of immobility (North
American Menopause Society, 2010). Currently, the majority of hip fractures occur in
Europe and North America. Over the next 50 years, due to demographic changes in the
number of older adults living in developing counties, 75 % of the world’s total hip
fractures will occur in developing countries (World Health Organization, 1999).
Healthcare Expenditures. The World Health Organization reported in 2003
that osteoporosis-induced fractures burden society by depleting available resources. In
1992, in the state of California, it was estimated that 62.4% of expenditures were used
for inpatient care, 28.2% for long-term care, and 9.4% for outpatient care to treat
osteoporotic-induced fractures (Ray, Chan, Thamer, & Melton, 1997). However, these
figures do not take into account indirect costs such as lost wages or the decreased
productivity of caregivers and the patient (National Institutes of Health Consensus
Development Panel on Osteoporosis, 2001). Researchers using the 1999-2005 Chronic
Conditions Warehouse dataset (Iowa Foundation for Medical Care, 2008) reported that
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the U.S. Medicare beneficiaries receiving payments for osteoporotic-induced fracture
incurred a cost of $7,788 (95% CI, $7,550-$8,025) for an average wrist fracture. The cost
to treat an average open hip fracture was $31,310 (95% CI, $31.0073-$31,547) per
beneficiary (Kilgore et al., 2009). Further, in 2005, it was estimated that the annual
cost to treat osteoporosis associated fractures will increase 50% by year 2025— $17 to
$25 billion—due to the growth of the aging population (Burge et al., 2007).
Due to the cost treating osteoporotic fall-induced fractures, the development of
effective interventions meant to slow the progression of or reverse bone loss could be
instrumental in decreasing the financial burden of healthcare for the aged, as well as
enhancing the quality of life for aging persons by helping them avoid long-term
care placement. Implementing a new intervention, such as the use of
photobiomodulation (light-treatment), may have the potential to preserve bone density
and prevent bone loss.
Background
Biological Aging & Oxidative Stress. The theory of biological aging has been
associated with cellular oxidative stress and mitochondrial dysfunction (Melov, 2000),
and this may induce bone loss (Srinivasan & Avadhani, 2007). Oxidative stress can
result from the generation of excess free radicals (Beckman & Ames, 1998) which causes
an imbalance with cellular antioxidants which in turn damages cellular components and
function (Sheweita & Khoshhal, 2007). Specifically, free radicals are unpaired electrons
on the electron orbitals or electron shells of a molecule. In this unstable state, the free
radicals are highly reactive with other molecules, and can instigate oxidative cell
destruction. The oxygen molecule has an atypical placement of electrons within electron
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orbitals, and during chemical reactions, oxygen prefers to accept one electron at a time
rather than two electrons. Accepting two electrons at a time would keep the oxygen
molecule in a stable state. When electrons are accepted one at a time, the oxygen
molecule becomes unstable and superoxide (O-) and hydrogen peroxide (H2O2) are
generated. These reactive oxygen species undergo further biochemical cellular
reactions, and the result is that an extremely reactive molecule, such as hydroxyl
radicals (OH-), is produced (Beckman & Ames, 1998) and affects mitochondrial
function, responsible for cellular energy production.
Mitochondrial Dysfunction. It is suggested that mitochondrial dysfunction via
oxidative stress may instigate premature apoptosis (programmed cell death) and alter
mechanical signaling in bone (Booth & Criswell, 1997; Hock et al., 2001; Yalin et al.,
2005). In a recent study using the RAW264.7 cell culture model (osteoclast precursor
cells), without the addition of osteoclast differentiation factors, hypoxia-mediated
mitochondrial stress increased reactive oxygen species (increased oxidative stress), which
resulted in osteoclastogenesis (the formation of bone-resorbing cells) (Srinivasan &
Avadhani, 2007).
Proposed Intervention. Photobiomodulation—referred to in the literature as
low-level laser therapy, cold-laser therapy, or laser biostimulation—was introduced in
the 1980s. Laser “light-treatment” uses light in the infrared to near-infrared region of the
absorption spectrum (630-1000nm), such as a NIR-LED, and known to affect numerous
cell functions that are dependent on the energy production in the mitochondria
(Desmet et al., 2006; Karu, Piatibrat, & Kalendo, 1987). It has been postulated that the
mechanism of the effect of a low-power laser works at the cellular level due to changes
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in components of the electron transport chain system within the mitochondria (Karu,
1988). The electron transport system of the cell is directly related to the production of
Adenosine triphosphate (ATP), the primary energy compound for the cell. These
discoveries have been investigated using a NASA invented NIR-LED technology as
previously mentioned (J. T. Eells et al., 2004; Sommer, Pinheiro, Mester, Franke, &
Whelan, 2001; Whelan et al., 2008).
NIR-LED Treatment. Light-treatment in numerous studies has been
documented to have beneficial cellular level mechanisms that reduce oxidative stress,
improve mitochondrial function, and prevent premature apoptosis (Desmet et al., 2006;
Eells et al., 2004; Karu et al., 1987). NIR-LED (630-1000nm) photobiomodulation—an
FDA-approved treatment—has been found to be effective in improving wound (Whelan
et al., 2003; Whelan, 2001), improving bone regeneration (Pinheiro et al., 2009),
improving mitochondrial function (Wong-Riley, Bai, Buchmann, & Whelan, 2001),
attenuating cellular oxidative stress (Desmet et al., 2006; Eells et al., 2004; Karu et al.,
1987), decreasing inflammation and pain (Whelan et al., 2003), aiding in recovery of
ischemic cardiac injury (Oron, 2006; Oron et al., 2001), and attenuating retinal/optic
nerve degeneration (Eells, 2007; Eells, 2004; Liang et al., 2006).
NIR-LED Cellular Effects. Specifically, NIR-LED treatment, using an
absorption spectrum of 670nm, activates the mitochondrial photo acceptor molecule
cytochrome c oxidase (CO), specifically, Complex IV (COX IV) of the electron chain
transport system (Karu, 1999). If cytochrome c (COX) does not properly function, the
cell electron transport system performs poorly, which alters the production of ATP, and
premature cell death can occur. Therefore, the use of light as a treatment to improve
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oxidative metabolism and mitochondrial function in bone tissue may prevent bone
demineralization and preserve cell life.
Research has been completed that has increased our understanding of NIRLED effects with osteoblast cell function (in vitro) (Renno, McDonnell, Parizotto, &
Laakso, 2007; Yamada, 1991), bone graft biomaterials (in vivo) (Pinheiro et al., 2008;
Pinheiro et al., 2009; Torres, dos Santos, Monteiro, Amorim, & Pinheiro, 2008), and
bone formation (in vivo) (Blaya, Guimaraes, Pozza, Weber, & de Oliveira, 2008). In
one study that investigated osteoblastogenesis, it was found that low-level laser
irradiation in cell culture significantly increased osteoblast proliferation and
differentiation (Stein, Benayahu, Maltz, & Oron, 2005), another study found that
photobiomodulation increased bone formation (Torres et al., 2008), increased the
amount of well-organized bone trabeculi (Pinheiro et al., 2008), and enhanced vertical
regeneration of bone (Blaya et al., 2008).
The evidence that NIR-LED increases osteoblastogenesis and bone formation is
documented in the literature, but little is known regarding the effects of NIR-LED on
osteoclastogenesis. Osteoblastogenesis and osteoclastogenesis need to be coordinated—
i.e., achieve “coupling” (Rodan & Martin, 1981)—to attain a healthy balance
(homeostasis) between bone gain and bone loss. It is with aging that the “uncoupling” of
the bone remodeling cycle occurs, resulting in increased bone resorption (Kiel, Rosen,
& Dempster, 2008; Lemaire et al., 2004). It is documented in the literature that
osteoblastogenesis is increased with NIR-LED (Stein et al., 2005). Therefore, in order
to develop effective and safe interventions for a vulnerable population, such as older
adults, it is imperative to investigate the cellular-level effects of NIR-LED to determine
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if osteoclastogenesis is amplified or suppressed due to uncoupling.
Research Questions and Hypothesises
Our primary goal in this study was to determine the effects of NIR-LED
treatment on osteoclast cell differentiation (osteoclastogenesis) in cell-cultured
RAW264.7 cells using the WARP 75 ™ NIR-LED light. Our specific research questions
and hypotheses were as follows:
Question 1. Is there a difference in osteoclast cell count between single lighttreated Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-induced cell
cultures as compared to non-light-treated controls? Hypothesis. Single light-treatment of
RANKL-induced cell cultures will attenuate osteoclastogenesis.
Question 2. Is there a difference in osteoclast cell count between light-treated
RANKL-induced cell cultures treated at different energy densities of light-treatment
(2.25, 4.5 and 45 J/cm2) compared to non-light-treated controls? Hypothesis. Lighttreatment of RANKL-induced cell cultures at a higher energy density (45 J/cm2) will
have a greater attenuation of osteoclastogenesis compared to lower energy densities (2.25
and 4.5 J/cm2).
Question 3. Is there a difference in osteoclast cell count between single lighttreated RANKL-induced cell cultures compared to multiple light-treated RANKLinduced cell cultures? Hypothesis. Multiple light-treatments of RANKL-induced cell
cultures will have a greater attenuation of osteoclastogenesis compared to single lighttreated RANKL-induced cell cultures.
Materials and Methods
Experiment Timeline. This pilot study is a description of two experiments using
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the WARP™ 75 light source. RAW 264.7 cells (obtained from the American Type
Culture Collection [ATCC]) were plated on cell culture Day 0 and then incubated at 37˚
Celsius for 24 hours. RANKL was added to cell culture medium on Day 1 at specific
experimental doses 0, 25, and 50ng/ml. Light-treatment began on Day 2 for all
experiments regardless of whether the experiment was testing single or multiple lighttreatments. Experiments that tested multiple light-treatments had repeated exposure on
Days 3-5 for a total of 4 light-treatments. The culture medium was changed and fresh
RANKL was added to the medium on Day 4 in all experiments. On Da y 7, cells were
stained for Tartrate-Resistant Acid Phosphatase (TRAP), and were prepared for cell
counting.
The first experiment tested only a single light-treatment; the second experiment
tested multiple and single light-treatments. All experiments tested energy densities of
4.5 and 45 J/cm2, but the second experiment tested an additional energy density of
2.25 J /cm2 to explore an energy density light-treatment dose response. Lastly,
experimental controls were tested for RANKL dose response at 0, 25, and 50ng/ml in
all experiments, and experimental controls were tested in the first experiment for
RANKL dose response at RANKL dose 0, 2.5, 10, 25 and 50ng/ml.
Cell Plating Procedure. On Day 0, RAW 264.7 cells were plated at 2 x 104
cells per well (4x104 cell/ml) in 15 wells of a 24-well plate (well diameter: 1.77mm)
for each experimental condition. The WARP™ 75 (Quantum Devices, Barneveld, WI)
illumination surface covered 15 wells (well rows A-C by columns 2-6). Some
experimental conditions did not require the full 15 wells; in those cases, only 10 wells
were used. Plates were divided into experimental treatment groups according to
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experimental condition: number of light-treatments (1 or 4), energy density (varied by
experiment: 2.25, 4.5 or 45 J/cm2), and RANKL dose (varied by experiment: 0, 2.5,
10, 25, or 50 ng/ml) with respective negative controls. The cells were cultured for 24
hours prior to RANKL induction. At the end of the 24-hour period, RANKL was added
to each well at 0, 2.5, 10, 25 or 50ng/ml, according to the experimental design.
Light-treatment Procedure. A continuous wave NIR-LED (WARP™75) with a
wavelength of 670nm, power intensity of 60mw/cm2 , and energy density of 5 J/cm2
was used in the experiments because it was shown in previous studies to produce
positive cellular effects (Desmet et al., 2006; Eells, 2007; Eells, 2004; Karu, 1988;
Liang, Whelan, Eells, & Wong-Riley, 2008; Pinheiro et al., 2002; Whelan et al., 2003;
Whelan et al., 2008; Wong-Riley et al., 2001; Wong-Riley et al., 2005). The dosage of
light-treatment was determined by applying the following formula: Power (mW/cm2) x
Time (seconds) ÷ 1,000 = Energy Density (J/cm2) in order to deliver 4.5 J/cm2 and
45J/cm2. In order to ensure delivery of an accurate energy density of 4.5 J/cm2 and 45
J/cm2, light-treatment was timed to 80 seconds to deliver 4.5J/cm2 and to 800 seconds to
deliver 45 J/cm2.
Light-treatment began on cell culture Day 2 (Yamada, 1991; Stein, 2005) under a
sterile laminar hood with the dish lid in place. Because one of the objectives of a
particular experiment was to test multiple light-treatments versus single light-treatment,
additional light-treatments were performed, once per day on three consecutive days.
Analysis
TRAP staining (SIGMA #387) was the method used for manual osteoclast cell
counting (Nakano, Toyosawa, & Takano, 2004). Using a visual cell counting
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classification tool, those multinucleated cells that were stained light pink/purple were
identified by light microscopy (inverted microscope, 10x magnifications; Nikon Eclipse
TS100) and counted. Mean osteoclast cell counts per well and standard deviations were
calculated by taking the sum of multinucleated TRAP+ osteoclast cells for each well and
dividing by the well surface area, expressed as cells per cm2. To determine lighttreatment effects, the difference between osteoclast cell counts in treatment plates and
controls was calculated. Results are expressed as means and standard deviations, and
groups were compared by one-way ANOVA with posthoc Tukey (p<0.05).
Results
Our experimental groups were organized according to the number of lighttreatments, energy density, and RANKL dose. Our first experiment tested single lighttreatments at energy densities of 4.5 J/cm2 and 45 J/cm2 at RANKL doses of 0, 2.5, 10,
25, and 50ng/ml; it demonstrated the experimental RANKL dose response curve, which
resulted in the expected stepwise two-fold increase in biological signal (see Table 1).
In treatment groups, stepwise dose response occurred approximately two fold between
energy densities 4.5 and 45 J/cm2 at RANKL dose 2.5ng/ml. However, in the RANKL
group 25 and 50 ng/ml at energy densities of 0, 4.5, and 45 J/cm2 were practically
inversed. The 10ng/ml RANKL group, only modestly increased at energy densities of 0,
4.5, and 45 J/cm2 (see Table 2).
One-way ANOVA comparing different energy densities for the single lighttreatment were computed. In the first experiment, significant difference found between
groups indicated an increased biostimulatory effect in energy density 45 J/cm2 and
RANKL dose 2.5ng/ml compared to controls and energy density 45 J/cm2 was more
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effective in amplifying osteoclast formation compared to 4.5 J/cm2 (F (2,12)= 61.17,
p<.0001). Further, energy densities of 0, 4.5 and 45 J/cm2 at RANKL dose 10ng/ml (F
(2, 12) = 8.04, p < .006) an increase in osteoclastogenesis was found compared to nolight treatment. (see Table 2). Energy densities of 0 J/cm2 (M = 484.4, SD = 87) and 4.5
J/cm2 (M = 485.2, SD = 53) yielded the same biostimulatory effect in the RANKL dose
2

50ng/ml experiment compared to the energy density groups of 45 J/cm (M = 419.4, SD
= 130). (see Table 2)
Our second experiment tested the effect of single light- treatment at energy
densities of 2.25, 4.5, and 45 J/cm2 at RANKL doses of 0, 25, and 50ng/ml; it also
compared multiple light-treatments versus a single light-treatment at an energy density
of 4.5 J/cm2. In this experiment, the expected dose response curve yielded a stepwise
increase in the 25ng/ml RANKL dose compared to control, however the stepwise
response in the 50ng/ml was only increased modestly. (see Table 3) This may be
attributed to possibly the minimum dose threshold was met by RANKL dose 25ng/ml,
but at the 50ng/ml dose, biological signal may drop.
In treatment groups, dose response in RANKL dose of 25 ng/ml and 50ng/ml
occurred in the 2.25 and 4.5 J/cm2 treatment groups; however, the single light-treatment
(45 J/cm2) group and the multiple light-treatment (4.5 J/cm2) group did not yield the
expected two-fold response. This finding may be attributed to the minimal energy
density threshold being met as biological signal is lost at the 45 J/cm2. This decrease
may also be attributed to light treatment effect. (see Table 4)
The energy density of 4.5 J/cm2 was the most effective in amplifying
osteoclastogenesis (M = 491.4, SD = 65) in the RANKL dose 25ng/ml experiment
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compared to 45 (M = 289.2, SD = 77) and 2.25 J/cm2 (M = 274.4 SD =92), as the 45
J/cm2 was less effective in stimulating osteoclastogenesis compared to the 4.5 J/cm2 (see
Table 4). However, the first experiment in the RANKL dose 10ng/ml experiment, equal
amplification was seen in both energy densities 4.5 (M = 68.8, SD = 13) and 45 J/cm2
(M = 69.6, SD =11) as compared to the control (M = 45.6, SD = 7). (see Table 2)
In order to determine which pairs of means were significantly different, a post hoc
Tukey honestly significant difference (HSD) test was used. Significant differences were
found between the groups, no-light treatment group and energy density 4.5 J/cm2 at
RANKL dose 25ng/ml. Energy density 4.5 J/cm2 significantly amplified
osteoclastogenesis compared to no light treatment and was more effective in osteoclast
formation than the 2.25 J/cm2 (F (3,16) = 4.52, p <.0176). Further significance
differences between groups were found in energy density 4.5 J/cm2 and no light
treatment, 2.25 and 45 J/cm2 in RANKL dose 25ng/ml (F (3,16) = 12.51, p < .0001). (see
table 4) Osteoclastogenesis increased in the energy density of 4.5 J/cm2 compared to nolight treatment and was more effective than the 2.25 J/cm2. A decrease in
osteoclastogenesis also was seen with 45 J/cm2 compared to 4.5 J/cm2 (see Table 4).
Further, a one-way ANOVA comparing single versus multiple light treatments for
energy density 4.5 J/cm2 and RANKL dose 0, 25and 50ng/ml were computed. A
significant difference was found between single and multiple light treatment as well as
no light treatment compared to single light treatment in the RANKL dose 25ng/ml
groups (F (2, 11) = 24.8, p < .0001) (see Table 5). In RANKL dose 25ng/ml,
biostimulation in the multiple light-treatment group was less (M = 258.6, SD = 30.9)
compared to single light-treatment (M = 511.5, SD = 52.3). The post hoc Tukey HSD
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test indicated a significant difference between single versus multiple light treatment (p =
.01) and single versus no light treatment (p = .01).
Discussion
Developing interventions to preserve bone density and t o prevent or reverse the
pathogenesis of osteoporosis (bone loss) is important because osteoporosis is a major
public health problem estimated to affect 44 million Americans (National Osteoporosis
Foundation, 2010). The U.S. population of older adults will be approaching 70 million by
2020; the financial burden to treat osteoporosis in older adults and osteoporotic-induced
fractures will be cost prohibitive and burdensome to the health care system (World Health
Organization Scientific Group, 2003).
Since the mid-1990s, overall there has been a decline in the incidence of low
femur BMD (Looker et al., 2010). Because health care expenditures for osteoporosis
associated fractures by 2025 will double (Burge et al., 2007), it may be helpful to
determine the most efficacious point in time to implement an intervention to
prevent/delay the onset of elemental bone loss (osteopenia). Commonly, studies
investigate interventions for post-menopausal women when loss of BMD has mostly
occurred. The most common preventive osteoporosis non-pharmacological
intervention is weight bearing exercise (Howe et al., 2011; Schmitt, Schmitt, & Doren,
2009). Pharmacological interventions include prescribing calcium and vitamin D
supplements (Elders et al., 1991; Rahmani & Morin, 2009; Shea et al., 2002; Weaver
& Heaney, 2008), estrogen/progestin (Cauley et al., 2003) and bisphosphonates
(Bonnick et al., 2007; Pols et al., 1999). The motivation to investigate the effects of
NIR-LED light-treatment on osteoclastogenesis is to begin a program of research
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developing a possible non-invasive intervention that may be appropriate for
perimenopausal and postmenopausal women.
We investigated the effects of NIR-LED light-treatment using the WARP 75™
on osteoclastogenesis in the RAW 264.7 cell line. The purpose of this study was to
pilot test a new protocol designed to answer the broad research question: Does NIRLED photobiomodulation affect RANKL-induced osteoclastogenesis in a cell culture
model? The integrity of our experiments and controls were evaluated by successful
results of RANKL-induced osteoclast formation by RAW cells. Our controls (negative
RANKL cell cultures) and the use of light treatment alone did not result is a measured
effect on osteoclast formation.
Our first hypothesis predicted that a single light-treatment of RANKL-induced
cell cultures would inhibit osteoclastogenesis; however, only two out of 19 single
light-treatment experimental groups actually inhibited osteoclastogenesis compared to
the control and were non-significant. In fact, two out of the 19 single lighttreatment experimental groups significantly increased osteoclastogenesis. (see Table 2
and 4).
Our second hypothesis predicted that light-treatment at a higher energy density
would less stimulatory toward osteoclast formation than lower energy densities; this
was found true, since in our first experiment energy density 45 J/cm2 stimulated
osteoclastogenesis less than the 4.5 J/cm2 in the RANKL dose 25 and 50ng/ml group.
On the other hand, in the 10ng/ml group, there was not a difference in effect between
4.5 and 45 J/cm2, but in the 2.5ng/ml group there was a significant difference between
0, 4.5 and 45 J/cm2 groups indication an increased biostimulatory effect with increased
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energy density. The second experiment demonstrated 45 J/cm2 was less
biostimulation compared to 4.5 J/cm2 in the RANKL dose 25 and 50ng/ml group.
Our third hypothesis predicted that multiple light treatments would stimulate
osteoclastogenesis less than single light-treatments. It was found that multiple lighttreatments compared to single light-treatment was less stimulatory in amplifying
osteoclastogenesis at energy density 4.5 J/cm2 and RANKL dose 25ng/ml group, as
shown in Table 5.
In order to evaluate our results, examples of low level laser light treatment
models in the literature that investigated osteoclastogenesis using a gallium aluminum
arsenide (Ga-Al-As) semiconductor laser (Aihara, Yamaguchi, & Kasai, 2006) and
others investigating osteoblastogenesis with a helium neon (He-LE) laser (Stein et al.,
2005; Yamada, 1991) were consulted. Further, two NIR-LED animal models studies
were found (Blaya et al., 2008; Torres et al., 2008).
The two cell culture models investigating osteoblastogenesis used helium neon
(He-LE) laser light in the near-infrared light spectrum and reported amplification of
osteoblastogenesis. The two animal studies that investigated bone as a living tissue and
histologically identified osteoblast and osteoclast activity, collectively, found that nearinfrared light treatment enhanced bone formation (Torres et al., 2008) and bone
architecture (Blaya et al., 2008). This is similar to our results of biostimulation with
NIR-LED light treatment.
Aihara and colleagues (2006) studied rat osteoclast precursor cells using a
continuous wave 810nm Ga-Al-As semi-conductor laser, with a power intensity of
50nW. Cell cultures were inducted with a RANKL dose of 10ng/ml and exposed to
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light treatment for 1, 3, 6, or 10 min/day for 8 consecutive days, delivering energy
densities of 9.99, 27.99, 55.98, and 93.30 J/cm2, respectively. They report a 1.3-fold
increase in osteoclastogenesis in the 27.99 and 55.98 J/cm2 groups (Aihara et al.,
2006). In contrast, our NIR-LED continuous wave 670nm, power intensity 60mw,
2

tested single light-treatment at energy densities at 2.25, 4.5, and 45 J/cm at RANKL
doses 0, 2.5, 10, 25, and 50ng/ml, as well as multiple light-treatments (4 consecutive
2

days) at an energy density of 4.5 J/cm . We report an increase in osteoclastogenesis
with a similar energy density; however, this was demonstrated with one single lighttreatment. Aihara and colleagues (2006) suggest photobiomodulation and higher
energy densities amplify osteoclastogenesis. Overall, we found that a single lighttreatment increased osteoclastogenesis, but when comparing the 4.5 J/cm2 group to the
2

highest energy density group, 45 J/cm2, the 4.5 J/cm group was more effective in
increasing osteoclastogenesis and multiple light-treatments stimulated
osteoclastogenesis less compared to a single light-treatment. These contrasting
results may be attributed to the use of different types of light sources and our
experimental model testing single-light treatment.
Yamada (1991) studied the clonal osteoblastic MC3T3-E1 cell line using
single light treatment with a continuous wave 632.8nm, power intensity of 3.03mW/cm2
He-Le laser at energy densities 0.01, 0.1, and 1.0J/cm2. Light treatment was
administered on cell culture day 2, as compared to our continuous wave 670nm, power
intensity of 60mW/cm2, NIR-LED light at an energy density of 2.25, 4.5, and 45cm2
administered on cell culture day 2. They found a significant increase in
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osteoblastogenesis (p < 0.05) at energy densities of 0.01 to 1.0 J/cm2 (Yamada, 1991).
Stein and colleagues used human osteoblast cells for cell culture. A single lighttreatment was administered on cell culture days 2 and 3 with a 632nm, power intensity
180mW/ cm2 He-Le laser, at energy densities 0.14, 0.43, and 1.43 J/cm2. They also
found a significant increase in osteoblastogenesis (p < 0.05) (Stein et al., 2005). Both
of these studies used low-energy densities, suggesting that lower energy densities had a
biological effect on osteoblastogenesis; thus, we tested an energy density of 2.25, which
was not found to significantly increase or decrease osteoclastogenesis.
We chose to test higher energy densities than in the osteoblastogenesis studies
because they were comparable to the successful 670 nm NIR-LED light treatment
studies used in a human model (Whelan et al., 2003) and in a neuronal cell culture
model (Wong-Riley et al., 2001; Wong-Riley et al., 2005). Further, these studies by
Whelan (2003) and Wong- Riley (2001, 2003) used the same NIR-LED light source
manufacture (Quantum Devices, Barneveld, WI) as ours. However, our NIR-LED light
source was a commercial product rather than the scientific grade NIR-LED.
Bone loss occurs rapidly during early menopause; osteoclastogenesis is, thus,
proportionally greater than osteoblastogenesis (Eriksen, 1990; Jilka et al., 1996)
followed by an age-related steady continuous loss of bone until the end of the life
span (Parfitt, 1990). Loss of estrogen in women results in rapid trabecular bone loss by
20-30% and in cortical bone loss by 5-10% (Khosla & Riggs, 2005; Parfitt, 1990).
However, it has been hypothesized that it may not be the mismatch of
osteoclastogenesis/osteoblastogenesis, but a decrease in the number of
stromal/osteoblastic cells (Manolagas & Jilka, 1995). A study (Jilka et al., 1996)
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investigating the validity of a senescence-accelerated osteopenic mouse model for the
study of metabolic bone disease reported a correlation between low bone mineral
density and impaired osteoblastogenesis due to a low number of stromal/osteoblastic
cells. The impairment of osteoblast formation resulted in a secondary impairment of
osteoclastogenesis. When adding exogenous stromal/osteoblast cells from neonate
mouse clavaria cells to the aging and osteopenic ex vivo marrow cell cultures,
osteoclastogenesis was restored (Jilka et al., 1996). This may suggest that the imbalance
between osteoblast/osteoclast activities may be due to the number of bone cells.
If osteoclastogenesis activity is thought to be proportionally greater than
osteoblastogenesis during the aging process, then as indicated by our results, as well as
those of Aihara and colleagues, NIR light treatment increases osteoclastogenesis.
Therefore, if osteoblastogenesis and osteoclastogenesis both increase by light treatment
and the bone remodeling cycle is already “uncoupled”, that is, imbalanced due to aging,
NIR-LED treatment could result in the same disrupted bone remodeling process seen
before light-treatment. The literature suggests that osteoblastogenesis and
osteoclastogenesis increase with low-energy light treatment, as we found. However, it
remains, based on our limited data, that the multiple light-treatments of NIR-LED
increases or decreases osteoclastogenesis, as opposed to multiple light-treatments,
increased osteoclastogenesis with a Ga-AL-Gs diode laser. Regardless, both light
sources deliver low-energy irradiation in the near-infrared range.
In this study, we investigated the effects of NIR-LED treatment solely on
osteoclastogenesis, but it would be useful to investigate both osteoblastogenesis and
osteoclastogenesis under the same experimental conditions to compare their rates of
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amplification or inhibition with NIR-LED treatment. After the effects of NIR-LED
light-treatment are determined by testing each cell type in culture, the next step would
be to investigate the effects of NIR-LED light-treatment on the bone remodeling
process, because the biological effects of NIR-LED light-treatment on a system of
homeostasis may be different from the biological response found in separate osteoclast
and osteoblast cell cultures.
The long-range goal of this program of research is to discover and test
interventions that may increase bone strength and integrity in the older adult population
to prevent bone fracture (specifically hip fractures) and improve skeletal health. There
is not sufficient evidence to draw a firm conclusion regarding the effects of NIR-LED
light-treatments on osteoclastogenesis in these pilot experiments. However, the majority
of the experimental groups yielded an increase in osteoclastogenesis. Furthermore, these
data must be interpreted with caution, since they are pilot data and meant to assist us in
designing other experiments. Several limitations to this study are discussed below;
they include the use of a commercial light source rather than a scientific grade light
source, the possibility of cell culture heat shock, and investigator subjectivity in manual
osteoclast cell counting.
Commercial NIR-LED Light Source. The light sources used in these
experiments are commercial grade and approximately calibrated at the factory for
energy density, wavelength, and light intensity. The scientific grade light source has the
advantage of controls for fine-tuning these variables. The commercial grade light source
used in the experiments turned off automatically every 80 seconds, requiring manual
restarting of the light during the 45 J/cm² experiments. This may have resulted in
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measurable effects on osteoclast formation similar to pulsing light-treatment (Karu,
1992, 1993). The manual restarting of the light-treatment (WARPTM 75) caused a
brief temperature surge in testing during development of the protocol, but the cell
o

culture medium never rose above 37 C. Temperature surges could be considered pulsing
light-treatment, which have been shown in the literature to give a greater biological
effect than continuous wave light-treatment (Karu, 1992). Given the existence of
temperature surges, heat shock cannot be ruled out; if heat shock did occur, the cultured
cells may have been stressed by the abrupt change in temperature resulting, in an effect
that was not brought about by the light-treatment. What is needed to control for these
possible confounding variables is a light source utilizing a built-in timing mechanism
and the capability to manually tune specific energy densities and light intensities. This
would give the investigator greater control to test specific irradiation wavelengths,
energy densities, and light intensities and to prevent heat shock by using consistent low
radiation intensity (670nm) (Karu, 1992; Letokhov, 1991), 1991). In future experiments,
obtaining a scientific grade continuous wave NIR-LED would be necessary for ensuring
reliable results.
Manual Cell Counting. Lastly, the manual cell counting technique is a
subjective process relying on visual interpretation of color and identification of cell
nuclei. A visual cell counting classification tool was developed to guide in the cell
counting process (see Appendix G). To be counted as an osteoclast cell, all cells were
TRAP+ with a pink/purple or dark purple bordering on black (if nuclei were still visible).
To determine the faintest acceptable pink, the stain color should match the RANKL
control pink stain. The counted cells should be stained darker than the control faint pink.
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The cell was counted if there were three or more nuclei present. Clumps of TRAP+
mono-nucleated cells were not counted, and cells connected by cell processes were
counted as separate cells. The plates were blinded and the investigator took frequent
breaks. Alternative methods for osteoclast quantification are described in the literature:
computer-imaging software that quantifies osteoclast by color, shape, and nuclei; and
by a TRAP5b assay (Alatalo, Halleen, Hentunen, Monkkonen, & Vaananen, 2000;
Halleen et al., 2000). The computer software captures multiple images within specific
boundaries demarcated by a gridded disk in the cell culture well, and counts osteoclasts
based on these specifications. This method of quantifying osteoclastogenesis is less time
consuming than manual cell counting.
Another way to confirm manual cell count reliability is the use of spectroscopy as
rapid screening method to determine osteoclast differentiation from a collected cell
culture medium has been demonstrated with the serum marker TRAP5b (Halleen et al.,
2000). The advantage to utilizing a TRAP5b assay is it changes data collection from a
binary value to total biological activity value. For example, osteoclasts with greater
numbers of nuclei are more effective in removing old bone and recruited macrophages
could be measured. This is another method to compare cell count to biological signal.
One method may be more valuable than the other or affirming of experiment results.
Conclusion
It is clear that the effects of the light on osteoclastogenesis are RANKL-dose and
light-intensity specific. We conclude at this time that a NIR-LED single light-treatment
may amplify osteoclastogenesis, and multiple light treatments may impair RANKLinduced osteoclastogenesis. The use of NIR-LED light therapy may be a beneficial
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intervention to return the bone remodeling process to homeostasis and preserve bone
integrity.
It remains unknown how NIR-LED light therapy affects the intricate
physiological signaling between osteoblasts and osteoclasts, as well as what effects it
may have on bone remodeling and absorption. NIR-LED may decrease oxidative stress,
preventing premature apoptosis, which is thought to occur with aging.
Continued experiments are planned with the use of a scientific-grade NIR-LED
light source that will allow for greater control of energy density and light intensity.
Repeated experiments will produce a larger sample size and enable a more substantial
statistical analysis. Understanding that aging impairs osteogenesis (bone remodeling)
due to an imbalance or “uncoupling” of osteoclastic/osteoblast activity, interventions
aimed at correcting this pathogenesis will further the science to provide knowledge in
reaching the goal of developing an intervention that may restore physiological function,
preserve or improve bone quality, improve bone mineralization with the hope of
preventing bone fragility and fracture, and ultimately improve the bone architecture to
withstand mechanical insult such as a fall.
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Table 1
Experiment 1
Dose Response Curve RANKL Dose 0, 2.5, 10, 25 and 50ng/ml with NO LIGHT TREATMENT
RANKL Dose
0 J/cm2

0 ng/ml
M (SD)
0.9 (1)

2.5 ng/ml
M (SD)
25.4 (2)

10 ng/ml
M (SD)
45.6 (7)

25 ng/ml 50ng/ml
M ( SD)
M ( SD)
250.6 (53) 484.4 (87)

F
102.22

P < .05
0.0001

Table 2
Experiment 1
Single Light Treatment for RANKL Dose 2.5, 10, 25 and 50ng/ml with Energy Density of 0, 4.5, 45 J/cm 2

Single Light Treatment
Energy Density J/cm2
0 ng/ml
2.5ng/ml
10ng/ml
25ng.ml
50ng/ml

0 J/cm2
M (SD)
0.9 (1)

25.4 (2)
45.6 (7)
250.6 (53)
484.4 (87)

4.5 J/cm2
M (SD)
0.8 (1)
24.8 (5)
68.8 (13)
226.2 (32)
485.2 (53)

45 J/cm2
M ( SD)
0
51.2 (6)
69.6 (11)
194.2 (34)
419.4 (130)

F
1.33
61.17
8.04
2.41
0.78

P < .05
0.3000
0.0001*
0.0060*
0.1318
0.4803

* = significant

Table 3
Experiment 2
Dose Response Curve RANKL Dose 0, 2.5, 10, 25 and 50ng/ml with NO LIGHT TREATMENT

RANKL Dose
0 J/cm2

0 ng/ml
M (SD)
0 (0)

25 ng/ml
M (SD)
254.4 (39)

50 ng/ml
M (SD)
F
276.8 (58) 69.86

P < .05
0.0001

Table 4
Experiment 2
Single Light Treatment for RANKL Dose 0, 25 and 50ng/ml with Energy Density of 0, 2.25, 4.5, 45 J/cm2

Single Light Treatment
Energy Density J/cm2
0 ng/ml
25ng/ml
50ng/ml
* = significant

0 J/cm2
M (SD)
0
245.4 (40)
276.8 (58)

2.25 J/cm2
M (SD)
0
274.4 (92)
316 (64)

4.5 J/cm2
M (SD)
3 (3)
491 (65)
336.8 (82)

45 J/cm2
M ( SD)
1 (1)
289.2 (77)
297.6 (33)

F
4.52
12.51
0.86

P < .05
0.0176*
0.0001*
0.4831
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Table 5
Single versus Multiple Light Treatments
Energy Density 4.5 J/cm2 and RANKL Dose 0, 25 and 50ng/ml
Number of Treatments
0 ng/ml
25ng/ml

Single
M (SD)
3.4 (3)
491(65)

Multiple
M (SD)
0.8 (1)
344 (70.6)

None
M (SD)
0
245.4 (39)

F
4.12
21.41

P< .05
0.0434*
0.0001*

50ng/ml

336.8 (81)

358 (61.7)

276.8 (58)

1.92

0.1890

* = significant

186

CHAPTER FIVE - DISCUSSION, CONCLUSIONS AND IMPLICATIONS
The purpose of this dissertation was to pilot test a new protocol designed to
answer the broad research question: Does Near-Infrared Light Emitting Diode (NIRLED) treatment affect Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)
induced osteoclastogenesis in a cell culture model? This study was conducted at the
NASA Ames Bone and Signaling Laboratory and consisted of four protocol development
experiments (Chapter Three) and two experiments for collection of data (Chapter Four).
In order to gain a robust understanding for the pathogenesis of bone loss, specifically
osteoporosis, three extensive reviews of the literature were completed. The first required
an understanding of the cellular mechanisms of NIR-LED and a search for existing NIRLED light treatment protocols using a cell culture model, specifically with RAW 264.7
cells. Based upon this knowledge, the second and third searches were conducted to
translate bench research into applicable knowledge for generalist nurses resulting in two
manuscripts that informed nursing practice regarding bone physiology and pathology and
nursing implications. The manuscripts describe gaps in the literature, provide literature
updates and implications for future research.
Synthesis of the Manuscripts
There are various updated clinical practice guidelines and many concerned
researchers, however, the point remains that by 2030, the US older adult population is set
to double with a significant portion over the age of 85 (U.S. Department of Health and
Human Services Administration on Aging, 2006), increasing the incidence of falls. The
costs to treat osteoporosis induced fractures estimated at $22 billion (Blume & Curtis,
2011). Most hip fractures result in hospitalization, and within the first year,
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approximately 37% of men and 26% of women will die from complications associated
with these fractures (Kannegaard, van der Mark, Eiken, & Abrahamsen, 2010). Of the
individuals who survive the first year many do not return to their pre-fall functional status
and suffer from fear, anxiety, and depression, all of which dramatically impacts their
quality of life (Eastwood et al., 2002; Harvey et al., 2013; National Institutes of Health
Consensus Development Panel on Osteoporosis [NIH-CDPO], 2001; National
Osteoporosis Foundation [NOF], 2010 [revised 2013]; Ziden et al., 2008). Ultimately, the
overall gap found in the osteoporosis literature was the inability to effectively identify
and treat patients prior to a fracture. Although osteoporosis research has been extensive
over the past two decades, only a modest impact has been shown is decreasing fracture
rates; thus, the societal economic impact to treat remains high and will only increase as
the population ages (Bilezikian & Cusano, 2013; Bonjour, Schurch, Chevalley, Ammann,
& Rizzoli, 1997; Burge et al., 2007; Challen, 1997; Chan, Uzer, & Rubin, 2013; Cohen &
Shane, 2013; Cummings et al., 2009; Looker, 2010; Looker, Melton, Borrud, &
Shepherd, 2012; Looker et al., 1997; Looker et al., 2008).
Two manuscripts were generated in order to understand nursing implications and
to identify gaps in the literature. The first manuscript provides the generalist nurse with a
review of the literature defining osteoporosis from a physiological perspective; reviewing
bone anatomy and physiology, overviewing the pathogenesis of osteoporosis,
osteoporosis outcomes, and presenting new treatment insights applicable to bone
physiology. The second manuscript’s focus is a review of nursing implications pertinent
to osteoporosis such bone loss and fall risk assessment, interventions, prevention, and
monitoring. These manuscripts identified the need for the experimental study.
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Therefore, results of the pilot data from the NASA Ames Bone and Signaling Laboratory
extrapolated from the developed bench research protocol (Chapter Three) testing the
effects of NIR-LED on osteoclastogenesis are reported in the third manuscript.
The first manuscript provided insight into understanding the etiology and
consequences of osteoporosis. The generalist nurse was presented with the most current
definition of osteoporosis, an overview of bone physiology and pathology, including its
causes, and negative health outcomes, including the societal financial burden to treat
osteoporotic induced fractures. Further, new methods to evaluate bone architecture
volume quantitative computed tomography (vQCT), micro-computed tomography (µCT)
and Trabecular Bone Score (TBS) (Silva et al., 2014) were discussed. Newer medications
were discussed such as parathyroid bone anabolic (Teriparatide [Forteo®]), Receptor
Activator of Nuclear Factor Ligand (RANKL)-inhibitor (Denosumab [Prolia ® or
XGEVA ®]), and experimental drugs; Calcilytics, stimulate PTH secretion in vivo
[animal study model] (JTT-305), and a newly discovered molecular pathway antagonist,
Wnt/ß-catenin, responsible for osteoblastic differentiation and recruitment (AMG 785).
The second manuscript provided the generalist nurse with the knowledge base to
appropriately assess and identify osteoporosis, implement tailored interventions, provide
disease monitoring and understand pertinent nursing implications for practice and policy.
Ultimately, nurses are active members of the multidisciplinary team and are positioned to
assist patients in understanding bone loss. Several gaps in the literature were highlighted:
few prospective studies exist to understand the specifics of the pathogenesis of bone loss
in the young and peri-menopausal women (Seifert-Klauss et al., 2012). This raises the
question; are clinicians screening for bone loss too late in the lifespan? Also, the
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majority of investigators have overlooked osteoporosis in men, as well as significantly
under diagnosing osteoporosis in general. In fact, some believe early diagnosis is
overlooked due to other comorbidities concomitantly occurring because they receive
more medical consideration, such as cardiac disease, simply because early osteopenia
occurs asymptomatically (Rachner, Khosla, & Hofbauer, 2012). Too often the diagnosis
of osteoporosis is made after a fracture. Thus, interventions are aimed towards preventing
further bone loss and consequential fractures, not efforts towards early diagnosis,
consequently not preventing the first fracture (Rachner et al., 2012). Osteoporosis must
be recognized as a disease that affects individuals across their entire life-span.
The main study of this dissertation tested the effects of NIR-LED
photomodulation on osteoclast formation investigating for a possible intervention that
may have benefits for bone health. This research could be applicable to improving bone
health for long-term space flight and general population. A protocol was developed over
a series of four experiments in preparation for a two experiment studies that constituted
the pilot study. The NASA award winning light treatment device used in this study was
created by Quantum Devices Incorporated, originally named, High Emissivity
Aluminiferous Lighting Substrate TM (HEALS), used to grow plants for space flight.
Using this technology, Quantum Devices Incorporated developed a commercial device,
Warfighter’s Accelerated Recovery by Photobiomodulation (WARP™ 10 & 75), a
portable NIR-LED, used in combat to provide first aid for minor injuries and pain
(National Astronautical Space Agency, 2008; Quantum Devices Incorporated, 2004;
Whelan, 2004). The size and portability of the NIR-LED was ideal for testing effects in a
cell culture model.
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RANKL-induced osteoclast formation by RAW264.7 cells occurred as expected
in all experiments. Light-treatment alone had no observable effect. A single lighttreatment at 4.5 J/cm2 with RANKL added (10 - 50ng/ml) suggested a biostimulatory
effect upon osteoclastogenesis compared to controls, as multiple light-treatments
compared to single light-treatment were less stimulatory in the energy density 4.5 J/cm2
and RANKL dose 25ng/ml group. The effects of the NIR-LED treatment on
osteoclastogenesis are RANKL dose and light-intensity specific. Concluding, NIR-LED
light-treatment affects RANKL-induced osteoclast formation, but multiple light
treatments compared to single light treatment may stimulate osteoclastogenesis less.
Although pilot data results must be cautiously interpreted, it was determined that
osteoclastogenesis was affected by NIR-LED light treatment. This was the first study that
investigated the effects of NIR-LED light treatment on osteoclastogenesis.
Limitations
Several study limitations existed. Challenges existed with producing consistent
negative control dose response curves. Experiment one was successful, but experiment
two, the RANKL stepwise dose response curve did not occur as expected. In fact, the
RANKL dose 25 and 50ng/ml had approximately the same biological effect. Thus, the
results of the first experiment yields more reliable results suggesting that single light
treatment is biostimulatory to osteoclastogenesis. Because the controls in experiment two
were inversely related, caution must be used in interpreting results. Single light treatment
appeared to be biostimulatory and multiple light treatments were less stimulatory
compared to controls.
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Evaluating the RANKL dose response curves, it appears that the RANKL dose
50ng/ml may meet the minimum dose threshold and adding a higher dose of RANKL
dose 75ng/ml would be advantages to more fully evaluate the dose response. The energy
density dose response curve is variable. However, based on experiment one, the energy
densities of 2.25 J/cm2 appears to be possibly meeting the minimal threshold, and then
increased biostimulation at the 4.5 J/cm2 is stepwise, but 45 J/cm2 biostimulation
decreases. Continuing testing energy densities in this stepwise dosing would be
beneficial to replicate.
These pilot data are to be interpreted with caution as the protocol has not
consistently produced trending results. However, with pilot data, dose response curves
can be adjusted and statistical control can be evaluated. Each experiment is unique and
the end result is to produce physiologically meaningful data. Ultimately, a successful
program of research should progress from cell culture into an animal model and then into
clinical studies, thus bringing bench research to the bedside. Further, in cell culture
animal and human cells will biologically respond differently to a same RANKL dose and
energy density. Once the protocol produces trending reliable results, and the most
important independent variables are identified, then at least three repeated experiments
must be conducted producing robust data appropriate to support or refute the hypothesis.
Because the experiments compare multiple variables between groups, better statistical
control of these comparisons could benefit from using the Holm-Bonferroni method
(Abdi, 2010). This type of analysis controls the family-wise error rate (probability of
type I errors) and is more powerful that the Bonferroni correction. Lastly, a power
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analysis should be calculated to ensure enough data is collected to reach significance
(Faul, Erdfelder, Lang, & Buchner, 2007).
Several limitations were encountered using a commercial light source rather than
a scientific grade light source, the possibility of cell culture heat shock, and investigator
subjectivity in manual osteoclast cell counting. The light sources used in these
experiments were commercial grade calibrated at the factory for energy density,
wavelength, and light intensity. A scientific grade light source has controls to fine-tune
variables and fans to cool the light.
The commercial grade light source used in the experiments turned off
automatically every 80 seconds, requiring manual restarting of the light during the 45
J/cm² experiments. This may have resulted in measurable effects on osteoclast formation
or inhibition similar to pulsing light-treatment which has a certain parameter of time set
between the light’s on/off times (Karu, 1992). Manually restarting the WARPTM 10
may have caused a brief temperature surge during protocol development, but the cell
culture medium never rose above 370 C , the temperature maintained by the incubator.
These temperature surges may be considered pulsing light-treatment, shown superior to
continuous wave light treatment dependent on cell type to inhibit or stimulate cells
(Hashmi et al., 2010). With this said, these possible temperature surges, could result in
heat shock; if heat shock did occur, the cultured cells may have been stressed by the
abrupt change in temperature resulting in an effect that was not brought about by the
light-treatment.
Modifications to the experimental protocol are required for future research studies
addressing these confounding variables created by the commercial light source. By using
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a light source with a built-in timing mechanism and capability to manually tune specific
energy densities and light intensities, giving greater control to test specific irradiation
wavelengths, energy densities, and light intensities, and to prevent heat shock by using
consistent low radiation intensity (670nm) (Karu, 1992; Letokhov, 1991). In future
experiments, obtaining a scientific grade continuous wave NIR-LED would be necessary
for ensuring reliable results.
Lastly, the manual cell counting technique is a subjective process relying on
visual interpretation of color and identification of cell nuclei. A visual cell counting
classification tool was developed to guide in the cell counting process (see Appendix G).
To be counted as an osteoclast cell, all cells were TRAP+ with a pink/purple or dark
purple bordering on black (if nuclei were still visible). To determine the faintest
acceptable pink, the stain color should match the RANKL control pink stain. The
counted cells should be stained darker than the control faint pink. The cell was counted if
there were three or more nuclei present. Clumps of TRAP+ mono-nucleated cells were
not counted, and cells connected by cell processes were counted as separate cells. The
investigator took frequent breaks. Alternative methods for osteoclast quantification are
described in the literature: computer-imaging software that quantifies osteoclast by
color, shape, and nuclei; and by a TRAP5b assay (Alatalo, Halleen, Hentunen,
Monkkonen, & Vaananen, 2000; Halleen et al., 2000). The computer software captures
multiple images within specific boundaries demarcated by a gridded disk in the cell
culture well, and counts osteoclasts based on these specifications. This method of
quantifying osteoclastogenesis is less time consuming than manual cell counting.
Using spectroscopy as a rapid screening method to determine osteoclast total

194

biological signal from the collected cell culture medium has been demonstrated with the
serum marker TRAP5b (Halleen et al., 2000). The advantage to utilizing a TRAP5b
assay is it changes data collection from a binary value to total biological activity value.
For example, osteoclast cell with multiple nuclei yield a higher biological signal and may
be more effective in removing old bone. These data compared to cell count are a
beneficial intra reliability measure.
Overall, three different perspectives of the bone loss literature were reviewed.
The first two manuscripts provide implications for nursing practice, public policy, and
future research; specifically health system wide comprehensive patient education
programs implemented across the life-span. The third manuscript presented pilot data that
must be interpreted with caution, but it can be determined that the study provided a solid
robust experimental protocol suitable for continued research. Continued experiments are
planned with the use of a scientific-grade NIR-LED light source that will allow for
greater control of energy density and light intensity. Repeated experiments will produce a
larger sample size and enable a more substantial statistical analysis. It remains unknown
how NIR-LED light therapy affects the intricate physiological signaling between
osteoblasts and osteoclasts, as well as what effects it may have on bone remodeling and
absorption, but new literature does provide some insight.
Implications
Implications for practice, policy, research and nursing research are offered based
on the results of this study. Nurses are able to evaluate a patient’s health care needs
holistically and integrate all physiological systems related to the human condition. For
example, a bone health scientist could make a suggestion for older adults to follow a
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vegan diet in order to preserve bone health. This dietary lifestyle is readily available
along the Pacific coast, and may be an ineffective intervention, because a vegan diet is
not as prevalent in the Midwest. Based upon the nurse’s prior rural home health
experience within the farming community, these older adults would not be willing to
remove dairy, eggs and meat from their diet based simply upon the social norms within
their personal culture. Therefore, implementing an educational program to follow a
vegan diet would most likely not be effective in a rural farming community.
Practice. Nurses have the opportunity to impact osteoporosis screening,
management and medication adherence through patient education. Because bone loss is a
multifaceted healthcare concern, the nurse can view the problem of attaining and
maintaining bone health across the human life-span. Nurses have the most frequent
patient contact, are trusted among many patient populations (Dinç & Gastmans, 2013),
embrace the implementation and improvement of evidence based practice (Lee et al.,
2013), and are an integral part of the multidisciplinary health care team (Wilkes et al.,
2014). Nurses have the opportunity to guide women and men to improve bone health and
reduce or reverse bone loss, thus preventing fractures and mortality and improving the
quality of life of older adults through thoughtful risk and clinical assessment, attentively
monitoring and implementing tailored interventions (Teng, Curtis, & Saag, 2009).
Effective nurse driven interventions have shown to be economical ($50 per
patient), successful using 70 minutes of one-on-one nurse case management by simply
providing patient education regarding the risks and benefits of bisphosphonate therapy,
arranging BMD testing, and assisting if needed to obtain prescriptions from their primary
care provider (Majumdar et al., 2007). With this said, nurses in outpatient clinic settings,
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can develop a comprehensive bone health educational programs that provides
intervention at the four points of the lifespan: maternal/infant health, pediatric, perimenopause/menopause (women’s health) and post-menopause (gerontology).
Policy. In order for a comprehensive bone health program to be effective,
hospital system must employ more registered nurses(RNs) in their clinic systems to
provide assessment and work in collaboration with advanced practice nurses to provide
data to support screening perimenopausal women beginning at age 45 for bone loss.
Between 2008-2013 only (9%) and (7%) RNS were employed in outpatient
clinics compared to (62%) and (60%) of medical assistants, respectively (Bureau of
Labor Statistics, 2008a, 2008b, 2013a, 2013b). Many of these nurses are performing
below their scope of practice while unlicensed assistive personnel are preforming above
their scope of practice (American Academy of Ambulatory Care, 2012). As health care
services shift from inpatient settings to outpatient setting, access to RNs will be
significantly less for the majority of the patient population (Bureau of Labor Statistics,
2013a).
Peri-menopause has been a focus in the literature since the mid-1990s, however
prevention and screening for osteopenia or evaluating perimenopausal women for bone
loss is lacking. Bone loss is reported to be stable during pre-menopause, but accelerates
significantly in late perimenopause (Finkelstein et al., 2008). In the 5-7 year span of
perimenopause and menopause, approximately, 12% of total bone mass is lost which is
equal to one T-score (-1 SD) of measured bone density by DEXA which corresponds to a
diagnosis of osteopenia (Armas & Recker, 2012). Most interventional studies focus on
post-menopausal women, at that point in the life-span the proverbial “horse is out of the
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barn”. Menopausal transition biomarker research is needed to identify the
perimenopausal women. The best clinical setting to improve bone health awareness
across the lifespan would be in the outpatient clinic setting for both generalist and
advanced practice nurses to increase screening, patient education, and management.
Research. A collaboration and translation of technologies applicable to astronaut
health may be useful in the general population. Currently, the International Space Station
uses NIR-LED to grow plants, but some day this technology may be applicable to bone
health. It has already been translated as a technology used in the general population for
pain relief (Quantum Devices Incorporated, 2004) and used for wound healing in the
military (Whelan et al., 2004).
According to the National Institutes of Health, translational research can be
defined as a two stage process; the application of innovative laboratory research into
preclinical studies to design human clinical trials that results in the implementation of
best practices into the community with objectives to achieve cost-effectiveness in
prevention and treatment (National Institutes of Health, 2007). Research is transferred
from the laboratory’s bench (basic research) to the patient’s bedside (clinical research)
then clinical study and trial findings transferred into the community and practice settings
to improve health outcomes (Rubio et al., 2010).
One example of translational research in collaboration with NASA was recently
presented at the International Osteoporosis Foundation - International Society for Clinical
Densitometry. These researchers from Johnson Space Center, Wyle; aerospace
contractor, Mercy Health, Cincinnati, and Lausanne University Switzerland investigated
a new measurement for bone strength, trabecular bone score (TBS) of the lumbar spine in
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long-duration spaceflight astronauts (Smith et al., 2014). They calculated for changes in
DEXA and TBS scores in three different bone loss countermeasure (intervention) groups.
Changes in mineral content, cortical vs. trabecular bone, may suggest independent effects
of bone loss according to group intervention. These data support the continued need to
investigate TBS as a significant measurement to evaluate bone architecture.
Education. Opportunities for nurses engaged in basic science research discovery
are available. The University Of Maryland School Of Nursing recently posted a nurse
physiologist research scientist tenure track faculty position. Further, access to
laboratories for nurse physiologists can be found directly in the Schools of Nursing at
Yale University and University of Pennsylvania. However, it still remains difficult to
find a good fit with a university that provides adequate support for basic science research
without relying on external laboratory space for the nurse scientist.
Most positions require at least one year of post-doctoral education (University of
Maryland School of Nursing, 2014). The Robert Wood Johnson Foundation supports a
Nurse Faculty Scholar Award providing research funding to junior faculty creating the
next generation of nurse leaders (Robert Wood Johnson Foundation, 2014).
More regionally, Medical College of Wisconsin Center for Clinical and
Translational Institute provides information regarding resources for specialized research
laboratories at partner institutions; Blood Center of Wisconsin, Children’s Hospital of
Wisconsin, Froedtert Hospital, Marquette University, Medical College of Wisconsin,
Milwaukee School of Engineering, University of Wisconsin-Milwaukee and Zablocki
VA Medical Center (Medical College of Wisconsin Center for Clinical and Translational
Institute, 2014). These resources may allow a bench research nurse scientist network and
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collaborate with those scientists with laboratory facilities if one is not available at their
primary institution. It is important that in becoming a basic science nurse scientist, a
commitment is made not only by higher educational institutions to employ basic science
nurse researchers but more importantly to foster relationships and mentor other doctoral
nursing students.
Implementing curriculum to prepare an Integrative Nurse Physiologist into the
Nursing Doctorate of Philosophy should be considered. Currently, there is not an
academic pathway for this course of academic study and typically, post-doctoral study is
required for employment in current nursing faculty positions. It would be most
advantageous to accommodate immediate employment upon completion of the PhD, thus,
providing colleges of nursing an applicant pool of nurse physiologists.
The curriculum should complement the student’s program of research and allow
for specialization. For example, flexibility in course choice would be most beneficial to
the student. Some appropriate courses to include, but not limited to, are cell biology,
clinical lab sciences, advanced anatomy and physiology, and chemistry. Before
implementing this academic pathway, resources such a laboratory facilities and research
funding for bench research opportunities must be secured. This may be established
through College of Nursing endowment funding and field sites with bench research
scientists. Nurse physiologists benefit the research community because their participation
among multidisciplinary members provides perspectives regarding the human condition,
and fosters creativity for research questions that involve multi disciplines. They are the
great collaborators, communicators, and teachers; and they tend to be the healthcare
expert and caring agents among the team. Many times their role is essential for bringing
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the team together to together to discuss solutions to problems, and interpreting results
then moving science forward.
Future Research
The main focus of this study was to test a biomedical device for effects in cell
cultured osteoclasts. Much laser light treatment research has advanced, particularly in the
field of dentistry. In the past, the most common use for lasers was seen in surgical
techniques to cut, coagulate, or ablate tissue. The laser’s mechanism of action in this
instance is to destroy tissue and provide precise surgical incisions. This is achieved by
heating the tissue at a high irradiation intensity and energy density. The use of low level
laser treatment is the utilization of a low power laser or light emitting diode in the
irradiance range of (1mW – 500MW) (Huang, 2009).
Recent search for NIR-LED treatment in combination with osteoporosis yielded
no studies. However, searching low level light treatment, a few new studies were found.
As with any use of a bio-technology, beneficial or harmful effects may occur in different
cell types. As stated biological aging related to human aging has been associated with
cellular oxidative stress (OS) and mitochondrial dysfunction (Melov, 2000), and this may
induce bone loss (Srinivasan & Avadhani, 2007). Mitochondrial DNA (mtDNA)
indicates that mutations of the mitochondrial genome are vulnerable to oxidative damage
(Linnane et al., 1989) and may cause degenerative diseases and aging. NIR-LED light
treatment has beneficial effects in reducing cellular oxidative stress, improving
mitochondrial function and preventing premature cell apoptosis (Karu, 1999; Desmet et
al., 2006; Wong-Riley et al., 2001). The following are updates to the NIR-LED
literature.
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As previously discussed, beneficial effects were found in improving wound
healing (Eells et al., 2004; Whelan et al., 2003), bone regeneration (Pinheiro et al.,
2009), decreasing inflammation and pain, aiding in recovery of ischemic cardiac injury
(Oron, 2006; Oron et al., 2001), and attenuating retinal/optic nerve degeneration (Eells et
al., 2007; Eells et al, 2004; Eells et al., 2003; Liang et al., 2006). Recent animal model
research has demonstrated continued positive effects in bone repair activating osteogenic
factors (Barbosa et al., 2013; Tim et al., 2014). Of interest, bisphosphonates-related
osteonecrosis of the jaw (BRONJ), a well-known adverse side effect of long-term use of
bisphosphonates, is an area of bone exposed in the maxillofacial region that does not
heal within two months (Khosla et al., 2007). Use of surgical laser-assited (low level
laser treatment) in BRONJ patients aided bone healing positively compared to traditional
medical treatment (Vescovi et al., 2012). Further, NIR-LED treatment was used in two
transgenic Alzheimer’s mouse animal models and found cerebral degeneration was
reversed or alleviated (Purushothuman, Johnstone, Nandasena, Mitrofanis, & Stone,
2014). Further, improvement in cognitive function in two traumatic brain injury patients
improved with forehead and scalp NIR-LED light treatment (Naeser, Saltmarche,
Krengel, Hamblin, & Knight, 2011). Detrimental effects of NIR-LED treatment were
found in a Meckel Syndrome animal model reporting that cystic kidneys did not improve
with light therapy as a twofold increase in BUN was reported (Lim et al., 2011). It
remains unknown how NIR-LED light therapy affects the intricate physiological
signaling between osteoblasts and osteoclasts, as well as what effects it may have on
bone remodeling and absorption.
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Continued Program of Research. Provided once the experiment protocol
produces trending reliable results and the most important independent variables are
identified, three repeated experiments will be conducted to produce robust data
appropriate to support or refute the hypothesis. However, understanding more fully that
aging impairs osteogenesis (bone remodeling) due to an imbalance or “uncoupling” of
osteoclastic/osteoblast activity, interventions aimed at correcting this pathogenesis will
further the science to provide knowledge in reaching the goal of developing an
intervention that may restore physiological function, preserve or improve bone quality,
improve bone mineralization with the hope of preventing bone fragility and fracture, and
ultimately improve the bone architecture to withstand mechanical insult such as a fall.
It is known that sex steroid deficiency (loss of estrogen) stimulates osteoblast and
osteocyte apoptosis leading to fewer osteocytes in the bone matrix (Almeida & O'Brien,
2013; Manolagas, 2010) because estrogen stimulates osteoprotegerin (OPG) production
and is vital to the regulation of osteoclastogenesis. As a result, menopausal transition and
post-menopause, RANKL cytosol concentrations are greater than the OPG generation
due to loss of estrogen (Tella, Gallagher, Tella, & Gallagher, 2013). Therefore,
osteoclastogenesis is appropriately regulated by OPG, and osteoclastogenesis is increased
due to higher concentration of RANKL. Low level light treatment is known to have the
above mentioned benefits to improve cellular oxidative stress, mitochondrial function,
and improved gene transcription. Further, transcription factor nuclear factor B (NF-κ-B),
regulated by changes in cellular redox state is activated with low level light treatment
producing protective and stimulatory gene products (Huang et al., 2011). This is the
same nuclear factor activated by the joining of the osteoblast RANKL and macrophage
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RANK receptor. There may be a link between light treatment and osteoclast formation.
A future research question may be to explore if LLLT induces osteoclast formation via
the activation macrophage nuclear factor B (NF-κ-B) in the absence of RANKL in cell
culture.
Discussion
Given the opportunity to work collaboratively with NASA was a unique
experience for a doctoral nursing scientist. Participating with a bench-research scientific
team, a nursing perspective was welcomed. Traditionally the specialty of space nursing
involves assisting flight surgeons in pre-flight preparation similarity to outpatient patient
care. Another role is the management and medical monitoring of specialized spacerelated research, for example managing and monitoring subjects in bed-rest and sleep
deprivation studies. Nursing has multiple perspectives to bring to bench research teams.
To summarize the major tenets of the considerable amount of available bone loss
literature, the current incidence of osteoporosis and fractures remains high, and is soon to
become a worldwide epidemic while many countries fail to consider this as a major
health problem. It is evident that estimates of cost to treat osteoporotic-induced fractures
are expected to at least double by 2040 placing a great societal financial burden to care
for the anticipated 70 million older adults by 2030. Access to quality and timely health
care services may become difficult due to the shortage of healthcare providers,
specifically, geriatric certified (Centers for Medicare & Medicaid Services, 2005;
Hartford Center of Geriatric Nursing Excellence at the Arizona State University College
of Nursing & Healthcare Innovation, 2008). Nurses have the most frequent patient
contact, are trusted among many patient populations, and embrace the implementation
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and improvement of evidence based practice. Therefore, nursing has an opportunity to
fill the foreseeable gaps in services by enhancing their knowledge base to efficiently
identify and implement appropriate interventions for the prevention and treatment for
osteoporosis across the life-span. Skeletal health researchers have one common goal,
which is to gain an in-depth understanding of how to prevent or reverse bone loss in order
to prevent fractures and mortality, thus improving the quality life of older adults (Teng et
al., 2009).
Conclusions
This pilot study accomplished two objectives. First the development of a
successful experiment protocol and second, concluding that NIR-LED affects
osteoclastogenesis. A challenge exists on how to effectively impact the identification and
treatment of osteoporosis in order to prevent initial osteoporotic induced fractures.
Osteoporosis and osteopenia are grossly underdiagnosed and usually are not assessed
until a fracture occurs. Fracture is a main causal factor for morbidity and mortality in the
older adult population and the most common trigger point for osteoporosis identification
and treatment; however, only modest results in improving osteoporosis management have
been achieved through patient and clinician education, but nurse driven interventions
have been found to be effective. Further research is warranted to investigate fully the
effects of NIR-LED light treatment and possible implications as an intervention to
prevent or preserve bone health.
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AEXP1381 Conditioned Medium Experiment on RAW264.7 Cells
Goal: Follow Exp1377, to collect more CM for pit assay, also use the irradiated cells to
repeat the replating exp, and possibly test different inhibitors

I. Part A. Conditioned Medium Collection
Day-1. Cell Plating (density of 7x104 cells/mL)
1. Cell Collection
___ aspirate medium
___ add 5mL pre-warmed medium to flask
___ use a sterile cell scraper gently remove cells from flask
___ transfer cell suspension into a sterile conical tube
___ centrifuge at 800rpm for 5 min
___ resuspend cells in 10mL medium
___ use 1mL pipetman to break up clumps by pipetting up and down
2. Hemocytometer Counting
___ take 5uL of cell suspension, and mix with 45uL of trypan blue (dilution: 1/10,
due to higher dilution if too concentrated.)
___ load the chamber with 20uL diluted cells suspension
___ count viable cells in 4 x 1mm2-squares with 10X objective under a
microscope
___ calculate the number of cells/mL
Cell Density = D1 = (____/4)x10x104= ____________cells/mL
Total Number of Cells in 10mL cell suspension =
(D1)*10=___________cells
___ add another 10mL of medium to cell suspension, mix well
3. Make _80_ mL cell stock with density of 7x104 cells/mL
___ add __________ uL cell suspension
___ mix with __________ mL α-MEM+10%FBS
4. Plating in T-75
___ pipet up and down several times to get an even suspension
___ add 12mL of cell suspension to each T-75
___ check under microscope
___ incubate at 37oC
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Day 0: Irradiation (this procedure will be carried by Ruth.)
1. Irradiation step will be carried out by Ruth (0Gy and 2Gy)
1. Immediately after IR, collect and replace with 12mL fresh medium.
Centrifuge medium collected at 1000rpm for 10 min, then store at -80oC.
 About _______ conditioned medium per flask was collected.
2. Incubate flasks at 37oC.
Flask# (CM#) IR dose (Gy) ∆ medium after IR IR Time (min), Position 3, Rotate
1, 2, 3
0Gy
∆
Sham IR
2Gy
∆
2.19 min
4, 5, 6
Day 3: Culture Medium Collection
1. Prepare and label 6 x sterile and pyrogen-free centrifuge tubes
2. Combine and transfer condition medium from flasks to centrifuge tubes
3. Centrifuge tubes at 1000rpm for 10 minutes
4. Collect supernatant and transfer to sterile, pyrogen-free tubes
Store at -80oC
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RAW 264.7 Culture Growth Medium Preparation:
Manufacture HyClone procedure was followed (HyClone, 2003).
1. Removed 500ml bottle of FBS from -80°C freezer and placed in
refrigerator to thaw overnight. Completed the thawing of serum the
following day by placing serum in a 37°C water bath (Polysciences)
with a water level higher than the serum level in the bottle. Mixed by
inversion.
2. Once serum was completely thawed, incubated for an additional 15
min to allow serum to equilibrate with the 37°C bath.
3. Raised the temperature setting of the bath to 56°C and continued
heating the bath and serum until the bath reached 56°C (approximately
35 minutes). During this incubation period, mixed the serum by
inversion every 10 min.
4. Once bath reached 56°C, incubated serum for 30min mixing the serum
bottle every 10 min.
5. Removed serum from water bath and allowed to cool at room
temperature for 30 min. Reset water bath to the 37°C mark.
6. Cleaned all surfaces in the cell culture hood, pipetman and conical
tube holder with 70% ethanol. Then cleaned external surfaces of ten
50ml conical tubes and the 500ml bottle of FBS from the water bath
with 70% ethanol (ETOH) to sterilize them to prevent contamination
of cultured cells. Aliquoted 50ml of treated serum into ten 50ml
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conical tubes (Fisher Scientific: catalog number 0553860) and stored
at 4°C or freeze at -20°C.
7. After the FBS was heat inactivated and filtered (Fisher Catalog
number: 0974028C), the FBS may be added to the growth culture
medium (Fisher Scientific, 2010b). Removed one 50ml conical FSB
(Fisher Scientific: catalog number 0553860) from freezer and thawed
in 37°C water bath (Polysciences).
8. Cleaned external surfaces of the vial and hood with 70% ethanol
(ETOH) to prevent contamination of cultured cells
9.

Removed 500ml bottle of ά-MEM from the refrigerator and filtered
through a 500ml filter Nalgene, 500/250ml capacity (surfactant-free
cellulose acetate (SFCA) membrane 0.2um: Fisher catalog number:
0974028C) followed by filtering 50ml of FBS (10% concentration).

a4. RAW264.7 Cell Thawing: The procedure for propagation of RAW
264.7 cells was as follows:
1. Prepared a water bath (Polysciences) to 37°C and pre-warmed άMEM-10% FBS for approximately 15min in water bath.
2. Thawed cells with a constant gentle agitation in the 37°C water bath.
3. Cleaned all surfaces in the cell culture hood, pneumatic pipette-man
(BrandTech Accu-Jet) and conical tube holder with 70% ethanol.
Cleaned external surfaces of two 50 ml conical tubes (Fisher
Scientific: catalog number 0553860) to be used in the transfer of
RAW 264.7 cells into cell culture dishes with 70% ethanol. Placed the
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two conical tubes in the hood and labeled one tube “cell suspension”
and the other “medium” with cryo marker (marker will not be removed
if sprayed with 70% ethanol). Added 10ml of culture medium to
“medium” conical tube.
4. Under the sterile hood, flamed lid of vial of RAW 264.7 cells.
Sterilized the lid prior to opening.
5. Under the hood, gently transferred thawed cells to 50ml conical tube.
6. Added warmed culture medium to “cell suspension” labeled conical
tube in a drop-wise fashion such that 10ml is added over about 2 min
then added the rest a little faster, gradually diluting cells and
preservative.
7. Centrifuged for 5 min at 100g (730 rpm Beckman GS-6KRl).
8. Discarded the supernatant (medium above visible ring of centrifuged
cells) and re-suspended the cells in 10 ml of fresh medium for culture.
9. Aspirated cells with pipetman to break up cells and gently expelled
them into three 10 cm tissue-culture treated Polystyrene petri dishes
(Corning, Fisher Catalog number: 0877222) (Fisher Scientific, 2010a)
in recommended cell suspension ratios 1:20, 1:10, 1:5 cell.
10. Cell suspension Ratios:


Added culture medium and adjusted accordingly to ratio for
a total of 10ml per culture dish
 1:20 2ml cells/8ml = 20% concentration
 1:10 1ml cells/9ml = 10% concentration
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 1:5 0.5ml cells/9.5ml = 5% concentration
Cells are then ready for propagation (the multiplication and division of cells by
natural reproduction)
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Appendix C
Procedure for Cell Passaging
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Procedure for Cell Passaging
The procedure to passage RAW 264.7 was as follows:
1. Cleaned all surfaces in the cell culture hood, pneumatic pipette-man
(BrandTech Accu-Jet) and conical tube holder with 70% ethanol.
Then cleaned external surfaces of two 50 ml conical tubes (Fisher
Scientific: catalog number 0553860) to be used in the transfer of
RAW 264.7 cells into cell culture dishes with 70% ethanol. Labeled
one tube “cell suspension” and the other “medium” with cryo marker.
2.

Removed 500ml bottle of ά-MEM-10% FBS from the refrigerator and
cleaned with 70% ethanol and place in hood. Transferred 50ml of
medium to the conical tube labeled “medium”. Removed and placed
in water bath.

3. Prepared a water bath (Polysciences) to 37°C and pre-warmed άMEM-10% FBS. When warmed to 37°C (approximately 10 min),
cleaned outside of conical tube with 70% ethanol prior to placing back
in hood.
4. While warming medium in water bath, gathered 10ml pipette tip (BDcatalog number 309604) and cell scraper (Falcon: catalog number
353085). Placed by sterile technique two 10cm tissue-culture treated
Polystyrene petri dishes (Corning, Fisher Catalog number: 0877222)
(Fisher Scientific, 2010a) in the hood.
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5. Labeled petri dishes with initials, date, the number of times cells have
been passaged, name of cell line (RAW 267.4) and cell concentration
suspension ratios of 1:10 and 1:5 cell with cryo marker.
6. Took incubated petri dishes of RAW 264.7 cells from incubator and
visualized under inverted microscope (inverted microscope, 10x
magnification; Nikon Eclipse TS100). Determined which cell culture
dish had the highest cell confluence. Saved other cell culture dish in
reserve.
7. Under hood, aspirated old culture medium from petri dish with suction
and replaced with 10 ml fresh medium.
8. Took cell scraper and gently whisked cells up off of the petri dish
surface moving in a clockwise fashion.
9. Aspirated 10ml from petri dish and placed in conical tube label “cell
suspension”, Centrifuge for 5 min at 800rpm (Beckman GS-6KRl).
10. While centrifuging, placed 9.5 ml and 9 ml of medium into petri dishes
respectively.
11. Took conical tube from centrifuge and discarded the supernatant and
re-suspended with cells in 10ml of fresh medium. Pipetted up and
down in conical tube to break up cell clumps, then gently expelled 1ml
of cell suspension into the labeled 1:10 petri dish and 0.5ml into the
1:5 label petri dish.


Cell suspension Ratios:




1:10 1ml cells/9ml = 10% concentration
1:5 0.5ml cells/9.5ml = 5% concentration
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Appendix D
Cell Plating Procedure

248

Cell Plating Procedure
The cell plating density was calculated by the following procedure:
1. Calculate number of required experiment wells
Control Plates: 5 wells per condition Total Wells: 50
4.5 J/cm2 Energy Density Control Plate
Plate 1:
Plate 2:
45 J/cm2 Energy Density Control Plate
Plate 1:
Plate 2:

0-0-0
0-0-0

0-0-2.5
0-0-25

0-0-10 15 wells
0-0-50 10 wells

0-0-0

0-0-2.5
0-0-25

0-0-10 15 wells
0-0-50 10 wells

Experimental Plates: 5 wells per condition Total Wells: 50
4.5 J/cm2 Energy Density Exp Plate
Plate 1:
1-4.5-0 1-4.5-2.5 1-4.5-10
Plate 2:
1-4.5-25 1-4.5-50

15 wells
10 wells

45 J/cm2 Energy Density Exp Plate
Plate 1:
Plate 2:

15 wells
10 wells

1-45-0

1-45-2.5
1-45-25

1-45-10
1-45-50

2. Total wells plated
___
___
___

Controls: 50 wells
Experimental: 50 wells
Total 100 wells

4. Used 24 well plates @ 0.5 ml/well culture medium
a. Equation:
Total needed medium: x of wells * 0.5 ml = y mls
 100 wells * 0.5ml =50 mls [make 55 mls of cell
stock (additional 5mls for reserve)]

b.

Cell plating density equation:
4 x104 cells * 0.5 ml = 2 x104 cells/well
1 ml
well

Day 0: Cell Plating: Density of 2 x 104 cells/well RAW264.7 cells were passaged 17
times in ά-MEM-10%FBS
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1.

Cleaned all surfaces in the cell culture hood, pneumatic pipette-man (BrandTech
Accu-Jet) and conical tube holder with 70% ethanol. Then cleaned external
surfaces of three 50 ml conical tubes (Fisher Scientific: catalog number 0553860)
to be used in the transfer of RAW 264.7 cells into cell culture dishes with 70%
ethanol. Labeled these three tubes “Cell Suspension”, “Plate Cell Suspension” and
“Medium” with cryo marker.

2.

Removed 500ml bottle of ά-MEM-10% FBS from the refrigerator and clean with
70% ethanol and place in hood. Transfer 50ml of medium to the conical tube
labeled “medium”. Remove and place in water bath.

3.

Prepared a water bath (Polysciences) to 37°C and then pre-warmed ά-MEM-10%
FBS. When medium is warmed to 37°C (approximately 10 min), cleaned external
surface with 70% ethanol prior to placing back in hood.


While warming medium in water bath, gathered 10ml
pipette tip (BD- catalog number 309604) and cell scraper
(Falcon: catalog number 353085). Placed by sterile
technique two 10cm tissue-culture treated Polystyrene petri
dishes (Corning, Fisher Catalog number: 0877222) (Fisher
Scientific, 2010a) in the hood.



Used cryo marker, labeled petri dishes with initials, date,
the number of times cells have been passaged, name of cell
line (RAW 267.4) and cell concentration suspension ratios
of 1:10 and 1:5 cells.
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Took incubating petri dishes of RAW 264.7 cells from
incubator and visualized under inverted microscope
(inverted microscope, 10x magnification; Nikon Eclipse
TS100). Decided which cell culture dish had the highest
cell confluence. Saved other cell culture dish in reserve.



Under hood, aspirated old culture medium from petri dishes
with suction and replaced with 10 ml fresh medium. Took
cell scraper and gently whisked cells up off of the petri dish
surface moving in a clockwise fashion.



Aspirated 10ml from petri dish and placed in conical tube
label “cell suspension”, Centrifuge for 5 min at 800rpm
(Beckman GS-6KRl).



While centrifuging, placed 9.5 ml and 9 ml of medium into
petri dishes respectively.



Took conical tube from centrifuge and discarded the
supernatant and re-suspended with cells in 10ml of fresh
medium. Pipetted up and down in conical tube to break up
cell clumps, then gently expelled 1ml of cell suspension
into the labeled 1:10 petri dish and 0.5ml into the 1:5 label
petri dish.


Cell suspension Ratios:

 1:10 1ml cells/9ml = 10% concentration
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 1:5 0.5ml cells/9.5ml = 5%
concentration
Save “Cell Suspension” conical to prepare plating cell suspension
procedure.
4. Hemocytometer Counting:
 took 10uL of cell suspension, and mixed with 20ul of trypan blue
(used to stain cells) (dilution: 1/10, go to higher dilution if too
concentrated.)
 loaded the hemocytometer chamber with approximately 10uL
diluted cell suspension
 counted viable cells in 4 x 1mm2 squares with 10x objective under
a microscope: squares need to be > 50cells.
 calculated the number of cells/ml
#cells in
hemocytometer


Cell Density = (_ 214 _/4) =
cells/ml

53.5

* 10 (1/10 dilution) *104 = 5.35 x 106

Dilution factor

5. Cell stock (Plating Cell suspension)
Made _55_ ml cell stock with density of 4x104 cells/ml
 100 wells * 0.5ml = 53.5 mls [make 55 mls of cell stock]
55ml x 4 x 104 = 2.2 x 106 cells/ml
1ml


Cell plating density
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Total
amount of
cell
suspension
needed 

2.2 x 106 | 1ml
6
Cells/ml
for hemocytometer
X
| 5.35 x10
= .411 ml or 411ul

 added 411ul cell suspension
 mixed with _54.5 ml ά-MEM+10% FBS in labeled “Plate cell
suspension” conical

6. Plated 25 wells in Control 24 well cell culture plates:

Divided plates by experimental treatment groups according to the RANKL dose
(0, 2.5, 10, 25 or 50 ng/ml), and the energy density (4.5 J/cm², 45 J/cm²) with respective
negative controls.
Plate 1: (4.5 J/cm2 controls)
1st control plate: 15 wells
[A2 – A6]: 0-0-0
[B2 – B6]: 0-0-25
[C2 – C6]: 0-0-50
Plate 2: (4.5 J/cm2 controls)
2nd control plate: 10 wells
[A2 – A6]: 0-0-2.5
[B2 – B6]: 0-0-10
Plate 3: (45 J/cm2 controls)
1st control plate: 15 wells
[A2 – A6]: 0-0-0
[B2 – B6]: 0-0-25
[C2 – C6]: 0-0-50
Plate 4: (45 J/cm2 controls)
2nd control plate: 10 wells
[A2 – A6]: 0-0-2.5
[B2 – B6]: 0-0-10

7. Plated in 25 wells of treatment 24 well cell culture plates:
Plate 5: (4.5 J/cm2 treatment plates)
1st treatment plate: 15wells
[A2 – A6]: 1-4.5-0
[B2 – B6]: 1-4.5-25
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[C2 – C6]: 1-4.5-50
Plate 6: (4.5 J/cm2 treatment plates)
2nd treatment plate: 10 wells
[A2 – A6]: 1-4.5-2.5
[B2 – B6]: 1-4.5-10
Plate 7: (45 J/cm2 treatment plates)
1st treatment plate: 15wells
[A2 – A6]: 1-45-0
[B2 – B6]: 1-45-25
[C2 – C6]: 1-4.5-50






Plate 8: (45 J/cm2 treatment plates)
2nd treatment plate: 10 wells
[A2 – A6]: 1-45-2.5
[B2 – B6]: 1-45-10
pipetted up and down several times for an even suspension
added 0.5ml cell suspension to each well
o expelled cells gently alongside of well wall, and swirled plate
for an even cell suspension
visualized cells under microscope to determine an even cell suspension
placed in incubator for 24hrs
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Appendix E
Receptor Activator of Nuclear Factor Ligand Induction (RANKL)
Induction Procedure
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- RANKL Induction Procedure
A 20µl RANKL dilution was prepared to be added to each treatment well.
20 wells @ 20µl of RANKL intermediate = 450µl of volume for each RANKL dose


Number of
treatment
wells per
RANKL
Dose

Each well contained 0.5ml of medium: added 20µl of RANKL intermediate to
each well.
1. Serial dilution: began with highest RANKL dose: 50ng/ml


50ng x 0.5ml x ____1______
ml
20 x 10-3 ml

2.

= 1.25 x 103 ng 20ul RANKL
Intermediate 50ng/ml
ml
concentration


20ul RANKL Intermediate
converted to ml
Calculated final
volume
for 50ng/ml
wells per
RANKL Dose

wells per RANKL Dose

dose.

(100 x 103ng)(____1_____) = 0.788 ml = 788µl final volume (round to 800µl)
ml
1.25 x 103 ng/ml


20ul RANKL
Original Stock RANKLIntermediate 50ng/ml
Concentration
concentration
wells per RANKL Dose

Calculated volume of RANKL from 10µl aliquot of RANKL stock needed for
50ng/ml concentration.
1250mg x 0.788 ul x ____ 1_______
ml
1.25 x 103 ng/ml


In
order to
Original Stock RANKL
Concentration

= 9.85 µl

simplify calculations refigured for using 10µl RANKL aliquot

value since the RANKL stock was aliquoted into 10µl volumes. Serial Dilution
for RANKL Intermediate Stock Concentration summarized below.

Tube
Number

Dilution
Factor

1: 50ng/ml

1:1

2: 25ng/ml
3: 10ng/ml
4: 2.5ng/ml

1:2
1:2.5
1:4

5: 0 ng/ml

0

Volume of
Previous
Stock/µl
35ul
RANKL
800
765
676

Add
medium
Volume/µl

Beginning
Tube
Volume/µl
765

Total final
Volume/µl

RANKL Intermediate
Stock Concentration

800

1.25 x 103 ng/ml

338
225
113

338
338
337

765
676
563

0.63 x 103 ng/ml
0.68 x 103 ng/ml
0.31 x 103 ng/ml

0

450

450
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3. Cleaned all surfaces in the cell culture hood, pneumatic pipette-man
(BrandTech Accu-Jet) and conical tube holder with 70% ethanol. Prepared
five 2ml cryotubes: removed from sterile packaging and placed in hood.
Labeled each tube with RANKL dose. Tube 1-5 labeled 50, 25, 10, 2.5, and 0
ng/ml, respectively. Then cleaned external surfaces of two 50 ml conical
tubes (Fisher Scientific: catalog number 0553860). Labeled both “medium”.
4.

Removed 500ml bottle of ά-MEM-10% FBS from the refrigerator and
cleaned with 70% ethanol and placed in hood. Transferred 50ml of medium to
the conical tubes labeled “medium”. Removed and placed in water bath.

5. Prepared a water bath (Polysciences) to 37°C and pre-warmed ά-MEM-10%
FBS. When medium was warmed to 37°C (approximately 10 min), cleaned
external surface of conical with 70% ethanol prior to placing back in the hood.
6. While water bath is warming medium, removed 10µl aliquot of RANKL from
the -70°C freezer. Slowly thawed 10µl aliquot of RANKL stock (1250ng/ml
concentration) over ice for approximately 15 minutes. Monitored closely
because cytokines derogate rapidly with warmth. When RANKL volume was
visually mobile in the cryotube, i.e. thawed, centrifuged for 3 seconds to
collect RANKL into one collected volume in the bottom of the cryotube. The
aliquot was now ready for dilution with culture medium.
7.

Added 25µl of culture medium to the 10µl of RANKL stock, thus yielding
35µl volume. Mixed thoroughly with pipetman.
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Changed pipette tips in-between mixing serial dilutions as to not alter the
concentration of the RANKL dose. Note all final volumes of RANKL
intermediate are greater than 450µl needed for RANKL induction.
8. Placed final volume amount in tubes 2-5. Placed 765µl into tube 1 to begin
dilution.
9. Aspirated 35µl RANKL stock and added to tube 1 to create the RANKL
intermediate.
10. Aspirated 338µl RANKL intermediate from tube 1 and added to tube 2.
11. Aspirated 225 RANKL intermediate from tube 2 and added to tube 3.
12. Aspirated 113 RANKL intermediate from tube 3 and added to tube 4.
13. Aspirated 20µl of RANKL intermediate from tube 2 and added to
corresponding RANKL dose well. Repeated until 20 wells have been filled.
Repeated procedure for tubes 1, 4, and 3. (Changed pipette tips when
changing to the next RANKL concentration as not to alter the RANKL
concentration.)
14. When adding RANKL intermediate to each well


tilted culture plate towards self



did not touch sides of well or bottom of well to avoid disturbing
cultured cells



gently pipetted up and down several times into the medium and
swirled plate to get even mixing



visualized cells under microscope to determine if there was any
disruption of plated cells
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placed in incubator for 24hrs

RANKL Induction Plate Labeling

Tube 1 : 50ng/ml
Energy Density J/cm2
Plate Number
1
4.5 (controls)
3
45 (controls)
5
4.5 ( treatment)
7
45 ( treatment)

RANKL Dose ng/ml
50
50
50
50

Tube 2: 25
Plate Number
1
3
5
7

RANKL Dose ng/ml
25
25
25
25

Tube 3: 10ng/ml
Plate Number
2
4
6
8

Tube 4: 2.5ng/ml
Plate Number
2
4
6
8

Energy Density J/cm2
4.5 (controls)
45 (controls)
4.5 ( treatment)
45 ( treatment)

Number of Wells
5
5
5
5

Well Number
[C2 – C6]: 0-0-50
[C2 – C6]: 0-0-50
[C2 – C6]: 1-4.5-50
[C2 – C6]: 1-45-50

Number of Wells
5
5
5
5

Well Number
[B2 – B6]: 0-0-50
[B2 – B6]: 0-0-50
[B2 – B6]: 1-4.5-50
[B2 – B6]: 1-45-50

Energy Density J/cm2
4.5 (controls)
45 (controls)
4.5 ( treatment)
45 ( treatment)

RANKL Dose ng/ml
10
10
10
10

Number of Wells
5
5
5
5

Well Number
[B2 – B6]: 0-0-10
[B2 – B6]: 0-0-10
[B2 – B6]: 1-4.5-10
[B2 – B6]: 1-45-10

Energy Density J/cm2

RANKL Dose ng/nl
2.5
2.5
2.5
2.5

Number of Wells
5
5
5
5

Well Number
[A2 – A6]: 0-0-2.5
[A2 – A6]: 1-4.5-2.5
[A2 – A6]: 1-45-2.5
[A2 – A6]: 0-0-2.5
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Appendix F
Tartrate-Resistant Acid Phosphatase Staining Protocol
(TRAP)-Staining Protocol
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TRAP Staining Protocol: using SIGMA Acid Phosphatase Leukocyte Kit (prod #387)
Solution not in kit, but required
 Acetone
 Formaldehyde, 37% (F1635 formaldehyde solution from SIGMA)
1. Preparation of Solutions
 Warm up dH2O to 37C ( 200ml)A. Prepare fixation Solution: (for cell cx only, use polypropylene or glass
containers and pipettes)- keep at room temp- in glass beaker
 Citrate solution:
25ml
18.75
12.5ml
8.3ml
6.25ml
 Acetone:
65ml
48.75ml
32.5ml
21.6ml
16.25ml
 37% Formaldehyde 8ml
6ml
4ml
2.6ml
2ml
TOTAL
98ml
73.5ml
49ml
32.5ml
24.5ml
0.5 ml/well
B. Prepare the Fast Garnet Solution: use glass pipettes, Mix in 1.5ml centrifuge
tube
 Fast Garnet GBC
0.75ml
0.5ml
0.35ml
 Sodium Nitrite Sol 0.75ml
0.5ml
0.35ml
TOTAL
1.5ml
1ml
0.7ml
Mix gently inversion for 30sec
let stand for 2min
C. Make the staining solution: (using a glass beaker): NEXT Experiment make up
74.25 & 34.65 for 100 wells
May mix in a polypropylene conical tube if amount is under 50ml.
 dH20, 37C
 Fast Garnet Sol
o (From B)
 Naphtol AS-BI phosphate
 Acetate Sol
 Tartrate Sol
TOTAL

67.5ml
1.5ml

45ml
1ml

31.5ml
0.7ml

0.75ml
3.0ml
1.5ml
74.25ml

0.5ml
2.0ml
1.0ml
49.5ml

0.35ml
1.4ml
0.7ml
34.65ml

D. Warm the Staining Solution in 37C water bath, protect from light.

2. Staining
A. Staining cell culture plates
 Aspirate media
 Wash the plate using PBS Ca+, Mg+ (2 times)
 Add the fixation solution from (from above 1A), enough to cover the cells
(e.g. 1ml per well for 12 well plates or 0.7ml per well for 24 well
plates)
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wait for 30sec
Rinse thoroughly with dH20 (3 times)
Note: Do not let sample dry out
 Add the Staining Solution (from step 1C), enough to cover the cells (same
as fixation sol)
 Incubate in 37C (protected from light) for 10min but check q 5 min
 Rinse thoroughly with dH20 (3times)
Air dry and evaluate with microscope – store plates protected from light
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Appendix G
Cell Counting Classification Tool
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Example/source E1384 NIR #3 RAW Cells 090713

Rule

Est.

Use 10x Magnification on cell cx
room microscope.

8/8/2009

TRAP Stain Counting Rules: Lisa Anderson-Antle

Entire well counted: Divided into
4ths. Counted OC that touched the
arrowed margins
Cells must be:
First—TRAP+
Then—Have 3+ nuclei

Counted
RUQ and LLQ Established 10/20/09
These are nuclei. Found in cell clump,
if defined cell margins and 3 nuclei
but did not count.

8/8/2009

Pale purple; counted numerous Lg OC
throughout all plates, decision to count

8/8/2009

e1385_NIR #4 Plate 1-4b

e1385_NIR #4 Plate 1-5b 0-0-25

e1385_NIR #4 Plate 1-4b 0-0-25

e1385_NIR #4 Plate 1-4b

e1385_NIR #4 Plate 1-5c 0-0-25

Counted

Counted dark purple

Deep Purple-pink; counted
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Counted OC with processes
e1385_NIR #4 Plate 1-4c 0-0-25 m

e1385_NIR #4 Plate 1-4b 0-0-25

e1385_NIR #4 Plate 1-5b 0-0-25

Dark Pink; counted

OC under cell clump; counted
Clear cytoplasm, no distinct pink or
purple around nuclei—this is not
TRAP+ Did not count

8/8/2009

e1385_NIR #4 Plate 1-4b 0-0-25

8/8/2009

e1385_NIR #4 Plate 1-4b 0-0-25

Did not count
clumps on side walls not counted
Scattered TRAP+ areas; not counted
Stained Cell clump: did not count
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Fusing not defined boarders; not
counted

e1385_NIR #4 Plate 1-4b 0-0-25

E1385 NIR #4: TRAP Stain-OC Counting Rules
24 well plates: 8 plates; 36 wells. 2 wells per plate; wells 3b & 4b
control plates [3a – 3e] [4a – 4e] [5a – 5e]
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Appendix H
Tables
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Table 1.
Cell Plate Labeling Example: 5 wells per Condition Labeled by Number of Light Treatments – Energy
Density - RANKL Dose
Plate Number
Row 1
Row 2
Row 3
Number of Wells Used
4.5 J/cm2 Energy Density Control Plate
Plate 1

0-0-0

0-0-2.5

0-0-10

15 wells

Plate 2

0-0-0

0-0-25

0-0-50

10 wells

45 J/cm2 Energy Density Control Plate
Plate 1

0-0-0

0-0-2.5

0-0-10

15 wells

Plate 2

*

0-0-25

0-0-50

10 wells

4.5 J/cm2 Energy Density Experimental Plate
Plate 1

1-4.5-0

1-4.5-2.5

1-4.5-10

15 wells

Plate 2

*

1-4.5-25

1-4.5-50

10 wells

45 J/cm2 Energy Density Experimental Plate
Plate 1:

1-45-0

1-45-2.5

1-45-10

15 wells

Plate 2:

*

1-45-25

1-45-50

10 wells

* Well not utilized

Table 2.
Serial Dilution for RANKL Intermediate Stock Concentration
Tube
Dilution
Volume of Add
Beginning
Number

1: 50ng/ml

Factor

Total
Final
Volume/µl

RANKL

765

800

1.25 x 103 ng/ml

Previous

Medium

Tube

Stock/µl

Volume/µl

Volume/µl

Intermediate Stock
Concentration

1:1

35ul

2: 25ng/ml

1:2

RANKL
800

338

338

765

0.63 x 103 ng/ml

3: 10ng/ml

1:2.5

765

225

338

676

0.68 x 103 ng/ml

4: 2.5ng/ml

1:4

676

113

337

563

0.31 x 103 ng/ml

5: 0 ng/ml

0

0

450

450
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Table 3
Summary of Experiment Variables by Experiment Number
Number of
WARP™ 10
Experiment
Light
Light
Energy
Number
Treatments
Source
Density J/cm2

e1380

e1383

e1384
e1385

RANKL Dose ng/ml

4.5

45

0

25

50

1

*

*

*

*

*

*

4

*

*

*

*

*

*

1

*

*

*

*

*

*

4

*

*

*

*

*

*

1

*

*

*

*

*

*

*

*

*

*

*

1
*
* Variable utilized in the experiment
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AWARDS
2010
Fall 2009

NASA Student Ambassador






Wisconsin Space Grant Graduate Fellowship
Porth Nurse Physiologist Scholarship
Exploration Space Mission Directorate/Wisconsin Space Grant
Internship
NASA Ames Research Center: Bone and Signaling Laboratory
Mentor: Ruth Globus, PhD
NASA Student Ambassadors Program: Nominated by the
International Astronautical Congress

Summer 2009


Exploration Space Mission Directorate/Wisconsin Space Grant
Internship
NASA Ames Research Center: Bone and Signaling Laboratory
Mentor: Ruth Globus, PhD
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Summer 2008
 NASA Science & Technology Institute: United Negro College
Fund-Special Programs
NASA Ames Research Center: Psychophysiology Laboratory
Mentor; Patricia Cowings PhD
SKETCH OF WORK HISTORY

(FULL LIST AVAILABLE UPON REQUE ST)

ACADEMIC RESEARCH
2009: Summer & Fall, NASA Ames Research Center

Doctoral Research Assistant
Responsibilities: Completed supervised independent research
2008: Summer, NASA Ames Research Center

Research Assistant-Medical Monitor
Responsibilities: Human Sleep Deprivation Study; medical monitoring
2007 – 2008 University of Wisconsin-Milwaukee: College of Health Sciences

Research Assistant

Responsibilities: Multi-disciplinary team participation; in vivo development and
experimentation
2006-2007 University of Wisconsin-Milwaukee: College of Nursing, Milwaukee, WI

Clinical Assistant Professor
Project Director: RO1 NIH randomized interventional study
Responsibilities:
o Implementation , budget accountability, management & supervision
o Database validity/reliability and statistical interpretation
o Validity of instrumentation and data collection
2004-2005 University of Wisconsin-Milwaukee: College of Nursing, Milwaukee, WI

Research Coordinator
Responsibilities: Implementing and coordinating a multi-grant/research site

study
ACADEMIC HIGHER EDUCATION
2010-2012 George Williams College of Aurora University

Adjunct Faculty
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2005-2006 Columbia/St Mary’s Health System College of Nursing, Milwaukee, WI

Assistant Professor

2003 Fall

Southwest Missouri State University Department of Nursing, Springfield, MO

Clinical Supervisor
2001-2003

Southwest Baptist University: Department of Nursing, Springfield, MO

Adjunct Faculty
1997-1998 Lester E. Cox Heath Systems: College of Nursing, Springfield, MO

Assistant Professor of Nursing
ADVANCED PRACTICE NURSING
2007 – 2008 In Your Home Internal Medicine & Geriatrics SC, Milwaukee, WI

Gerontological Advance Practice Nurse
2004-2005

Evercare Wisconsin: United Health Group, Milwaukee, WI

Nurse Practitioner
2000-2003

Gerontological Consulting Services, Springfield, MO

Gerontological Advanced Practice Nurse
1996-1997

Lester E. Cox Health Systems, Springfield, MO

Gerontological Clinical Nurse Specialist
FIELDS OF INTEREST




Space Biomedical Countermeasures; Skeletal and Bone Health-Translational
Medicine
Bio-Gerontological Preventive Aging Research: Photobiomodulation
Population Health Research: Gerontological Community/Home Care &
Institutional Based Long-Term Care

PROFESSIONAL ORGANIZATIONS








The American Society for Bone and Mineral Research
American Nurses Association
Sigma Theta Tau International Nursing Honor Society
Wisconsin Nurse Association
American Medical Directors Association
Midwest Nursing Research Society:
Missouri Nurses Association: Board member (select years) 1992- 2003

275







Missouri League of Nursing
National Conference of Gerontological Nurse Practitioners
The American Geriatric Society
The Gerontological Society of America
Student Nurses Association: President 1990-1991

PUBLICATIONS
Marek, K. D., & Antle, L. L. (2008) Medication management of the community-dwelling
older adult. In R. Hughes (Ed.), Advances in Patient Safety & Quality – An Evidence-based
Handbook for Nurses. Rockville, MD: Agency for Healthcare Research and Quality.
Antle, L. A. (2004). Advanced practice nurse controlled substance authority. The Missouri
Nurse, 1, 11-12, 25.
Antle, L. A. (1995). Defining the Role of Advanced Practice Nursing: Clinical Nurse Specialists' and
Nurse Practitioners' Perceptions of Their Roles. Unpublished Masters Thesis, St. Louis,
MO, St. Louis University.
CONFERENCE PRESENTATIONS
Anderson-Antle, L. L., & Globus, R. (2011, October 3-7). Effects of Photobiomodulation and
Osteoclast Formation in Vitro: a Pilot Study. Paper Presented at the 62nd International
Astronautical Congress: African Astronaissance, Cape Town, South Africa.
Submitted.
Anderson-Antle, L. L., Cowings, P., Toscano, W., Orasanu, J., & DeRoshia, C. W. (2009,
October 12 – 16). Consequences of sleep deprivation on performance and mood states. Paper
presented at the 60th International Astronautical Congress: Space for Sustainable
Peace and Progress, Daejeon Republic of Korea.
Anderson-Antle, L. L., & Globus, R. (2010). Near Infrared Laser Emitting Diode
Photobiomodulation and Osteoclast Formation In Vitro. Poster presented at the 34th
Midwest Nursing Research Society: “Nursing Research: Bench to Bedside”. Kansas City,
Missouri.
Anderson-Antle, L. L., Globus, R. (2009). Near Infrared Laser Emitting Diode Photobiomodulation
and Osteoclast Formation In Vitro, Poster Presentation at the Ames’ 70th Anniversary
Celebration. NASA Ames Research Center, Moffett Field, California.
Anderson-Antle, L. L., Cowings, P., and Toscano, W. (2008). Consequences of Sleep Deprivation
on Performance & Mood States, Poster Presentation at the NLSI Lunar Science
Conference. NASA Ames Conference Center, Moffett Field, California.
Anderson-Antle, L. L., Bauer, D., Gopalakrishnan, S., Lark, D.S., Sandoval, C., Eells, J. T.,
and Snyder, A.C. (2008). Streptozotocin-Induced Diabetic Animal Model Recapitulates Many
Features of Frailty in Older Adults with Diabetes. Poster Presentation Experimental
Biology 2008, “Today’s Research: Tomorrow’s Health”. San Diego, California.
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Marek, K. D., Antle, L. L. (2006). Pharmacy Screen Results and Consumer Satisfaction of a Home
Care Medication Management Program, Paper Presentation at the 30th Annual Midwest
Nursing Research Society Research Conference “Linking Research and Practice: A
Roadmap for the Future”, Milwaukee, Wisconsin.
Antle. L. L. (May, 2005). Clinical Outcomes of Aging in Place: Karen Dorman Marek PhD, MBA,
RN, FAAN, Paper Presentation at the 7th Annual Southeastern Wisconsin Nursing
Research Conference “Building Bridges to Research Based Practice”. Pewaukee, Wisconsin.
Antle, L. (2001). Role of the Advanced Practice Nurse in Long Term Care. Paper presented at the
Southwest Missouri Geriatric Symposium, Springfield, Missouri.
Antle, L. (1995). Defining the Role of Advanced Practice Nursing: Clinical Nurse Specialists’ and Nurse
Practitioners’ Perceptions of Their Roles. Paper presented at the Missouri Nurses
Association “Coming together in Advanced Practice”. Columbia, Missouri.

LICENSES AND CERTIFICATIONS
Registered Nurse: Wisconsin
Registered Nurse: California inactive
Registered Nurse: Missouri inactive
Advanced Practice Nurse: Missouri inactive
Advanced Practice Nurse Prescriber: Wisconsin
Gerontological Clinical Nurse Specialist: American Nurse’s Credentialing Center

